Updated 7/7/11
CURRICULUM VITAE
GREGORY T. EVERSON, M.D., F.A.C.P.
PROFESSOR OF MEDICINE
DIRECTOR, SECTION OF HEPATOLOGY
PHONE
FAX
(303) 724-1857
(720) 848-2246
DIVISION OF GASTROENTEROLOGY
UNIVERSITY OF COLORADO SCHOOL OF MEDICINE
TRANSPLANT CENTER & HEPATOLOGY CLINIC, B154
UNIVERSITY OF COLORADO HOSPITAL AOP, ROOM 7085
1635 AURORA CT. B154
P.O. BOX 6510
AURORA, COLORADO 80045
PERSONAL
Birth:
Home:
Married:
Children:
Grafton, North Dakota
6112 S. Nome Court
Englewood, CO 80111
Linda
Bradley, 1981; Todd, 1983
EDUCATION
University of North Dakota
Cornell University Medical College
1968 - 1972
1972 - 1976
B.S. (Chemistry)
M.D.
MEDICAL TRAINING
1976-1977 Intern, Internal Medicine, Creighton University
Affiliated Hospitals, Omaha, Nebraska
1977-1979 Resident, Internal Medicine, Creighton University
Affiliated Hospitals, Omaha, Nebraska
1979-1982 Fellow, Division of Gastroenterology,
University of Colorado School of Medicine,
Denver, Colorado
ACADEMIC APPOINTMENTS
1982-1988 Assistant Professor of Medicine
Division of Gastroenterology
University of Colorado School of Medicine
Denver, Colorado
1988-1996 Associate Professor of Medicine
Division of Gastroenterology
University of Colorado School of Medicine
Denver, Colorado
1988-1995 Director, Gastroenterology Fellowship Training Program
1985-1996 Core Director, GC/MS Laboratory, Hepatobiliary Research Center
1
ACADEMIC APPOINTMENTS (cont’d)
1996-PRESENT
Professor of Medicine
Division of Gastroenterology
University of Colorado School of Medicine
Denver, Colorado
1990-PRESENT
Director, Section of Hepatology
University of Colorado School of Medicine
Denver, CO
CERTIFICATION
Internal Medicine, 1979 Certificate Number: 72225
Gastroenterology, 1982 Certificate Number: 72225
LICENSURE
Colorado 22430 (1979)
MEMBERSHIPS
American Association for the Study of Liver Disease
American College of Physicians
American Federation for Medical Research
American Gastroenterological Association
American Society of Transplant Physicians
International Association for the Study of Liver Disease
Western Society for Clinical Investigation
Denver Medical Society
Colorado Medical Society
HONORS
Phi Beta Kappa
National Institutes of Health Clinical Investigator Award, 1983-1986
American Gastroenterological Association Research Award, 1983-1984
American College of Physicians Teaching & Research Scholarship, 1983-1986
Polycystic Kidney Research Foundation, Research Award, 1992-1993
Best Doctors in America Award, 1999, 2004, 2005, 2006, 2007, 2009, 2010, 2011
Fellow, American College of Physicians (FACP), 1999
INVITED LECTURES
AASLD meeting “Meet the Professor”, November, 1995
AASLD meeting “Meet the Professor”, November, 1998
American Liver Foundation Meeting 1998
Participant University Health Talk Radio Show, October, 1998
St. Mary’s Hospital 21st Annual Winter Symposium, Grand Junction, CO, January, 1999
Medical University of South Carolina 4th Annual Liver Disease and Transplantation Symposium,
Charleston, SC, February, 1999
University of Maryland 3rd Annual Liver Disease Seminar, Baltimore, MD, April, 1999
American Osteopathic College of Occupational & Preventive Medicine, Kansas City, MO, April, 1999
Bonfils Blood Center, Denver, CO, May, 1999
Faculty Presenter; Educational Advisory Board, “Treating Hepatitis C: Solutions for a
Critical Need” UCHSC, June, 1999
American College of Physicians, State Conference, Kalispell, MT, August, 1999
2
INVITED LECTURES (cont’d)
American College of Chest Physicians/Society of Critical Care Medicine, Orlando, FL, August, 1999
University of North Carolina Grand Rounds, Chapel Hill, NC, October, 1999
Rush-Presbyterian Hospital Grand Rounds, Chicago, IL, October, 1999
American College of Gastroenterology, Phoenix, AZ, October, 1999
Poudre Valley Hospital, Ft. Collins, CO, Grand Rounds, December, 1999
European Association of Critical Care Physicians, Linz, Austria, Dr. Kurt Lenz, September, 1999
University of Utah, Park City, UT, Advances in Internal Medicine, February, 2000
AST Transplant 2000, May, 2000
Denver VA Hep C Program, June, 2000
AASLD/ILTS Transplant Course Director and Speaker, Dallas, TX October, 2000.
NIH Workshop on Living Donor Liver Transplantation, Member and Speaker, Washington, DC,
November, 2000
Long-Term Risk Factors for Solid Organ Transplant Recipients, Phoenix, AZ, November, 2000
Brown University, Rhode Island Hospital, Providence, RI, December, 2000
Controversies In Transplantation, Breckenridge, CO, March, 2001
Fifth Annual Liver Symposium, Medical College of Virginia, Richmond, VA, March, 2001
Rush-Presbyterian Continuing Medical Education Program, Treatment Strategies in Managing
Chronic HCV, Houston, TX, March, 2001
Hepatobiliary Diseases in Clinical Practice Annual Course/Meeting, Living Related Donors, March,
2001, University of Miami School of Medicine, Miami, FL
Ft. Collins/Greeley/Loveland, Colorado Gut Club and Hep C Connection, Hepatitis C: What Does the
Future Hold, June, 2001
Faculty/Speaker, University of Wisconsin Medical School/AdvancedMed, LLC, CME course
“Augmenting Adherence to Therapy, Denver, CO, July, 2001
Controversies in Transplantation, Breckenridge, CO. March, 2002
Gastroenterology Pathophysiology Course, 2001-2002. University of Colorado Health Sciences
Center, Denver, CO.
Southwest Regional Hepatitis C Symposium, Good Samaritan Regional Medical Center, Phoenix AZ,
June, 2002.
American Council of Life Insurers/University of Colorado Health Sciences Center CME Course,
“Epidemiology & Mortality Trends-Global Perspectives of HIV/AIDS & HCV”, Denver, CO, June, 2002
American College of Chest Physicians/Society of Critical Care Medicine, “Upper & Lower GI
Bleeding, Hepatic Failure”, Chicago, IL, August, 2002
Denver STD/HIV Prevention Annual Update, Denver, CO, September, 2002
University of Colorado Hospital Outreach/CME Program, “Update on Hepatitis C”, Montrose/Delta,
CO, September, 2002
Cornell University Alumni Reunion, ‘Current Status of Living Donor Liver Transplantation in the United
States” New York, NY, October, 2002
American College of Gastroenterology Postgraduate Course, Seattle, WA, October, 2002
Good Samaritan Regional Medical Center Internal Medicine Grand Rounds, “Current Therapy of
Hepatitis C, An Update”, Phoenix, AZ, October, 2002
University of Iowa Grand Rounds, “Adult to Adult Liver Transplantation”, Iowa City, IA, October, 2002
American Association of the Study of Liver Disease Postgraduate Course, Boston, MA, October,
2002
Pegasys® Speakers Bureau, “Point/Counterpoint: Controversies in Hepatitis C Therapy, Does the
Patient Really Need Treatment, Does the Patient Really Need a Liver Biopsy?” Roche Laboratories,
Half Moon Bay, CA, January, 2003
Memorial Hospital Grand Rounds, “The Vital Role of Vaccination Against Hepatitis A and B”
Colorado Springs, CO, February, 2003
3
INVITED LECTURES (cont’d)
ILTS Single Topic and Consensus Development Conference on Liver Transplantation and Hepatitis
C, “Treatment of HCV Patients on the Waiting List”, Phoenix, AZ, March, 2003
Eighteenth Annual Conference New Treatments in Chronic Liver Disease, “Challenges in Treating the
Patient with Advances Hepatitis C”, LaJolla, CA, April, 2003
Advancmed CME Course Co-Chair “Maximizing Treatment Outcomes for Patients with HCV”,
Denver, CO, April, 2003
American Academy of Physicians Assistants Controversies in Hepatitis C Therapy, CME Course
Moderator, New Orleans, LA, May, 2003
American Academy of Physicians Assistants Controversies in Hepatitis C Therapy, CME Course
Moderator, Atlanta, May, 2003
Hepatitis C Depression Symposium, “Controversies in Hepatitis C Therapy: Debating the Options for
Patients with Depression, Alcoholism, or Substance Abuse”, Anaheim, CA, June, 2003
Prague Hepatology Meeting, “Outcomes Beyond the First Post-Transplant Year: Causes of Death in
Relation to Graft Function”, Prague, CZ, June, 2003
Rush Presbyterian Hospital Grand Rounds, Emerging Advances in HCV Management: A Pegasys®
Educational Program, Chicago, IL, July, 2003
AASLD Liver Meeting Wrap-Up, University of Louisville, “Update in Hepatitis C”, Louisville, KY,
December, 2003
Hepatitis Open Forum, Hepatitis Neighborhood Organization, Orlando, FL, January 20, 2004.
Roth Visiting Professorship, “Current Issues in Pre and Post-Transplant Management of Hepatitis C,”
Montreal Canada, September 2, 2004.
Adult Clinical Medicine Course for UCHSC PA Program, “Liver Diseases” Denver, CO November 23,
2005.
Department of Medicine Research Conference, University of Colorado Health Sciences Center,
“Noninvasive Assessment of the Portal Circulation in Man” Denver, CO, April 12, 2007.
National Institute of Diabetes and Digestive and Kidney Diseases, Liver Disease Branch, Monthly
Visiting lectureship, “Clinical Approach to the Patient” Bethesda, MD, April 25-26, 2007.
NATIONAL/INTERNATIONAL COMMITTEES
Member of 1985-1987 AASLD Research Committee
Core Director, GC/MS Laboratory, Hepatobiliary Research Center, UCHSC, 1985-1996
Member of the Abstract Selection Committee for the National Meetings of the American
Gastroenterological Association (AGA) and the American Association for the Study of Liver
Disease (AASLD), 1987-1988
Chairman, 1990 AGA Abstract Selection Committee, Biliary Disorders Section
Member of the Abstract Selection Committee for the National Meeting of the AGA, 1991, 1992
Chairman, 1993 AGA Abstract Selection Committee, Biliary Disorders Section
Member of the Graduate Faculty of Department of Preventative Medicine and Biometrics, 1993
Member of the 1994 Western Section Meeting Reviewers, 1993
Member of the Nominating Committee of the American Society of Transplant Physicians (ASTP),1997
Chairman & Member of the Liver and Intra-abdominal Organs Committee of the ASTP, 1997-1999
CIFN Consensus Interferon Study Group *see related articles
AST Abstract Review Chair, 1999
Chairman, Concurrent Session, Liver I, Viral Hepatitis, AST, 1999.
Co-Moderate, Parallel Luncheon Workshop, Exclusion Criteria for Liver Transplantation, AST, May,
1999
Advisory Council, HEP C Connection, 1999
Training and Education Committee of the AASLD, 1992-present
Member of the Data and Safety Monitoring Board for the PBC Ursodiol Methotrexate Placebo Study
(DSMB /PUMPS), 1995 – present
4
NATIONAL/INTERNATIONAL COMMITTEES (cont’d)
Board Member, American Liver Foundation, 1996- present
Co-Chair, Ancillary Committee, NIH-NIDDK 98-4 Hepatitis C Clinical Trial, 1999 - present
Steering Committee, National Institute of Health, HALT-C Clinical Trial, 1999- present
Exemption Committee, National Institute of Health, HALT-C Clinical Trial, 2000 – present
Recruitment Committee, National Institute of Health, HALT-C Clinical Trial, 2000- present
Clinical Outcomes Committee, National Institute of Health, HALT-C Clinical Trial, 2002 - present
Hepatitis C Caring Ambassadors, 1999- present
Executive Board Member, American Liver Foundation, 1996 – present
Medical Advisory Committee – Donor Alliance, 2000
AASLD/ILTS Course Director, November, 2000
NIH LDLT/AASLD Planning Committee, December, 2000
Member of Abstract Review Committee for Clinical Science- AST Transplant 2001
Consultant, Roche Pharmaceutical Advisory Board Meeting, March, 2001
Panelist, Special Emphasis, Viral Resistance to Antiviral Therapy of chronic hepatitis C (Virahep-C):
Clinical Centers, Data Coordinating Center, Ancillary Studies, for NIH/NIDDK, April, 2001
Panelist, Novo Nordisk Symposium, Treatment of Bleeding and Thrombotic Disorders,
Copenhagen, Denmark, May, 2001
AASLD Abstract Review Committee, 2001, 2002, 2003
Hepatitis Interventional Therapy Group *see related articles
Participant, Roche Pegasys 2nd Annual Pegasys Global Investigators Event, England,
May, 2001
Advisory Board Member, GenQuest Biomedical Education Services/Human Genome Sciences
June, 2001
Faculty/Peer Member, Clinicians Companion V Development, June, 2001
NovoNordisk Pharmaceutical Advisory Board, May, 2002
Roche Pharmaceutical Investigators Board, 2002
American Society of Transplantation Awards Committee, 2002 – present
American College of Physicians, MKSAP Reviewer, 2002 –2003
HCV Committee, National Institute of Health A2ALL Living Donor Liver Transplant Trial, 2002
Regeneration Committee, National Institute of Health A2ALL Living Donor Liver Transplant Trial,2002
AST Membership Committee, 2003
Faculty, School of Medicine, Virginia Commonwealth University, Controversies in the Management of
Hepatitis C CME, 2003
Moderator, Managing Hemostasis in Patients with Liver Disease, DDW, 2003
Coordinator, Oncology Nursing Society Congress Instructional Session, 2003
Roche Liver Transplant Advisory Board, 2003
United Network for Organ Sharing (UNOS) Region 8 Committee Member, 2003
Chair, Scientific Session, ILTS Annual Congress, Barcelona, SP, 2003
Member, AST Awards and Grants Committee, 2006
Chair, AST Membership Committee, 2005-2007
Chair, Abstract Review Committee for Liver Transplantation and Hepatology, AASLD, 2007
Chair, Viral Hepatitis Review Committee, American Association for the Study of Liver Disease,
December 2007-January 2008
Faculty, Transplant Hepatology CAQ, American Association for the Study of Liver Disease, 20072008
Chair, Abstract Review Committee for Clinical Transplantation (Viral Hepatitis), American Association
for the Study of Liver Disease, June 2008.
Member, Surgery and Liver Transplantation Committee, American Association for the Study of Liver
Disease, 2008
5
UCHSC COMMITTEES
University Hospital Bylaws Committee, 1988-1997
Research Committee for Gastroenterology Fellows, 1989-90
Vice-Chairman, University Hospital Liver Transplantation Selection Committee, 1988-89
Chairman, University Hospital Liver Transplantation Selection Committee, 1990-1999
Scientific Advisory Committee of the Clinical Research Center, 1991-1998
Member of the Research Committee for the Hepatobiliary Research Center, 1992-1995
Member of the Search Committee for Director of Transplant Immunology, 1993-1994
Member of the Board of the Biomedical Research Foundation of Colorado, 1994-1997
Chairman, Transplant Outcomes Committee, 1997-present
Medical Advisor, Hep C Connection, 1998
Member of the Clinical Practice Committee, 1998-present
Chairman, Association of Transplant Physicians and Surgeons, 1996-present
Faculty Committee to Review Infrastructure Support for Clinical Research, 1999- present
Chairman, Patient Selection Committee for Liver Transplantation, 1991- present
Dissertation Committee Member, UCHSC School of Pharmacy, 1997 – 2000
Faculty Advisor's (StAAT Groups - Student Academic Advising Teams), 2003-04
EDITORIAL BOARDS
Associate Editor, Journal of Lipid Research, 1990-1996
Associate Editor, Hepatology Section for Medical Knowledge, Self-Assessment Program 12 (MKSAP
12) of the American College of Physicians, 1998-2000 DDSEP Project; Editor of Gallbladder/Biliary
Section, 1998-2000
Hepatology, 2000
Guest Editor, Liver Transplantation Supplement 2, AASLD, Vol 6:6 November, 2000
Associate Editor, Liver Transplantation, 2001-2002
AASLD/DDW Abstract Reviewer, 2001-2002
AASLD/DDW Abstract Reviewer, 2002- 2003
ASTS/AST Co-Chair, Abstract Reviewer, 2003
Science Press, Reviewer, 2003
REFEREE FOR FOLLOWING JOURNALS (CURRENT)
American Journal of Gastroenterology
American Journal of Physiology
Annals of Internal Medicine
Gastroenterology
Gut Club
Hepatology
Journal of Clinical Investigation
Journal of Hepatology
Obstetrics and Gynecology
Digestive Diseases and Sciences
Journal of Lipid Research
Liver Transplantation and Surgery
Transplantation
New England Journal of Medicine
DATA AND SAFETY MONITORING BOARDS
Methotrexate (MTX) Plus Ursodeoxycholic Acid (UDCA) in the Treatment of Primary Biliary Cirrhosis
(PBC). NIH, PUMPS Study.
6
FELLOWS AND RESIDENTS TRAINED
Michael Lawson
Antal Nemeth
Don Zogg
Roshan Shrestha
John-Paul Morfin
Clark Kulig
Saroj Bangarou
Bryan Kim
Jeff Frank
Tom Trouillot
MENTORSHIPS/SPONSORSHIPS: MEDICAL STUDENTS
Student: Adam Braddock
Project Title: Gender and Age Difference in Serum Fatty Acid Ethyl Ester Levels in a HospitalBased Population with Positive Ethanol Screenings.
NIH Short-Term Training Grant 5T35 DK07496-19
Dates: 6/04-8/04
Student: Michael Martucci
Project Title: Deconvolutional analysis on clearance curves of simultaneously administered oral
and intravenous doses of 2,2,4,4-2H cholate and 24-13C cholate: minimal model to determine
first-pass hepatic extraction of cholate in humans.
NIH Short-Term Training Grant 5T35 DK07496
Dates: 6/04-8/04
Steve Sanko, M.D.,
Project Title: HCV replication in peripheral monocytes
Robinson-Durst Scholarship
Dates: 8/05-7/06
PAST RESEARCH SUPPORT
Serum Bile Acid Kinetics and Regulation of Biosynthesis
NIH K08 AM 01156
NIADDK Clinical Investigator Award
Gregory T. Everson, M.D., Principal Investigator
Period of Funding: 4/1/83-3/31/86
Total Budget: $150,000
Serum Bile Acid Kinetics
Research Award, American Gastroenterological Association
Gregory T. Everson, M.D., Principal Investigator
Period of Funding: 1/1/83-12/31/83
Total Budget: $15,000
Research and Teaching Scholarship
American College of Physicians
Gregory T. Everson, M.D., Principal Investigator
Period of Funding: 1983-1986
Total Budget: $150,000
7
PAST RESEARCH SUPPORT (cont’d)
Estrogen Effects on Biliary Lipids and Bile Acid Kinetics
NIH 2R01 DK 19605
Gregory T. Everson, M.D., Principal Investigator
Period of Funding: 6/87-5/91
Total Budget: $421,733
Liver Function in Polycystic Liver Disease
NIH 5P01 DK 34039
Patricia Gabow, M.D. (Program Project), Principal Investigator
Gregory T. Everson, M.D. (Sub-Project), Principal Investigator
Period of Funding: 10/85-3/90
Total Budget: $365,143
Hepatobiliary Research Center: GC/MS Core
NIH 5P 30 DK 34914
Francis Simon, M.D. (Center), Principal Investigator
Gregory T. Everson, M.D. and Paul Fennessy, M.D. (Core)
Period of Funding: 9/85-8/90
Total Budget: $242,446
Effects of Psyllium Mucitloid on Hepatic Lipid Metabolism (Proctor and Gamble)
Gregory T. Everson, M.D., Principal Investigator
Period of Funding: 9/88-8/90
Total Budget: $155,424
Functional Characteristics of Hepatic Cystic Epithelium in Autosomal Dominant Polycystic
Disease (Pilot Feasibility Study)
NIH 5P30 DK34914
Period of Funding: 12/91-3/92
Total Budget: $4,738
Hepatobiliary Function in Sickle Cell Disease (Pilot Feasibility Study)
NIH 5P30 DK34914
Period of Funding: 1987-1989
Bile Acid Synthesis by Liver Cell Hybrids (Pilot Feasibility Study)
NIH 5P30 DK34914
Period of Funding: 1987-1989
Schering-Plough Trials for Treatment of Hepatitis:
a.) C89-9-140: Dose - Response Study of Intron A in Chronic Hepatitis C
Gregory T. Everson, M.D., Principal Investigator
Total Project Period: 1/31/91-94
Budget: Approximately $400/pt/yr, 4 pts.
b.) C92-131: Randomized, Open Trial of PEG-IFN Vs Intron in Treatment of
Chronic Hepatitis C
Gregory T. Everson, M.D., Principal Investigator
Total Project Period: 8/28/92-12/94
Budget: $61,372 (Note: Study canceled early; exact budget unclarified)
8
PAST RESEARCH SUPPORT (cont’d
An Open-Label, Randomized, Multicenter, Comparison of the Efficacy and Safety of
Twenty-Four and Forty-Eight Weeks of De-escalating Regimen of Roferon-A
(Interferon Alpha-2a, Recombinant/Roche) in the Treatment of Patients with Chronic
Hepatitis C (Equivalence Study) (Hoffman-LaRoche)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 6/94-5/96
Total Direct: $195,100
(maximum allowable, dependent upon patient recruitment)
Effects)of Multiple Oral Administration of Orlistat on Bile Composition in Obese Volunteers
(Hoffmann-LaRoche)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 8/94-7/95
Total Direct: $241,716
Phase I, Multiple Dose, Open Study Designed to Compare Safety and Disposition of
Ziprasidone in Subjects with Normal Hepatic Function to Subject with Hepatic Impairment
(Pfizer, Inc.)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 7/95 - 6/96
Total Direct: $108,382
NIH 5P30 DK34914: Hepatobiliary Research Center
Francis R. Simon, M.D., Principal Investigator
Gregory T. Everson, M.D., Director, Bile Acid GC/MS Core Laboratory
Total Project Period: 12/90-11/95
Total Direct: $187,071
C92-130: Randomized, Open Trial of Zn-IFN Versus Intron in the Treatment of Chronic
Hepatitis C (Schering-Plough)
Gregory T. Everson, M.D., Principal Investigator
Total Project Period: 8/28/92-12/94
Budget: $53,699
Polycystic Kidney Research Foundation Grant
Gregory T. Everson, M.D., Principal Investigator
Current Project Period: 6/94-5/95
Total Direct: $18,360
A Study of Lamivudine or Placebo in Patients with Chronic Hepatitis B Infection who
are Treatment Naïve” (Glaxo Inc.)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 7/95 - 6/97
Total Direct: No funding
Placebo Controlled Study of Lamivudine and Intron A in Patients with Chronic
Hepatitis B Infection Who are Interferon Alpha Non-responders (Glaxo, Inc.)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 7/95 - 6/97
Total Direct: No funding
9
PAST RESEARCH SUPPORT (cont’d)
Screening Procedure for Identification of Patients for Participation in Research Protocols
Evaluating Intron A, Alone or In Combination with Other Agents for the Treatment of Chronic
Hepatitis C (Schering-Plough Research Institute)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 1/96 - 3/96
Total Direct: No Funding
Assessment of the Health-Related Quality of Life in Adult Chronic Hepatitis C (CHC)
Patients with Different Categories of Disease and Sustained Responders to INTRON A
(Schering-Plough)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 9/95 - 8/96
Total Direct: $12,500
A Phase III, Open Label, Randomized, Multicenter Trial to Determine the Efficacy of
Recombinant-Methionyl Interferon-Consensus (r-metIFN-Con1) in Patients with Chronic
Hepatitis C Virus (HCV) after Prior Treatment with r-metIFN-Con1 or Interferon alfa-2b
Recombinant (Amgen)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 8/94 - 7/98
Total Direct: $122,900 (Dependent upon patient recruitment)
Grant: 2531433
Intron A monotherapy vs. Intron A + Ribavirin for treatment of chronic hepatitis C in
interferon naïve patients (Schering-Plough, 95-132)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 3/96-6/98
Total Direct: $278,399 (Dependent upon patient recruitment)
Grant: 2531942
Intron A monotherapy vs. Intron A + Ribavirin for the treatment of relapse in patients with
chronic hepatitis C (Schering-Plough, 95-144)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 3/96-6/98
Total Direct: $187,708 (Dependent upon patient recruitment)
Grant: 2531945
Lamivudine Hepatitis B Open Label Treatment Program for Subjects with Three LifeThreatening Forms of Hepatitis B Infection
Gregory T. Everson, M.D. - Principal Investigator
Total Direct: No funding
Intron A monotherapy vs. Intron A Plus Ribavirin at Varying Doses for Treatment of Chronic
Hepatitis C in Interferon Naive Patients (Schering-Plough, 96-114)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 1/97-8/98
Total Direct: $154,912 (Dependent upon patient recruitment)
Grant: 2532319
10
PAST RESEARCH SUPPORT (cont’d)
Treatment of Relapse in Patients with Chronic Hepatitis C Comparing Intron A monotherapy
vs. Intron A Plus Ribavirin (Schering-Plough, 96-318)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 4/97-5/98
Total Direct: $91,416 (Dependent upon patient recruitment)
NV15489: A Phase II Open-Label, Randomized, Multicenter, Ascending Dose Study
Evaluating Safety and Efficacy of PEG-2a (Ro 25-8310) versus Roferon7-A in
the Treatment of Non-Cirrhotic Patients with Chronic Hepatitis C
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 3/97-9/98
Total Direct: $227,353 (Dependent upon patient recruitment)
Grant: 2532318
A Phase III Study to Compare the Safety and Efficacy of Alferon7 N injection to Intron7A in
Previously Untreated Patient with Chronic Hepatitis Infection (Interferon Sciences Inc.
IFN9503)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 6/96-3/99
Total Direct: $140,000 (Dependent upon patient recruitment)
Grant: 2532047
96L-05: A Pivotal Phase II/III, Multicenter, Randomized, Controlled, Parallel Group Study of
the HepatAssist Liver Assist System (LAS) Compared to Standard SICU Care in Patients
with Acute Hepatic Failure
Gregory T. Everson, M.D. – Principal Investigator
Project Period: 6/98 – 4/99
Total Direct: $49,823.00
PEG-rHuMGDF 980132: A Dose Ranging Study of Pegylated Recombinant Human
Magakaryocyte Growth and Development Factor (PEG-rHuMGDF) in Thrombocytopenic
Patients with Cirrhotic Liver Disease
Gregory T. Everson, M.D. – Principal Investigator
Project Period: 4/98 – 12/98
Total Direct: No funding
IFN 9701: Evaluation of the Safety and Efficacy Alferon N Injection in the Treatment of
Subjects Co-Infected with HIV and Hepatitis C
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 9/98 – 3/99
C93-007Continuing Versus 24 Week Courses of Intron A Therapy for Treatment in
Patients with Chronic Active Hepatitis C (Schering-Plough)
Gregory T. Everson, M.D., Principal Investigator
Total Project Period: 9/94-9/99
Budget: $654,000 (dependent upon patient recruitment)
Grant: 2532198
11
PAST RESEARCH SUPPORT (cont’d)
Comparison of PEG-IFN vs. Intron A for Treatment of Adult Subjects with Chronic Hepatitis C
not previously Treated with Interferon: Dose Finding Study (Schering-Plough, 97-010)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 6/97-9/99
Total Direct: $459,930 (Dependent upon patient recruitment)
Grant: 2531507
Intron A plus Ribavirin for the Treatment of Patients with Chronic Hepatitis C not previously
treated with Interferon (Schering-Plough, 97-024)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 10/97-12/99
Total Direct: No funding
Grant: 2531682
R96-419: Intron A + Ribavirin for Treatment of Patients with Interferon-Refractory or
Interferon- Relapsed Chronic Hepatitis C
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 9/97-6/00
Total Direct: $195,000 (Dependent upon patient recruitment)
Grant: 2531515
A Double-blind placebo controlled, randomized dose ranging study of recombinant human
Interlukin-10 (Tenovil) for treatment of hepatic fibrosis in patients with chronic hepatitis C
who failed to respond previous combination therapy (Interferon alfa –2b plus ribavirin)
(Schering-Plough)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 12/99 – 12/00
Total Direct: $85,853
Grant: 2531668
A Randomized, Double-Blind, Double-Dummy, Active Comparator Controlled Multicenter
Study of the Efficacy and Safety of Valganciclovir vs. Oral Gangcyclovir for Prevention of
Cytomegalovirus Disease in High Risk Heart, Liver, and Kidney Allograft Recipients (Pfizer)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/00 – 8/02
Total Direct: $60,940
Grant: 2531800
Long Term Follow Up to Assess Patients After Completing 24 Weeks of Follow Up in a SPRI
Clinical Trial for the Treatment of Chronic Hepatitis C (Schering-Plough 97-501/ 9703908,
C97-139 )
Gregory T. Everson, M.D., Principal Investigator
Project Period: 10/97 – 8/02
Total Direct: $124,500
Grant: 2531573
12
PAST RESEARCH SUPPORT (cont’d)
A Phase III Dose Escalation Trial of Heptazyme Alone and in Combination with Infergen in
Patients with Chronic Hepatitis C Virus (HCV) Infection (Ribozyme RPI0006)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 9/01 – 6/03 (discontinued by sponsor, 7/02)
Total Direct: $168,160
Grant: 2597018
PR00-30-019: A Randomized, Double-Blind, Placebo-Controlled Study to Compare the
Effect of PROCRIT® (Epoetin alfa) Once –a-Week Versus Placebo in the Treatment of
Anemia and Maintenance of Optimal Ribavirin Dose in Hepatitis C Virus Infected Patient
Treated with Combination Ribavirin/Interferon or Ribavirin/Pegylated Interferon (Scripps
Clinic Liver Consortium/Ortho-BioTech)
Total Direct: $321,254
Grant: 2532080
Gregory T. Everson, M.D., Principal Investigator
Project Period: 9/01 – 8/02
Total Direct: $82,542
Grant: 2597017
NR-15997: A randomized, open-label, multicenter, efficacy and safety study of Pegasys
for the treatment of hepatitis C virus infection administered to patients six to sixty months
post liver transplantation (Roche NR15997)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 1/00 – 12/03
Total Direct: $84,587
Grant: 2531435
A Phase II, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of InterferonGamma 1B (IFN-1B) in Patients with Severe Liver Fibrosis or Compensated Cirrhosis Due
to Hepatitis C
Gregory Everson, M.D., Co-Principal Investigator
Project Period: 1/02 – 5/04
Total Direct: $84,923
Grant: 2597023
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Escalation
Doses of Albuferon Recombinant Human Albumin-Interferon Alpha Fusion Protein in
Subjects with Chronic Hepatitis C (Human Genome Sciences HC-01)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 10/02 – 10/04
Total Direct: $115,446
Grant: 2597034
A Randomized, Double-Blind Trial of Telbivudine (LDT) versus Lamivudine in Adults with
Decompensated Chronic Hepatitis B and Evidence of Cirrhosis (Idenix)
Gregory Everson, M.D., Principal Investigator
Project Period: 6/04 – 6/05
Total Direct: $94,130
Grant: 2597058
13
PAST RESEARCH SUPPORT (cont’d)
A double-blind, randomized, placebo-controlled, multi-centre, dose-ranging, parallel group,
phase II study to assess efficacy, safety/tolerability, and pharmacokinetics of a
thrombopoietin receptor agonist, SB-497115-GR, when administered as 30, 50, and 75 mg
once daily for 12 weeks in subjects with chronic hepatitis C–related thrombocytopenia who
are potential candidates for antiviral treatment with pegylated interferon and ribavirin
(GlaxoSmithKline)
Gregory Everson, M.D., Principal Investigator
Project Period: 4/05 – 2/06
Total Direct: $94,256
Grant: 2597076
A double-blind, placebo-controlled, randomized phase III study of intravenous terlipressin in
patients with hepatorenal syndrome type 1 (Orphan Therapeutics, LLC)
Gregory Everson, M.D., Principal Investigator
Project Period: 11/04 – 10/05
Total Direct: $34,005
Grant: 2597064
A Phase 2, Double-Blind, Multi-center, Randomized Study Comparing Tenofovir Disoproxil
Fumarate, Emtricitabine Plus Tenofovir Disoproxil Fumarate, and Entecavir in the Treatment
of Chronic Hepatitis B Subjects with Decompensated Liver Disease and in the Prevention of
Hepatitis B Recurrence Post-Transplantation (Gilead Sciences, Inc).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/06 – 5/08
Total Direct: $35,576
Grant:
Pre-Study Serial Histology as a Predictor of Response to Continuous Therapy During the
HALT-C Trial *Ancillary Study to HALT-C (above)
Gregory Everson, M.D., Principal Investigator
Project Period: 8/02 – 5/03
Total Direct: No additional funding
Grant: none assigned
A Prospective, Randomized, Multicenter, Open-Label, Comparative Safety and Efficacy
Study of Prophylactically Administered Pegylated Interferon alfa-2a (Pegasys®) Plus
Ribavirin vs. No Prophylaxis Following Liver Transplantation for Hepatitis C (Roche)
Gregory Everson, M.D., Principal Investigator
Project Period: 7/04 – 6/05
Total Direct: $171,289
Grant: 2597066
Hepatitis C: Gene Expression Profiling of Host Response to Infection and Response to
Standard Therapy (Source MDx).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/06 – 5/08
Total Direct: $29,687
Grant: 2597101
14
PAST RESEARCH SUPPORT (cont’d)
A Multiple-Center, Observer-Blinded, Randomized, Placebo-Controlled, Single and Multiple
Ascending Dose Study to Investigate the Pharmacokinetics, Pharmacodynamics, Safety,
Tolerability, and Food Effect of RO5024048 in Healthy Volunteers and in Patients with
Chronic HCV Infection of Genotype I (Pharmasset, Inc)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/07 – 2/10
Total Direct: $159,299
Grant: 2597128
A Phase 1 Double-Blind, Placebo Controlled, Dose-Escalation, Multi-center Therapeutic
Trial of the Safety, Immunogenicity, and Efficacy of GI-5005; an Inactivated Recombinant
Saccharomyces cerevisiae Expressing a Hepatitis C Virus NS3-Core Fusion Protein, in
Patients with Chronic Hepatitis C Infection (GlobeImmune).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/05 – 10/07
Total Direct: $118,392
Grant: 2597083
A Phase 2 Study of VX-950 in Combination with Peginterferon alfa-2a (Pegasys®) With
Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C who have not Received
Prior Treatment - VX05-950-104 (Vertex Pharmaceuticals Inc.)
Gregory Everson, M.D., Principal Investigator
Project Period: 4/06 – 4/08
Total Direct: $129,475
Grant: 2597098
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin
Interferon Alaf-2B (ALB-IFN) in Combination with Ribavirin Compared with Peginterferon
Alfa-2A (Pegasys or Peg-IFN2A) in Combination with Ribavirin in Interferon Alfa Naive
Subjects with Chronic Hepatitis C Genotype 1. Achieve -1 (Human Genome Sciences)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/07 – 12/09
Total Direct: $606,683
Grant: 2597132
Studies of Primary Sclerosing Cholangitis (STOPSC), (Morgan Foundation/EMMES Corp.).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/07 – 12/09
Total Direct: $9,540
Grant: 2597146
Randomized, placebo-controlled, double-blind, parallel group, multicenter, dose response
trial utilizing four doses of CTS-1027, administered orally once daily, in outpatients with
chronic hepatitis C virus (HCV) infection - CTS-1027-0, (Conatus Pharmaceuticals).
Gregory Everson, M.D., Principal Investigator
Project Period: 9/08 – 12/09
Total Direct: $31,037
Grant: 2597174
15
PAST RESEARCH SUPPORT (cont’d)
98-4: NIH-NIDDK 9-2327 Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial
(HALT-C): National Institute of Health. A randomized controlled trial to evaluate the safety
and efficacy of long-term Peg-interferon alfa-2a for treatment of chronic hepatitis C in
patients who failed to respond to previous interferon therapy (NIH/Roche)
Gregory T. Everson, M.D. - Principal Investigator
Project Period: 5/99 – 4/10
Total Direct: $2,868,238
Grant: 2532385
Quantitative Assessment of Hepatic Function in Chronics HCV. (QLFT). Ancillary study of
98-4: NIH-NIDDK 9-2327 Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial
(HALT-C) (study above) (Roche/NIH-NIDDK)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 5/00 – 4/08
Total Direct: $1,243,471
Grant: 2532080
A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa2A
(Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C who have
not Achieved Sustained Viral Response with a Prior Course of Interferon Based TherapyVX06-950-106 (Vertex Pharmaceuticals, Inc)
Gregory Everson, M.D., Principal Investigator
Project Period: 2/07 – 1/10
Total Direct: $128,161
Grant: 2597129
A Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2A
(PEGASYS®) and Ribavirin (COPEGUS®) in Subjects Enrolled in the Control Group (Group
A) of Study VX06-950-106 who did not Achieve or Maintain an Undetectable HCV RNA
Level Through Sustained Viral Response-VX06-950-107 (Vertex Pharmaceuticals)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/07 – 1/10
Total Direct: $9,262
Grant: 2597129
A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin
Interferon Alfa-2B (ALB-IFN) in Combination with Ribavirin Compared with Peginterferon
Alfa-2A (PEGASYS® or PEG-IFN2A) in Combination with Ribavirin in Interferon Alfa Naive
Subjects with Chronic Hepatitis C Genotype 2 or 3 –Achieve 2/3 (Human Genome Sciences)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/07 – 2/10
Total Direct: $496,038
Grant: 2597133
16
PAST RESEARCH SUPPORT (cont’d)
A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating The
Efficacy And Safety Of The HCV Polymerase Inhibitor Prodrug (RO4588161) When Given In
Combination With Pegasys® And Copegus® Versus The Currently Approved Combination
Of Pegasys® And Copegus® In Treatment-Naive Patients With Chronic Hepatitis C
Genotype 1 Virus Infection-NV19865 (Hoffmann LaRoche).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/07 – 10/10
Total Direct: $74,552
Grant: 2597149
The A2ALL LADR Protocol: Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C
After Living Donor Liver Transplantation (National Institute of Health - NIDDK, ScheringPlough, and Ortho-Biotech.
Gregory Everson, M.D., Principal Investigator
Project Period: 11/05 – 10/05
Total Direct: $64,146
Grant: 2597087
Restoration of Hepatic Function in Living Liver Donors (An Ancillary Study of A2ALL),
National Institute of Health (NIH).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/06-8/08
Total Direct: $109,.324
Grant: 2597140
A Phase 2 Randomized, Open Label, Multi-Center, Therapeutic Trial Of The Efficacy,
Immunogenicity, And Safety Of GI-5005; An Inactivated Recombinant Saccharomyces
Cerevisiae Expressing A Hepatitis C Virus NS3-Core Fusion Protein, Combined With
Pegylated Interferon Plus Ribavirin Standard Of Care Therapy Versus Standard Of Care
Alone, And GI-5005 Salvage Of Standard Of Care Failures, In Patients With Genotype 1
Chronic Hepatitis C Infection (GlobeImmune).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/07 – 10/10
Total Direct: $25,826
Grant: 2597148
A Randomised, Double-Blind, Placebo-Controlled, Multi-Centre Study to Evaluate the Safety
and Efficacy of Eltrombopag to Reduce the Need for Platelet Transfusion in
Thrombocytopenic Subjects with Chronic Liver Disease Undergoing Elective Invasive
Procedures-ELEVATE (TPL104054), (GlaxoSmithKline).
Gregory Everson, M.D., Principal Investigator
Project Period: 4/08 – 3/11
Total Direct: $40,610
Grant: 2597165
17
PAST RESEARCH SUPPORT (cont’d)
An Open-Label, Multicenter Protocol Providing Pegylated Interferon Alfa-2a (PEGASYS®)
As Monotherapy Or In Combination With Ribavirin (COPEGUS®) For Patients With Chronic
Hepatitis C Who Have Participated In Previous Roche Or Roche Partner ProtocolsNV17590B (Hoffmann LaRoche).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/07 – 9/10
Total Direct: $19,826
Grant: 2597150
Trial of CTS-1027 in Interferon-Naïve Hepatitis C Patients - CTS-1027-03 (Conatus
Pharmaceuticals)
Gregory Everson, M.D., Principal Investigator
Project Period: 5/09 – 5/12
Total Direct: $55,543
Grant: 2597199
A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination With Peginterferon Alfa2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotype 1
Chronic Hepatitis C - VX07-950-108 (Vertex Pharmaceuticals)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/08 – 3/11
Total Direct: $119,079
Grant: 2597163
CURRENT RESEARCH SUPPORT
2U01DK062536-08-NIH Adult to Adult Living Donor Liver Transplantation Cohort Study
(A2ALL)
Gregory T. Everson, M.D., Principal Investigator
Project Period: 9/09 – 8/14
Total Direct: $1,417,054
Grant: 2597202
A Randomized, Partially-blind Study to Evaluate the Safety, Tolerability and Effect on
Virological Response of Treatment with the HCV Protease Inhibitor RO5190591 in
Combination with Pegasys and Copegus for 12 or 24 weeks, versus treatment with Pegasys
and Copegus alone, in Treatment-Naïve Patients with Chronic Hepatitis C Genotype 1 Virus
Infection,” #NV21075 (Roche).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/09 – 5/12
Total Direct: $21,731
Grant: 2597191
A Phase 3, Safety and Efficacy Study of Boceprevir in Previously Untreated Subjects with
Chronic Hepatitis C Genotype 1” P05216-166 (Schering Plough)
Gregory Everson, M.D., Principal Investigator
Project Period: 9/08 – 9/11
Total Direct: $76,878
Grant: 2597177
18
CURRENT RESEARCH SUPPORT (cont’d)
Randomised, Placebo-Controlled, Multi-Centre Study To Assess The Efficacy And Safety Of
Eltrombopag In Thrombocytopenic Subjects With Hepatitis C Virus (Hcv) Infection Who Are
Otherwise Eligible To Initiate Antiviral Therapy (Peginterferon Alfa-2a Plus Ribavirin)-Enable
1 (GlaxoSmithKline).
Gregory Everson, M.D., Principal Investigator
Project Period: 7/07 – 6/11
Total Direct: $170,832
Grant: 2597154
Randomised, placebo-controlled, multi-centre study to assess the efficacy and safety of
eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are
otherwise eligible to initiate antiviral therapy (peginterferon alfa-2b plus ribavirin)-ENABLE 2
(GlaxoSmithKline).
Gregory Everson, M.D., Principal Investigator
Project Period: 9/09 – 9/12
Total Direct: $38,132
Grant: 2597209
A Single-Arm Study to Provide Boceprevir Treatment inSubjects with Chronic Hepatitis C
Genotype 1 Deemed Nonresponders toPeginterferon/Ribavirin in Previous Schering-Plough
Boceprevir Studies. P05514-84 (Schering Plough).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/09 – 4/12
Total Direct: $15,565
Grant: 2597192
A randomized, double-blind, placebo-controlled Phase III trial of telaprevir with pegylated
interferon alfa-2a (Pegasys®) and ribavirin (Copegus®) in subjects with genotype 1 chronic
hepatitis C infection who did not achieve sustained virologic response following prior
treatment with pegylated interferon plus ribavirin -VX950-TiDP24-C216 (Tibotec)
Gregory Everson, M.D., Principal Investigator
Project Period: 8/08 – 8/11
Total Direct: $95,907
Grant: 2597171
A Randomized Study of Stopping Treatment at 24 Weeks or Continuing Treatment to 48
Weeks in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C who Achieve an
Extended Rapid Viral Response (eRVR) While Receiving Telaprevir, Peginterferon Alfa2a
(Pegasys®) and Ribavirin (Copegus®) – VX07-950-111 (Vertex Pharmaceuticals)
Gregory Everson, M.D., Principal Investigator
Project Period: 8/08 – 8/11
Total Direct: $184,383
Grant: 2597172
19
CURRENT RESEARCH SUPPORT (cont’d)
Randomized, Controlled Phase 2a/b Study of the Efficacy and Safety of PEG-rIL-29
Administered in Combination with Ribavirin to Treatment-Naive Subjects with Chronic
Hepatitis C Virus Infection” to be conducted pursuant to Protocol #526H04 (Zymogenetics
and BMS).
Gregory Everson, M.D., Principal Investigator
Project Period: 10/09 – 9/12
Total Direct: $121,728
Grant: 2597204
A Blinded, Randomized, Placebo-controlled, Dose Ranging Study to Evaluate the Safety,
Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-450 with
Ritonavir (ABT-450/r), ABT-333 or ABT-072 Each Administered Alone and in Combination
with Peginterferon α-2a and Ribavirin (PegIFN/RBV) in Treatment-Naïve Subjects with
Genotype 1 Chronic Hepatitis C Virus (HCV) Infection – M11-602 (Abbott).
Gregory Everson, M.D., Principal Investigator
Project Period: 3/10 – 3/13
Total Direct: $158,730
Grant: 2597216
An Open-Label Trial of Pegylated Interferon plus Ribavirin in Combination with CTS-1027 in
HCV Null-Responders - CTS-1027-04 (Conatus Pharmaceuticals).
Gregory Everson, M.D., Principal Investigator
Project Period: 1/10 – 1/13
Total Direct: $115,750
Grant: 2597215
Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and
Efficacy of Filibuvir Plus Pegylated Interferon Alfa-2A and Ribavirin in Treatment Naive, HCV
Genotype 1 Infected Subjects - A8121014 (Pfizer).
Gregory Everson, M.D., Principal Investigator
Project Period: 6/09 – 6/12
Total Direct: $111,714
Grant: 2597205
EXTEND: A 3-Year Virology Follow-up Study in Subjects Previously Treated With Telaprevir in
Select Clinical Studies - VX08-950-112 (Vertex Pharmaceuticals).
Gregory Everson, M.D., Principal Investigator
Project Period: 8/09 – 9/12
Total Direct: $67,282
Grant: 2597206
An Open-Label, Randomized, Parallel-Group, Dose-Ranging Study to Evaluate Efficacy,
Safety, Pharmacokinetics, and Antiviral Activity of VX-222 and Telaprevir in Combination
With and Without Peginterferon-Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in
Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C - VX09-222-103 (Vertex
Pharmaceuticals).
Gregory Everson, M.D., Principal Investigator
Project Period: 5/10 – 5/13
Total Direct: $215,308
Grant: 2597220
20
CURRENT RESEARCH SUPPORT (cont’d)
A Placebo Controlled, Multicenter, Double-Blind, Randomized Trial of Pegylated Interferon
plus Ribavirin With or Without CTS-1027 in HCV Null-Responders - CTS-1027-05 (Conatus
Pharmaceuticals).
Gregory Everson, M.D., Principal Investigator
Project Period: 12/10 – 12/13
Total Direct: $129,293
Grant: 2522819
A Parallel, Open-Label, Randomized, Multiple-Dose Study to Evaluate the Safety,
Pharmacokinetics and Pharmacodynamics of BMS-790052 and BMS-650032 in
Combination in Null Responders to Standard of Care Infected with Chronic Hepatitis C Virus
Genotype 1-AI447-011 (Bristol Myers Squibb)
Gregory Everson, M.D., Principal Investigator
Project Period: 12/09 – 2/14
Total Direct: $190,477
Grant: 2597210
A Phase 2a Study of BMS-790052 in Combination with Peginterferon Alfa-2a (Pegasys®)
and Ribavirin (Copegus®) in Treatment Naive Subjects with Chronic Hepatitis C Virus
Genotype 1 Infection-AI444-014 (Bristol Myers Squibb)
Gregory Everson, M.D., Principal Investigator
Project Period: 12/09 – 2/14
Total Direct: $51,043
Grant: 2597187
A Phase 2b Study of BMS-790052 in Combination with Peg-Interferon Alfa-2a and Ribavirin
in Treatment Naive Subjects with Chronic Hepatitis C Genotype 1 and Infection-AI444-010
(Bristol Myers Squibb)
Gregory Everson, M.D., Principal Investigator
Project Period: 7/10 – 7/13
Total Direct: $65,025
Grant: 2597223
A Phase 2B Study of BMS-790052 in Combination with Peginterferon Alfa-2a and Ribavirin
in Chronic Hepatitis C Genotype 1 Infected Subjects Who are Null or Partial Responders to
Prior Treatment with Peginterferon Alfa plus Ribavirin Therapy-AI444-011 (Bristol Myers
Squibb)
Gregory Everson, M.D., Principal Investigator
Project Period: 8/10 – 8/13
Total Direct: $60,138
Grant: 2597227
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA)
treatment-resistant mutations or the durability of sustained virological response (SVR) in
patients treated with DAA-containing regimens for chronic hepatitis C infection (CHC),”
#NV22688 (Roche).
Gregory Everson, M.D., Principal Investigator
Project Period: 6/10 – 5/13
Total Direct: $14,682
Grant: 2522694
21
CURRENT RESEARCH SUPPORT (cont’d)
A Randomized, Open label, Multicenter, Dose and Duration-Finding Study to Evaluate the
Sustained Virologic Response of the HCV Protease Inhibitor Danoprevir (RO5190591)
Boosted with Low Dose Ritonavir (danoprevir/r) in Combination with Pegasys® and
Copegus® versus Pegasys® and Copegus® alone in Treatment-Naïve Patients with ChronicNV22776 (Roche)
Gregory Everson, M.D., Principal Investigator
Project Period: 11/10 – 11/13
Total Direct: $193,778
Grant: 2597233
A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy,
safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including
peginterferon alfa-2a and ribavirin in treatment-naïve, genotype 1 hepatitis C-infected
subjects–TMC435-TiDP16-C208 (Tibotec)
Gregory Everson, M.D., Principal Investigator
Project Period: 11/10 – 10/13
Total Direct: $83,904
Grant: 2597238
A Phase III, randomized, double-blind, placebo controlled study to investigate the efficacy,
safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including
peginterferon alfa-2a and ribavirin in hepatitis C, genotype 1 infected subjects who relapsed
after previous interferon-based therapy–TMC435HPC3007 (Tibotec)
Gregory Everson, M.D., Principal Investigator
Project Period: 11/10 – 10/13
Total Direct: $76,065
Grant: 2597240
A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8
hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve
subjects with genotype 1 chronic hepatitis C virus infection -VX950-C211 (Tibotec)
Gregory Everson, M.D., Principal Investigator
Project Period: 10/10 – 10/13
Total Direct: $66,651
Grant: 2597239
An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics
of ABT-450 with Ritonavir (ABT_450/r) Dosed in Combination with ABT-333 and Ribavirin
(RBV) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C Virus (HCV)
Infection - M12-746(Abbott Pharmaceuticals)
Gregory Everson, M.D., Principal Investigator
Project Period: 3/14/11-3/13/14
Total Direct: $37,998
Grant: 2597241
22
CURRENT RESEARCH SUPPORT (cont’d)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating 16 and 24
Weeks of a Four-Drug Regimen and 24 Weeks of a Three-drug Regimen of GS-9451,
Peginterferon Alfa 2a (PEG, Pegasys) and Ribavirin (RBV, Copegus) With and Without
Tegobuvir (GS 9190) Followed by Response Guided PEG and RBV in Treatment Naïve
Subjects with Chronic Genotype 1 Hepatitis C Virus Infection - GS-US196-0140 (Gilead
Sciences)
Gregory Everson, M.D., Principal Investigator
Project Period: 01/15/11-01/14/14
Total Direct: $99,167
Grant: 2597243
A Phase 2B, randomized study to evaluate the safety and efficacy of Pegylated Interferon
Lambda (BMS-914143) administered with Ribavirin plus a single direct antiviral agent (BMS790052 or BMS-650032) versus Pegasys administered with Ribavirin (Part A) and of
Pegylated Interferon Lambda (BMS-914143) administered with or without Ribavirin plus 2
direct antiviral agents (BMS 790052 and BMS-650032) (Part B) in chronic hepatitis C
genotype-1 treatment naïve subjects - AI452-008 (Bristol-Myers Squibb, Inc.)
Gregory Everson, M.D., Principal Investigator
Project Period: 03/23/11-03/15/14
Total Direct: $123,629
Grant: 2597242
A Randomized, Open-label, Multicenter Study to Evaluate the Sustained Virologic
Response of the HCV Protease Inhibitor Danoprevir Boosted with Low Dose Ritonavir
(DNV/r) and Copegus, in Combination with the HCV Polymerase Inhibitor Prodrug
RO5024048 and/or Pegasys in Chronic Hepatitis C Genotype 1 Patients Who Failed with
a Previous Course of Peginterferon alfa plus Ribavirin Combination Therapy - WV21913
(F. Hoffmann-La Roche, Ltd)
Gregory Everson, M.D., Principal Investigator
Project Period: 5/03/11-05/02/14
Total Direct: $121,167
Grant: 2522931
Pending Research Support
A Randomized, Open-Label, Multicenter Study to Evaluate the Antiviral Activity, Safety, and
Pharmacokinetics, of ABT-450 with Ritonavir (ABT-450/r) in Combination with ABT-267
and/or ABT-333 With and Without Ribavirin (RBV) for 8, 12 or 24 Weeks in Treatment-Naïve
and Null Responder Subjects with Genotype 1 Chronic Hepatitis C Virus Infection – M11652, Abbott Pharmaceuticals, August 2011.
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response
Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with
Chronic Genotype 1 Hepatitis C Virus Infection - GS-US-256-0124, Gilead Sciences, Inc.,
August 2011.
23
Pending Research Support (cont’d)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response
Guided Therapy with GS-5885 Alone or in Combination with GS-9451 or GS-9256 with
Peginterferon Alfa 2a and Ribavirin in Treatment Naïve Subjects with Chronic Genotype 1
Hepatitis C Virus Infection - GS-US-256-0148,Gilead Sciences, Inc., August 2011.
A Multicenter, Open-label, Randomized, Duration Finding Study to Investigate the Safety,
Tolerability, Pharmacokinetics and Pharmacodynamics following Oral Administration of PSI7977 in Combination with Pegylated Interferon and Ribavirin in Treatment-Naïve Patients
with Chronic HCV Infection Genotype 1, 4, 5, or 6 - P7977-0724, Pharmasset, August 2011.
Publications
MANUSCRIPTS IN PEER REVIEWED JOURNALS
1. Everson GT, Braverman DZ, Johnson ML, Kern F Jr. A Critical Evaluation of
Real-time Ultrasonography for the Study of Gallbladder Volume and Contraction.
Gastroenterology, 79(1):40-46, 1980.
2.
Nair CK, Runco V, Everson GT, Boghairi A, Mooss AN, Mohiuddin SM,
Sketch MH. conduction Defects and Mitral Annulus Calcification. Brit Heart J,
44(2):162-167, 1980.
3.
Everson GT, Kern F, Jr.
1981;80(5 pt. 1): 1084-5.
4.
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Erfling W, Braverman DZ, Szczepanik- VanLeeuwen P, Klein PD. Biliary lipids, Bile Aids and
Gallbladder Function in the Human Female: Effects of Pregnancy and the
Ovulatory Cycle. J Clin Invest, 68:1229-1242, 1981.
5.
Everson GT, McKinley C, Lawson M, Johnson M, Kern F Jr.
Gallbladder
Function in the Human Female: Effect of the Ovulatory Cycle, Pregnancy and
Contraceptive Steroids. Gastroenterology, 82:711-719, 1982.
6.
DeMark BR, Everson GT, Klein PD, Showalter RB, Kern F Jr. A Method for the
Accurate Measurement of Isotope Ratios of Chenodeoxycholic and Cholic Aid in
Serum. J Lipid Res, 23(1):204-210, 1982.
7.
Kern F Jr, Everson GT, DeMark B, McKinley C, Showalter R, Braverman DZ,
Szczepanik-VanLeeuwen P, Klein PD. Biliary lipids, Bile Acids and Gallbladder
Function in the Human Female:
Effects of Contraceptive Steroids.
J Lab Clin Med, 99(6):798-805, 1982.
8.
Everson GT, Lawson MJ, McKinley C, Showalter R, Kern F Jr. Gallbladder and
Small Intestinal Regulation on
Biliary Lipid Secretion During Intraduodenal
Infusion of Standard Stimuli. J Clin Invest, 71:596-604, 1983.
9.
Lawson M, Everson GT, Klingensmith W, Kern F Jr. Coordination of Gastric and
Gallbladder Emptying After Ingestion of a Regular Meal. Gastroenterology,
85:866-870, 1983.
Quantitative Cholescintigraphy.
Gastroenterology
24
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
10. Lawson M, Everson GT, Kern F Jr. Gastrointestinal Transit Time in Human
Pregnancy: Prolongation in the Second and Third Trimesters Followed by Postpartum Normalization. Gastroenterology, 89:996-999, 1985.
11. Everson GT, Polokoff M. HepG2: A Human Hepatoblastoma Cell Line Exhibiting
Defects in Bile Acid Synthesis and Conjugation. J Biol Chem, 261(5):2197-2201,
1986.
12. Perino LP, Shuffler MD, Mehta SJ, Everson GT. Radiation-induced Intestinal
Pseudo-obstruction. Gastroenterology, 91:994-998, 1986.
13. Polokoff MA, Everson GT. Hepatocyte-hepatoma Cell hybrids: Characterization
and Demonstration of Bile Acid Synthesis. J Biol Chem, 261(9):4085-4089, 1986.
14. Everson GT. Steady-state Kinetics of Serum Bile Acids in Healthy Human Subjects: Single and Dual Isotope Techniques Using Stable Isotopes and Mass
Spectrometry. J Lipid Res, 28:238-252, 1987.
15. Kern F, Everson GT. Contraceptive Steroids Increase Cholesterol in Bile:
Mechanisms of Action. J Lipid Res, 28:828-839, 1987.
16. Everson GT, Fennessey R, Kern F.
Contraceptive Steroids
Steady-state Kinetics of Bile Acids. J Lipid Res, 29:68-76, 1988.
Alter
the
17. Everson GT,
Scherzinger A,
Berger-Leff N,
Reichen J,
Lezotte D,
Manco-Johnson M, Gabow P.
Polycystic Liver Disease:
Quantitation of
Parenchymal and Cyst Volumes from Computed Tomography Images and
Clinical Correlates of Hepatic Cysts. Hepatology, 8(6):1627-1634, 1988.
18. Rector WG, Hoefs JC, Hossack KF, Everson GT. Hepatofugal Portal flow in
Cirrhosis: Observations on Hepatic Hemodynamics and the Nature of the Arterioportal Communications. Hepatology, 8(1):16-20, 1988.
19. Everson GT, Ahnen D, Harper PC, Krawitt E. Benign Recurrent Intrahepatic
Cholestasis:
Treatment
with
S-adenosylmethionine
(Brief
Report).
Gastroenterology, 96:1354-1357, 1989.
20. Everson GT, Nemeth A, Kourourian S, Zogg D, Leff N, Dixon D, Githens J,
Pretorius D.
Gallbladder function is Altered in Sickle Hemoglobinopathy.
Gastroenterology, 96:1307-1316, 1989.
21. Everson GT, Emmett M, Brown WR, Redmond P, Thickman D.
Functional
Similarities of Hepatic Cystic and Biliary Epithelium: Studies of Fluid Constituents
and in Vivo Secretion in Response to Secretion. Hepatology, 1(4):557-565, 1990.
22. Everson GT. Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease
(Editorial). Mayo Clinic Proceedings, 65:1020-1025, 1990.
25
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
23. Gabow PA, Johnson AM, Kaehny WD, Manco-Johnson M, Duley IT, Everson GT.
Risk Factors for the Development of Hepatic Cysts in Autosomal Dominant
Polycystic Kidney Disease. Hepatology, 11(6):1033-1037, 1990.
24. Rector WG Jr, Lewis F, Robertson AD, Everson GT. Renal Sodium Retention
Complicating Alcoholic Liver Disease: Relation to Portal-systemic Shunting and
Liver Function. Hepatology, 12(3):455-459, 1990.
25. Reveille RM, Stiegmann GV, Everson GT. Increased Secondary Bile Acids in the
Contents of a Choledochal Cyst: Possible Role in the Development of Biliary
Metaplasia and Carcinoma. Gastroenterology, 99:525-527, 1990.
26. Straka MS, Junker LH, Zacarro L, Zogg DL, Dueland S, Everson GT, Davis RA.
Substrate stimulation of 7alpha-hydroxylase, An Enzyme Located in the
Cholesterol-poor Endoplasmic Reticulum. J Biol Chem, 265(13):7145-7149,
1990.
27. DeRoche GM, Portz B, Rector WG Jr, Everson GT. Simultaneous Determination
of Caffeine and Antipyrine in Plasma and Saliva Using HPLC. J
Liquid Chromatography, 13(17):3493-3505, 1990.
28. Everson GT, McKinley C, Kern F Jr. Mechanisms of Gallstone Formation in
Women: Effects of Exogenous Estrogen (PremarinR) and Dietary Cholesterol on
Hepatic Lipid Metabolism. J Clin Invest, 87:237-246, 1991.
29. Everson GT.
Gallbladder
function
in
Gastroenterol Clin North Am, 20(1):85-110, 1991.
Gallstone
Disease.
30. Lewis FW, Adair O, Hossack KF, Everson GT, White C, Rector WG Jr. Plasma
Glucagon Concentration in Cirrhosis is Related to Liver Function But Not to
Portal-systemic Shunting, Systemic Vascular Resistance, or Urinary Sodium
Excretion. J Lab Clin Med, 117:67-75, 1991.
31. Everson GT, Krawitt EL. Trial of S-adenosylmethionine in Patients in Two
Families with Cholestatic Syndromes. Gastroenterology 100(6):1784, 1991
32. Dueland S, Reichen J, Everson GT, Davis RA. Regulation of Cholesterol and
Bile Acid Homeostasis in Bile- obstructed Rats. Biochem J, 280:373-377, 1991.
33. Kaehny W, Everson GT. Extra-renal Manifestations of ADPKD. Semin Nephrol,
11(6):661-670, 1991.
34. Axelson M, Mörk B, Everson GT. Bile acid synthesis in Cultured Human
Hepatoblastoma Cells. J Biol Chem, 266(27):17770-7, 1991.
35. Panini SR, Everson GT, Spencer TA. Effects of Specific Inhibition of Sterol
Biosynthesis on the Uptake and Utilization of Low Density Lipoprotein Cholesterol
by HepG2 Cells. J Lipid Res, 32:1657-1665, 1991.
26
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
36. Everson GT, Daggy BP, Story JA, McKinley C. Effects of Psyllium Hydrophilic
Mucilloid on LDL-cholesterol and Bile Acid Synthesis in Hypercholesterolemic
Men. J Lipid Res 1992; 33:1183-1192.
37. Everson GT. Gastrointestinal motility in pregnancy. Gastroenterol Clin North Am
1992; 21(4):751-776.
38. Everson GT. Bile acid metabolism and Its Role in Human Cholesterol Balance.
Semin Liv Dis 1992; 12(4): 420-428.
39. Everson GT. Pregnancy and Gallstones (Editorial). Hepatology 1993; 17(1):159161.
40. Everson GT. Hepatic Cysts in Autosomal Dominant Polycystic Kidney Disease.
American J of Kidney Diseases 1993; 22(4):520-525.
41. Cooper AD, Craig WY, Taniguchi T, Everson GT. Characteristics and Regulation
of Bile Salt Synthesis and Secretion by Human Hepatoma HepG2 Cells.
Hepatology, 20(6):1522-1531, 1994.
42. Rector, WG., Jr., Everson, GT, Robertson, A. Sodium Retention Does Not Occur
at a Critical Threshold of Liver Function in Alcoholic Cirrhosis. J Lab Clin Med,
1994; 123:218-24.
43. Durham J, LaBerge J, Altman S, Kam I, Everson G, Gordon R, Kumpe D. Portal
Vein Thrombolysis and Closure of Competitive Shunts Following Liver
Transplantation. Journal of Vascular and Interventional Radiology, 5(4):611-617,
1994.
44. Everson GT. Mechanism of Gallstone Formation in Obese Women Undergoing
Weight Loss. Liver Update, Vol. 8(No. 1):5-6, 1994.
45. Stegall M, Everson GT, Schroter G, Bilir BM, Karrer F, Kam I, University of
Colorado Medical Center, Denver, CO. Metabolic Complications After Liver
Transplantation: Diabetes, Hypercholesterolemia, Hypertension, and Obesity.
Transplantation 1995; 60(9):1057-60.
46. Shrestha R, McKinley C, Bilir BM, Everson GT.
Possible Idiopathic
Thrombocytopenic Purpura Associated
with Natural Alpha Interferon Therapy
for Chronic Hepatitis C (HCV) Infection. American Journal of Gastroenterology,
90(7):1146-47, 1995.
47. Lawrence SP, Lezotte DC, Durham JD, Everson GT, Bilir BM. Course of
Thrombocytopenia of Chronic Liver Disease After Transjugular Intrahepatic Porto
systemic Shunts (TIPS): A Retrospective Analysis. Digestive Diseases and
Sciences, 40(7):1575-1580, 1995.
27
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
48. Shrestha R, Bilir BM, Everson GT, Steinberg SE. Endoscopic Stenting of
Gallbladder for Symptomatic Cholelithiasis in Patients with End Stage Liver
Disease Awaiting Orthotopic Liver Transplantation.
American Journal of
Gastroenterology 1996; 91:595-598.
49. Lindsay KL, Davis GL, Schiff ER, Bodenheimer HC, Balart LA, Dienstag JL,
Perrillo RP, Tamburro CH, Goff JS, Everson GT, Silva M, Katkov WN, Goodman
Z, Lau J, Maertens G, Gogate J, Sanghvi B, Albrecht J, Hepatitis Interventional
Therapy Group. Response to Higher Doses of Interferon Alfa-2b in Patients with
Chronic Hepatitis C: A Randomized Multicenter Trial.
Hepatology 1996;
24(5):1034-1040.
50. Kaur S, Rybicki L, Bacon BR, Gollan JL, Rustgi BK, Carey WD, and the National
Hepatitis Surveillance Group. [Everson GT]. Performance Characteristics and
Results of a large-scale Screening Program for Viral Hepatitis and Risk Factors
Associated with Exposure to Viral Hepatitis B and C: Results of the National
Hepatitis Screening Survey. Hepatology 1996; 24:979-986.
51. Durham JD, LaBerge JM, Altman S, Kam I, Everson GT, Gordon RL, Kumpe DA.
Portal vein thrombolysis and closure of competitive shunts following liver
transplantation. Journal of Vascular & Interventional Radiology 1996; 5:611-5.
52. Lau JY, Davis GL, Prescott LE, Maertens G. Lindsay KL, Qian K, Mizokami M,
Simmonds P, Hepatitis Interventional Therapy Group [Everson GT]. Distribution
of Hepatitis C Virus Genotypes Determined by Line Probe Assay in Patients with
Chronic Hepatitis C Seen at Tertiary Referral Centers in the United States.
Annals of Internal Medicine, 124(10):868-76 May, 1996.
53. Shrestha R, McKinley C, Showalter R, Wilner K, Marsano L, Vivian B, Everson
GT. Quantitative Liver Function Tests (QLFTs) define the functional severity of
liver disease in early stage cirrhosis. Liver Transplantation and Surgery 1997;
3:166-173.
54. Everson G, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I,
Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. LongTerm Follow-up of patients with alcoholic liver disease who underwent hepatic
transplantation. Liver Transplantation and Surgery 1997; 3:263-274.
55. Simon DM, Gordon SC, Kaplan MM, Koff R, Regenstein F, Everson G, Lee YM,
Weiner F, Silverman A, Plasse T, Fedorczyk D, Liao MJ. Treatment of Chronic
Hepatitis C with Interferon Alfa-n3: A Multicenter, Randomized, Open-label Trial.
Hepatology 1997; Feb 25:445-8.
56. Stegall M, Everson G, Schroter G, Karrer F, Bilir B, Sternberg T, Shrestha R,
Wachs M, Kam I. Prednisone withdrawal late after adult liver transplantation
reduces diabetes, hypertension, and hypercholesterolemia without causing graft
loss. Hepatology Jan 1997; 25:173-7.
28
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
57. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner T, Showalter R, Everson
GT.
Postmenopausal estrogen therapy selectively stimulates hepatic
enlargement in women with Autosomal dominant polycystic kidney disease.
Hepatology 1997; 26:1282-86.
58. Everson GT. A hepatologist’s perspective on the management of coagulation
disorders prior to liver transplantation. Liver Transplantation and Surgery, 1997;
3(6):646-52
59. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe EB, Kneteman NM,
Lake JR, Martin P, McDiarmid SV, Rakela J, Shiffman ML, So SK, Wiesner RH.
Minimal criteria for placement of adults on the liver transplant waiting list: a report
of a national conference organized by the American Society of Transplant
Physicians and the American Association for the Study of Liver Diseases. Liver
Transpl Surg. 1997 Nov;3(6):628-37
60. Shrestha R, Durham JD, Wachs M, Bilir BM, Kam I, Trouillot T, Everson GT. Use
of Transjugular Intrahepatic Porto systemic shunt as a bridge to transplantation in
fulminant hepatic failure from Budd-Chiari Syndrome. Amer J of Gastroenterology
1997 Dec; 92(12):2304-6.
61. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F,
Kam I.
Prednisone withdrawal 14 days after liver transplantation with
mycophenolate: a prospective trial of cyclosporine and tacrolimus.
Transplantation 1997; 64:1755-1760.
62. Sokol RJ, McKim JM Jr., Goff, MC, Ruyle SZ, Devereaux MW, Han D, Packer L,
Everson G. Vitamin E Reduces Oxidant Injury to Mitochondria and the
Hepatotoxicity of Taurochenodeoxycholic Acid in the Rat.
Gastroenterology
1997; 114:164-174.
63. Everson GT, Kam I. Liver transplantation: current status and unresolved
controversies. (Review). Advances in Internal Medicine, 42:505-53, 1997.
64. Heathcote EJL, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert
DG, Jr., Witt K, Blatt LM, and Consensus Interferon Study Group*. Retreatment of
chronic hepatitis C with consensus interferon. Hepatology 1998; 27:1136-1143.
65. Everson GT, Lin TC, Overview of viral hepatitis. Gastroenterology & Endoscopy
News 1998; 1:1-4.
66. Everson GT, Lin TC, Overview of viral hepatitis. Pharmacy Practice News 1998;
1: 1-4
67. Everson GT, Lin TC, Overview of viral hepatitis. Infectious Disease Special
Edition 1998; 1: 1-4.
68. DiBisceglie A, Everson GT, Herrine S, Jeffers L, Nikias G, Hepatitis C: containing
an invisible epidemic. Patient Care 1998; 32:96-119.
29
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
69. Everson GT. Liver problems in pregnancy: part 2 –managing pre-existing and
pregnancy-induced liver disease. (Review) Medscape Women’s Health, 3(2):2
March, 1998.
70. Everson GT. Liver problems in pregnancy: distinguishing normal from abnormal
hepatic changes. (Review), Medscape Women’s Health, 3(2): 3, March 1998.
71. Ryu R, Lin TC, Kumpe D, Krysl J, Durham JD, Goff JS, Everson GT, Kam I,
Wachs M, Russ P, Shrestha R, Bilir B. Percutaneus mesenteric venous
thrombectomy and thrombolysis: successful treatment followed by liver
transplantation. Liver Transplantation and Surgery, 4(3) 222-5, May, 1998.
72. Goff, JS, Hamman RF, Wamboldt FS, Lezotte DC, Steinberg T, Talamantes M,
Kam I, Wachs M, Everson GT, Bilir BM. Quality of life after liver transplantation:
the effect of hepatitis C status. Submitted to Liver Transplantation and Surgery,
June 1998.
73. Everson GT. Ob-Gyn interactive case challenge-liver disease in the third
trimester of pregnancy. Medscape Women’s Health, 3(4):2, July, 1998.
74. Shivaram KN, Winklhofer-Roob BM, Straka MS, Devereaux MW, Everson GT,
Mierau GE, Sokol RJ. The Effect of Idebenone, a Coenzyme Q Analogue, on
Hydrophobic Bile Acid Toxicity to Isolated Red Hepatocytes and Hepatic
Mitochondria. Free Radical Biology & Medicine, 25(4):480-92 September, 1998.
75. Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keefe EB, Kneteman NM,
Lake JR, Martin P, Rakela J, Shiffman ML, So S, Wiesner RH. Minimal criteria
for placement of adults on the liver transplant waiting list: a report of a national
conference organized by the American Society of Transplant Physicians and the
American Association for the Study of Liver Diseases.
Transplantation,
66(7):956-62, October, 1998.
76. Wachs ME, Bak TE, Karrer FM, Everson GT, Shrestha R Trouillot T, Mandell MS,
Steinberg TG, Kam I. Adult living donor liver transplantation using a right hepatic
lobe. Transplantation, 66(10):1313-6, November, 1998.
77. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman Ml,
Zeuzern S, Craxi A, Ling MH, Albrecht J, International Hepatitis Interventional
Therapy Group.
Recombinant interferon alfa-2b (Intron A) alone or in
combination with ribavirin (Rebetol) for Retreatment of interferon relapse in
chronic hepatitis C. N Engl J Med, November, 1998; 339(21):1432-9.
78. McHutchison JG, Grodon S, Schiff ER, Shiffman ML, Lee WM, Rustgi VK,
Goodman Z, Ling MH, Albrecht J, Hepatitis Interventional Therapy Group.
Interferon alfa-2b monotherapy versus interferon alfa-2b plus ribavirin as initial
treatment for chronic hepatitis C: Results of a US Multicenter randomized
controlled trial N Engl J Med, November, 1998; 339(21)suppl:1485.
30
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
79. Ryu RK, Durham JD, Krysl J, Shrestha R, Everson GT, Stephens J, Kam I,
Wachs ME, Kumpe DA. Role of TIPS as a bridge to hepatic transplantation in
Budd-Chiari syndrome. Journal of Vascular & Interventional Radiology, 10(6):
799-805, June, 1999.
80. Everson GT, Jensen D, Craig JR, van Leeuwen D, Bain V, Ehrinpreis M, Albert
D, Joh T, Witt K, Consensus Interferon Study Group*. Efficacy of Interferon
treatment for patients with chronic hepatitis C: comparison of response in
cirrhotic, fibrotics, or nonfibrotic. Hepatology, July, 1999. 30:1;271-276.
81. Shrestha R, Trouillot T, Everson GT. Endoscopic Stenting of the Gallbladder for
Symptomatic Gallbladder Disease in Patients with End-stage Liver Disease
Awaiting Orthotopic Liver Transplantation. Liver Transplantation and Surgery,
July 1999; 5:4 275-281.
82. Everson GT, Trouillot T, Wachs M, Bak T, Steinberg T, Kam I, Shrestha R, Stegal
M. Early Steroid Withdrawal in Liver Transplantation is Safe and Beneficial.
Liver Transplantation and Surgery, July 1999; 5; 4; S48-S57.
83. Jenny E, Heathcote L, James S, Mullen KD, Hauser SC, Rosenblate H, Albert D,
Consensus Interferon Study Group*. Chronic Hepatitis C Virus Patients with
Breakthroughs During Interferon Treatment Can Successfully Be Retreated with
Consensus Interferon. Hepatology, August 1999:30:2; 562-566.
84. Keeffe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR,
Donovan J, Albert D, Consensus Interferon Study Group*. Utility of hepatitis C
virus serotypes in predicting response to treatment of chronic hepatitis C.
Cytokines, Cellular & Molecularly Therapy, August 1999; 5,207-210.
85. Trouillot T, Shrestha R, Kam I, Wachs M, Everson GT. Successful Withdrawal of
Prednisone After Adult Liver Transplantation for Autoimmune Hepatitis. Liver
Transplantation and Surgery, 5:5; 375-380, September, 1999.
86. Dienstag J, Schiff E, Wright T, Perrillo R, Hie-Won H, Goodman Z, Crowthers L,
Condreay L, Woessner M,
Rubin M, Brown N, U.S. Lamivudine Investigator
Group. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United
States. New England Journal of Medicine, 341:17; 1256-1263, October, 1999.
87. Everson GT, Lasseter KC, Anderson KE, Bauer LA,
Johnson A, Anziano RJ, Smolarek TA, Turncliff RZ.
Ziprasidone in Subjects with Normal and Impaired
Journal of Clinical Pharmacology, 49, 1:7, 21S-26S
1999.
Carithens RL, Wilner KD,
The Pharmacokinetics of
Hepatic Function. British
supplemental, December,
31
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
88. Jensen DM, Krawitt EL, Keefe EB, Hollinger FB, James SP, Mullen K, Everson
GT, Hoefs JC, Fromm H, Black M, Foust RT, Pimstone NR, Heathcote EJ, Albert
D, Consensus Interferon Study Group*. Biochemical and Viral Response to
Consensus Interferon (CIFN) Therapy in Chronic Hepatitis C Patients: Effect of
Baseline Viral
Concentration.
American Journal of Gastroenterology,
94(12):3583-8, December, 1999.
89. McHutchison J, Blatt L, Medina M, Craig J, Conrad A, Schiff E, Tong M,
*Consensus Interferon Study Group. Measurement of serum hyaluronic acid in
patients with chronic hepatitis C and its relationship to liver histology. Journal of
Gastroenterology and Hepatology, 2000(15); 945-951.
90. Keeffe E, Dusheiko G, Tong M, Hollinger FB, Heathcote EJ, McHutchison J,
Albert D, Consensus Interferon Study Group*. Genotype Does Not Affect
Pattern of HCV RNA Decrease Among Responders During Interferon Treatment
of Chronis Hepatitis C. Cytokines, Cellular & Molecular Therapy 1999; 5:211-216.
91. Keeffe E, Dusheiko G, James S, Mullen K, Everson GT, Pimstone N, Donovan J,
Albert D, Consensus Interferon Study Group*. Utility of Hepatitis C Virus
Stereotypes in Predicting Response to Treatment of Chronic Hepatitis C.
Cytokines, Cellular & Molecular Therapy 1999; 5:207-210.
92. Trotter JF, Wachs M, Trouillot T, Steinberg T, Bak T, Everson GT, Kam I.
Evaluation of 100 Patients for Living Donor Liver Transplantation. Liver
Transplantation 6 ;( 3):290-295, May, 2000.
93. Stephens J, Everson GT, McCune C, Kam I, Wachs M, Haney J, Bartlett S,
Franklin W. Fatal transfer of malignant melanoma from multi-organ donor to four
allograft recipients. Transplantation 70(1):232-236, July, 2000.
94. Nieto Y, Russ P, Everson GT, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ.
Acute pancreatitis during immunosuppression with tacrolimus following an
allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2002
Jul: 26(1):109-11.
95. Trotter JF, Bak T, Wachs M, Everson GT, Kam I. Combined liver-pancreas
transplantation in a patient with primary sclerosing cholangitis and insulindependent diabetes mellitus. Transplantation, 2000 Nov27; 70 (8):1469-71.
96. Everson GT. Maintenance Interferon for Chronic Hepatitis C: More Issues Than
Answers? Editorial for Hepatology, 2000, Aug:32(2):426-8.
97. Beresford, T, Everson GT. Liver Transplantation for Alcoholic Liver Disease: Bias,
Beliefs, 6 Month Rule, and Relapse; But “Where’s the Data?” Liver
Transplantation, Editorial, August 2000.
98. Everson GT. Increasing Incidence and Pre-transplantation Screening of
Hepatocellular Carcinoma. Liver Transplantation Suppl 2; 6 (6):S2-S10,
November, 2000.
32
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
99. Everson GT. Advances and controversies in liver transplantation: Hepatocellular
cancer (Part I), viral hepatitis (Part II), and living donor liver transplantation in
adults (Part III). Liver Transpl. 2000 Nov; 6(6 Suppl 2);S1
100. Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson GT, Reindollar R, Fried
M, Purdum PP, Jensen D, Smith C, Lee W, Pedder S, DePamphilis J. Efficacy
and Safety of Pegylated Interferon -2a Compared with Interferon -2a in NonCirrhotic Patients with Chronic Hepatitis C. Hepatology; 33(2):2: 433-438,
February, 2001.
101. Trotter JF, Everson GT. Benign focal lesions of the liver. Clin Liver Dis. 2001
Feb;5(1):17-42.
102. Trotter JF, Wachs M, Bak T, Trouillot TE, Stolpman N, Everson GT, Kam I. Liver
Transplantation Using Sirolumus and Minimal Corticosteroids (3-Day Taper).
Liver Transplantation 7(4):343-351, April, 2001.
103. Sokol R, Straka MS, Dahl R, Devereaux MW, Yerushalmi B. Gumpricht E,
Everson GT. Role of Oxidant Stress in the Permability Transition Induced in Rat
Hepatic Mitochondria by Hydrophobic Bile Acids. Pediatr Res, 2001, April;
49(4):519-31.
104. Sandhu IS, Jarvis C, Everson GT. Total parenteral nutrition and cholestasis. Clin
Liver Dis. 1999 Aug;3(3):489-508, viii.
105. Trotter JF, Wachs M, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson GT.
Dyslipidemia During Sirolumus Therapy in Liver Transplant Recipients Occurs
With Concomitant Cyclosporine But Not Tacrolimus. Liver Transplantation 7;
(5):401-408, May, 2001.
106. Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Haeussler J, Guerciolini R,
Showalter R, Everson GT. Orlistat maintains biliary lipid composition and
hepatobiliary function in obese subjects undergoing moderate weight loss. Am J
Gastroenterol. 2001 Jun;96(6):1888-94.
107. Trotter JF, Talamantes M, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M,
Everson GT, Kam I. Right Hepatic Lobe Donation for Living Donor Liver
Transplantation: Impact on Donor Quality of Life. Liver Transplantation. 7(6);
485-493; June, 2001.
108. Fontana R, Hann HW, Wright T, Everson GT, Baker A, Schiff E, Riely C,
Anschuetz G, Hopkins M, Brown N, Lamivudine Compassionate Use Study
Group. A US Compassionate Use Study of Lamivudine Treatment in Nontransplant Candidates with Decompensate Hepatitis B Virus-Related Cirrhosis.
Liver Transplantation 7(6); 504-510; June, 2001.
33
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
109. Lindsay K, Trepo C, Heintges T, Shiffman M, Gordon S, Hoefs J, Schiff E,
Goodman Z, Laughlin M, Yao R,
Albrecht J, for the Hepatitis Interventional
Therapy Group.* A Randomized, Double-Blind Trial Comparing Pegylated
Interferon Alfa-2b to Interferon Alfa-2b as Initial Treatment for Chronic Hepatitis
C. Hepatology 34(2); 395-409; August, 2001.
110. Bak T, Wachs M, Trotter J, Everson G, Troulliot T, Kugelmas M, Steinberg T,
Kam I. Adult-to-adult living donor liver transplantation using right-lobe grafts:
Results and lessons learned from a single-center experience. Liver
Transplantation 7(8):680-686, August 2001.
111. Trouillot TE, Pace DG, McKinley C, Cockey L, Zhi J, Haeussler J, Guerciolini R,
Showalter R, Everson GT.
Orlistat maintains biliary composition and
hepatobiliary function in obese subjects undergoing moderate weight loss.
American Journal of Gastroenterology June, 2001; 96:1888-1894.
112. Manns M, McHuthison J, Gordon S, Rustgi V, Shiffman M, Reindollar R,
Goodman Z, Koury K, Ling M, Albrecht J, International Hepatitis Interventional
Therapy Group*. Peg interferon alfa-2b plus Ribavirin with interferonalfa-2b plus
Ribavirin for initial treatment of chronic hepatitis C: a randomized trial. The
Lancet 358; (9286); 958-965, September, 2001.
113. Trotter JF, Everson GT.
Transference of Peanut Allergy Through Liver
Transplantation. Liver Transplantation, Letter to the Editors, October, 2001.
114. Trotter JF, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T,
Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C
Patients: Short-Term Results Compared to Cadaveric Transplantation. Am J
Tranpl 2001; 1S:316A.
115. Trotter JF, Everson GT, Bock SA, Wachs M, Bak T, Kam I. Transference of
peanut allergy through liver transplantation. Liver Transpl. 2001 Dec;7(12):10889.
116. Shiffman M, Brown R, Olthoff K, Everson GT, Miller C, Siegler M, Hoofnagel J.
Living Donor Liver Transplantation: Summary of a Conference at the National
Institute of Health. Liver Transplantation February, 2002; 8:2; 174-188.
117. Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas, Kam I, Everson GT. Living
donor liver transplant recipients achieve relatively higher immunosuppressant
blood levels than cadaveric recipients. Liver Transplantation 8(3):212-218, March
2002.
118. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-Adult transplantation of the
right hepatic lobe from a living donor.
New Engl J Med, 2002 April
4;346(14):1074-82.
34
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
119. Bostom A, Brown R, Chavers B, Coffman T, Cosia F, Culver K, Curtis J,
Danovitch G, Everson G, First R, Garvey C, Grimm R, Hertz M, Hricik D,
Hunsicker L, Ibrahim H, Kasiske B, Kennedy M, Klag M, Knatterud M,
Koschigawa J, Lake J, Light J, Matas A, McDiarmid S, Miller L, Payne W,
Rosenson R, Sutherland D, Tajani A, Textor S, Valantine H Wiesner R.
Prevention
of
Post-Transplant
Cardiovascular
Disease-Report
and
Recommendations of an Ad Hoc Group. American Journal of Transplantation,
2002, 2:491-500.
120. Everson GT. Treatment of Hepatitis C. American College of Gastroenterology,
2002 Annual Postgraduate Course Board Review and Update in Clinical
Gastroenterology: 571-597, October, 2002.
121. Everson GT. Impact of immunosuppressive therapy on recurrence of hepatitis C.
Liver Transpl. 2002 Oct;8(10 Suppl 1):S19-27.
122. Hann HW, Fontana RJ, Wright T, Everson G, Baker A, Schiff ER, Riely C,
Anschuetz G, Gardner SD, Brown N, Griffiths D; United States Lamivudine
Compassionate Use Study Group. A United States compassionate use study of
lamivudine treatment in nontransplantation candidates with decompensated
hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan;9(1):49-56.
123. Everson GT.
MELD:
The Answer or Just More Questions? Editorial,
Gastroenterology 2003; 124(1):251-4.
124. Trotter JT, Mackenzie S, Wachs M, Bak T, Steinberg T, Polsky P, Kam I, Everson
GT. Comprehensive Cost Comparison of Adult-to-Adult Right Hepatic Lobe
Living-Donor
Liver
Transplantation
with
Cadaveric
Transplantation.
Transplantation 2003 Feb 27, 75(4):473-6.
125. Everson, GT. Treating Hepatitis, An Update. Gastroenterology & Endoscopy
News, April, 2003.
126. Dunkelberg J, Trotter J, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson G
and I. Kam. Sirolimus as primary immunosuppression in liver transplantation is
not associated with hepatic artery or wound complications. Liver Transplantation
2003 May; 9(5):463-468.
127. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T,
Wachs ME, Bak T, Kam I, Everson GT. Different Immunosuppressive Regimens
and Recurrence of Primary Sclerosing Cholangitis after Liver Transplantation.
Liver Transplantation 2003 Jul; 9:727-732.
128. Hayashi PH, Forman L, Steinberg T, Bak T, Wachs M, Kugelmas M, Everson GT,
Kam I, Trotter JF. Model of End-Stage Liver Disease Score Does Not Predict
Patient or Graft Survival in Living Donor Liver Transplant Recipients. Liver
Transplantation 2003;9:737-740.
129. Everson GT, Trotter J. Role of Adult Living Donor Liver Transplantation (LDLT) in
Patients with Hepatitis C. Liver Transplantation 2003 9S1:S64-S68.
35
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
130. Everson GT. Treatment of Patients with Hepatitis C Virus on the Waiting List.
Liver Transplantation 2003 9(11):S3:S90-S94.
131. Everson GT, Trotter JF, Kugelmas M, Forman L. Immunosuppression in liver
transplantation. Minerva Chir. 2003 Oct;58(5):725-40.
132. Shiffman ML, Vargas HE, Everson GT. Controversies in the Management of
Hepatitis C Virus Infection After Liver Transplantation. Liver Transplantation
2003 9(11):1129-1144.
133. Kugelmas M, Osgood M, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson
GT. Hepatitis C Virus Therapy, Hepatocyte Drug Metabolism, and Risk for Acute
Cellular Rejections. Liver Transplantation 2003;9(11):1159-65.
134. Hayashi P, Trotter JF, Everson GT. Hepatocellular Carcinoma Extension Into the
Right Atrium. Liver Transplantation 2003 9(11):1225-1226.
135. Mandell, MS, Durham J, Kumpe D, Trotter JF, Everson GT, Niemann CU. The
Effects of Desflurane and Propofol on Portosystemic Pressure in Patients with
Portal Hypertension. Anesth. Analg 2003; Dec; 97(6):1573-7.
136. Medeiros BC, Seligman PA, Everson GT, Forman LM. Possible autoimmune
thrombocytopenia associated with pegylated interferon-alpha2a plus ribavarin
treatment for hepatitis C. J Clin Gastroenterol. 2004 Jan;38(1):84-6.
137. Hayashi PH, Trotter JF, Forman L, Kugelmas M, Steinberg T, Russ P, Wachs M,
Bak T, Kam I, Everson GT. Impact of Pretransplant Diagnosis of Hepatocellular
Carcinoma on Cadaveric Liver Allocation in the Era of MELD. Liver Transpl
2004; 10:42-48.
138. Shiffman JL, Di Bisceglie AM, Lindsay KL, Morishima C, Wrigth EC, Everson GT,
Lok AS, Morgan TR, Bonkovsky HL, Lee WM, Dienstag JL, Ghany MC, Goodman
ZD, Everhart JE, HALT-C Trial Group. Peginterferon Alfa-2a and Ribavirin in
Patients with Chronic Hepatitis C Who Have Failed Prior Treatment.
Gastroenterology 2004;126:1015-1023.
139. Fontana RJ, Everson GT, Tuteja S, Vargas HE, Shiffman ML. Controversies in
the Management of Hepatitis C Patients with Advanced Fibrosis and Cirrhosis.
Clinical Gastroenterology and Hepatology 2004;2:183-197.
140. Hayashi PH, Ludkowski M, Forman LM, Osgood M, Johnson S, Kugelmas M,
Trotter JF, Bak T, Wachs M, Kam I, Durham J, Everson GT. Hepatic artery
chemoembolization for hepatocellular carcinoma in patients listed for liver
transplantation. Am J Transplant. 2004 May;4(5):782-7.
141. Hayashi PH, Mao J, Slater K, Liao R, Durham JD, Carroll J, Everson GT, Kam I,
Forman LM. Atrial septal perforation from TIPS stent migration. J Vasc Interv
Radiol. 2004 Jun;15(6):629-32.
36
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
142. Everson GT. Treatment of Chronic Hepatitis C in Patients with Decompensated
Cirrhosis. Rev Gastroenterol Disord. 2004; 4(suppl 1): S31-S38.
143. Demetriou AA, Brown RS Jr, Busuttil RW, Fair J, McGuire BM, Rosenthal P,
AmEsch JS 2nd, Lerut J, Nyberg SL, Salizzoni M, Fagan EA, de Hemptinne B,
Broelsch CE, Muraca M, Salmeron JM, Rabkin JM, Metselaar HJ, Pratt D, De La
Mata M,McChesney LP, Everson GT, Lavin PT, Stevens AC, Pitkin Z, Solomon
BA. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in
treating acute liver failure. Ann Surg. 2004 May;239(5):660-7; discussion 667-70.
144. Everson GT. Shifting Paradigms in Liver Transplantation.
Conference, New Orleans, May 2004.
Syllabus, DDW
145. Everson GT. Treatment of chronic hepatitis C in patients with decompensated
cirrhosis. Rev Gastroenterol Disord 2004; 4 Suppl 1:S31-8.
146. Kleinschmidt-DeMaster BK, Mardar B, Levi M, Laird SP, McNutt T, Escott E,
Everson GT, Tyler KL. Naturally-Acquired West Nile Virus Encephalomyelitis in
Transplant Recipients: Clinical, Laboratory, Diagnostic, and Neuropathological
Features. Ach Neurol 2004 Aug; 61 (8):1210-20.
147. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic Palliation of Polycystic
Liver Disease. Surg Endosc 2005 Jan; 19(1):130-2.
148. Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML,
Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC,
Everhart JE. Evolution of the HALT-C Trial Pegylated Interferon as Maintenance
Therapy for Chronic Hepatitis C in Previous Interferon Nonresponders. Controlled
Clinical Trials 2004. 25(5):472-92.
149. Everson GT, Taylor MR, Doctor RB.
Hepatology 2004 Oct 40 (4): 774-782.
Polycystic Disease of the Liver.
150. Brown RS, Everson GT. What You Should Know About Living Donor Liver
Transplantation. Patient Care, December 2004:26-33.
151. Everson GT, Taylor MR. Management of Polycystic Liver Disease.
Gastroenterology Reports; 2005 Feb; 7(1):19-25.
Current
152. Everson, GT. Hepatitis C Therapy With Pegylated Interferon. Literature Review,
June 2004.
153. Rothman AL, Morishima C, Bonkovsky HL, Polyak SJ, Ray R, DiBisceglie AM,
Lindsay KL, Malet PF, Chang M, Gretch DR, Sullivan DG, Bhan AK, Wright EC,
Koziel MJ, and the HALT C Trial Group. Associations Among Clinical,
Immunological, and Viral Quasispecies Measurements in Advanced Chronic
Hepatitis C. Hepatology 2005;41(3):617-25.
37
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
154. Morishima C, Ray R, Polyak SJ, Sullivan DG, Di Bisceglie AM, Malet PF,
Bonkovsky HL, Bhan AK, Gretch DR, Doherty MC, Rothmann AL, Koziel MJ,
Lindsay KL, and the HALT-C Trail Group. HCV-specific Immunity in Advanced
Disease is Associated with Non-response to Antiviral Therapy. Submitted to
Publications Committee, NIDDK, and Roche
155. Di Bisceglie AM, Sterling R, Chung R, Everhart JE, Dienstag JL, Bonkovsky HL,
Wright EC, Everson GT, Lindsay KL, Lok ASF, Lee WM, Morgan TR, Ghany MG,
Gretch DR, and the HALT-C Trial Group. Serum Alpha-Fetoprotein Levels in
Patients with Advanced Hepatitis C: Results from the HALT-C Trial. J Hepatol
2005 Sep; 43(3):434-41.
156. Robinson RN, Stiegmann GV, Everson, GT. Laparoscopic palliation of polycystic
liver disease. Surgical Endoscopy (2005) 19:130-132.
157. Everson GT. Management of cirrhosis due to chronic hepatitis C. Journal of
Hepatology 42 (2005) S65-S74.
158. Everson GT. Should we treat patients with chronic hepatitis C on the waiting list?
Journal of Hepatology 2005; April 42(4):456-62.
159. Everson GT. Antiviral Therapy in the Liver Transplant Candidate and Recipient.
Current Hepatitis Report 2005; 4:75-82.
160. Polyak SJ, Sullivan DG, Austin MA, Dai JY, Shuhart MC, Lindsay KL, Bonkovsky
HL, Di Bisceglie AM, Lee WM, Morishima C, Gretch DR, and the HALT-C Trial
Group. Comparison of Amplification Enzymes for Hepatitis C Virus Quasispecies
Analysis. Virol J 2005; 2(1):41.
161. Everson GT. Treatment of Hepatitis C in the Patient with Decompensated
Cirrhosis. Clin Gastroenterol Hepatol, 2005;3:S106-S112.
162. Trotter J, Pieramici E, Everson GT. Chronic Albumin Infusions to Achieve
Diuresis in Patients with Ascites Who Are Not Candidates for Transjugular
Intrahepatic Portosystemic Shunt (TIPS). Digestive Dis and Sciences 2005 Jul;
50(7):1356-60.
163. Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey, B, Ray C.
Treatment of Advanced Hepatitis C with a Low Accelerating Dosage Regimen
(LADR) Of Antiviral Therapy. Hepatology 2005, 42(2):255-262.
164. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart
JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag
JL, Morishima C, the HALT-C Trial Group. Predicting cirrhosis in Patients with
Hepatitis C Based on Standard Laboratory Tests: Results of the HALT-C Cohort.
Hepatology 2005, 42(2):282-292.
38
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
165. Fontana RJ, Bieliauskas LA, Back-Madruga C, Lindsay KL, Kronfol Z, Lok AS,
Padmanabhan L, the HALT-C Trail Group. Cognitive Function in Hepatitis C
Patients with Advanced Fibrosis Enrolled in the HALT-C Trial. J of Hepatology
2005; 43:614-622.
166. Everson GT. Treatment of Hepatitis C in Patients who have Decompensated
Cirrhosis. Clinics in Liver Disease 2005, Aug; 9(3):473-86.
167. Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, Pockros
PJ, Govindarajan S, Lopez-Talavera JC, Heathcote EJ. Histologic benefits of
Peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced
fibrosis or cirrhosis. Submitted J Hepatology, October 2005.
168. Swize L, Everson GT. Chronic Hepatitis C: Reasons to Treat Besides the Liver.
Submitted, July 2005.
169. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH,
Dickson RC, Garcia A, Moore PA, Yu R, Subramanian GM. Modulation of
interferon Specific Gene Expression by Albumin-interferon-Alpha-Experienced
Patients with Chronic Hepatitis C. Antivir Ther, 2006; 11(7):901-8.
170. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL,
Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Interferon Alfa-2b
Continuous Long-Term Therapy Versus Repeated 24-Week Cycles for Retreating
Chronic Hepatitis C. Submitted to Hepatology, 2005.
171. Sieja KS, Everson GT. De Novo Hepatocellular Carcinoma in a Patient with
Chronic Hepatitis C 5 years after Sustained Virologic Response to
Interferon/Ribavirin Therapy. Dig Dis Sci, 2006 Mar;51(3):600-2.
172. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson
GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR, and the
HALT-C Trial Group. Portal Hypertensive Gastropathy in Chronic Hepatitis C
Patients with Bridging Fibrosis and Compensated Cirrhosis: Results from the
HALT-C Trial. Am J Gastroenterol 2006; 101(5):983-92.
173. Kulig CC, Beresford TP, Everson GT. Rapid, Accurate, and Sensitive Fatty Acid
Ethyl Ester Determination by Gas Chromatography-Mass Spectometry. J Lab
Clin Med. 2006 Mar;147(3):133-8.
174. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT,
Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR
and the HALT-C Trial Group. The Prevalence and Risk Factors Associated with
Esophageal Varices in Subjects with Hepatitis C and Advanced Fibrosis.
Gastrointest Endosc 2006;64:855-64.
39
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
175. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH,
Dickson RC, Post AB, Redfield RR, Davis GL, Neumann AU, Osborn BL,
Freimuth WW, Subramanian GM. A Phase I/II study evaluating escalating doses
of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis
C patients who have failed previous interferon-alpha-based therapy. Antivir Ther.
2006;11(1):35-45.
176. Schlenker C, Trotter JF, Shah RJ, Everson G, Chen YK, Antillon D, Antillon MR.
Endoscopic gallbladder stent placement for treatment of symptomatic
cholelithiasis in patients with end-stage liver disease. Am J Gastroenterol. 2006
Feb;101(2):278-83.
177. Morishima C, Polyak SJ, Ray R, Doherty MC, Di Bisceglie Am, Malet PF,
Bonkovsky HL, Sullivan DG, Gretch DR, Rothman AL, Koziel MJ, Lindsay KL,
and the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis Trial Group.
Hepatitis C Virus-Specific Immune Responses and the Quasi-Species Variability
at Baseline are Associated with Nonresponse to Antiviral Therapy during
Advanced Hepatitis C. J Infect Dis 2006; 193(7):931-40.
178. Morishima C, Morgan TR, Everhart JE, Wright EC, Shiffman ML, Everson GT,
Lindsay KL, Lok ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL,
Ghany MG, Gretch DR, and the HALT-C Trial Group. HCV RNA Detection by
TMA during the hepatitis C antiviral long-term treatment against cirrhosis (HALTC) Trial. Hepatology, 2006; 44:360-367.
179. Arrazola L, Moonka D, Gish RG, Everson GT. Model for End-Stage Liver
Disease (MELD) Exception for Polycystic Liver Disease. Liver Transplantation
2006;12:S110-S111.
180. Bonkovsky HL , Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR,
Rogers TE, Banner BF, Sterling RK, Donovan JA, Fontana RJ, DiBisceglie AM,
Ghany MG, Morishima C, and the HALT-C Trial Group. Roles of Iron and HFE
Mutations on Severity and Response to Therapy during Retreatment of Advanced
Chronic Hepatitis C. Gastroenterology 2006;131:1440-1451.
181. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML,
Kahn JA, Lok ASF, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG,
Morishima C, and the HALT-C Trial Group. Impact of Disease Severity on
Outcome of Antiviral Therapy for Chronic Hepatitis C: Lessons from the HALT-C
Trial. Hepatology 2006;44:1675-1684.
182. Trotter JF, Campsen J, Bak T, Wachs M, Forman L, Everson G, Kam I.
Outcomes of donor evaluations for adult-to-adult right hepatic lobe living donor
liver transplantation. Am J Transplant 2006; Aug;6(8):1882-9.
183. Everson GT, Kulig CC. Antiviral Therapy for Hepatitis C in the Setting of Liver
Transplantation. Current Treatment Options in Gastro 2006;9:520-529.
184. Everson GT. Everolimus and mTOR Inhibitors in Liver Transplantation: Opening
the “Box.” Liver Transplantation 2006;12:1571-1573.
40
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
185. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT,
Lok ASF, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, and the HALT C Trial
Group.
Systemic Factors Associated with Virologic Nonresponse to
Peginterferon/Ribavirin Retreatment of Choronic Hepatitis C. Submitted to J
Hepatology, December 2006.
186. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA,
Kugelmas M, Doherty MC, Wright EC, and the HALT-C Trial Group. Quantitation
of Liver Function in Patients with Fibrosis and Compensated Cirrhosis due to
Chronic Hepatitis C: Results from the HALT-C Trial. In preparation, 2006.
187. Bieliauskas LA, Back-Madruga C, Lindsay KL, Wright EC, Kronfol Z, Lok ASF,
Fontana RJ, and the HALT-C Trial Group.
Cognitive Reserve and
Neuropsychological Functioning in Patients Infected with Hepatitis C. Submitted
to Journal of International Neuropsychological Society, May 2006.
188. Fontana RJ, Sanyal AJ, Mehta S, Doherty MC, Neuschwander-Tetri BA, Everson
GT, Kahn JA, Malet PF, Sheikh MY, Chung RT, Ghany MG, Gretch DR; HALT-C
Trial Group. Portal hypertensive gastropathy in chronic hepatitis C patients with
bridging fibrosis and compensated cirrhosis: results from the HALT-C trial.
Am J Gastroenterol. 2006 May;101(5):983-92.
189. Morfin JP, Kulig C, Everson GT, Beresford T. Controlling for Serum Albumin
Improves the Correlations Between Serum-Fatty Acid Ethyl Esters and Blood
Ethanol Level. Alcohol Clin Exp Res 2007;31(2):265-8.
190. Terrault NA, Shiffman ML, Lok AS, Saab S, Tong L, Brown RS, Everson GT,
Reddy KR, Farr JH, Kulik LM, Pruett TL, Seeff LB. Outcomes in Hepatitis C Virus
Infected Recipients of Living Donor Versus Deceased Donor Liver
Transplantation. Liver Transpl 2007;13(1):122-129.
191. Shiffman ML, Ghany MG, Morgan TR, Wright EC, Everson GT, Lindsay KL, Lok
ASF, Bonkovsky HL, Di Bisceglie AM, Lee WM, Dienstag JL, Gretch DR, and the
HALT-C Trial Group. Impact of reducing peginterferon alfa-2a and ribavirin dose
on virologic response in patients with chronic hepatitis C. Gastroenterology
2007;132(1):103-12.
192. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Greenson JK, Shiffman ML,
Everson GT, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR,
Ghany MG, Morishima C; HALT-C Trial Group. Hepatic steatosis in hepatitis C:
comparison of diabetic and nondiabetic patients in the hepatitis C antiviral longterm treatment against cirrhosis trial. Clin Gastroenterol Hepatol. 2007
Feb;5(2):245-54.
193. Bonkovsky HL, Snow KK, Malet PF, Back-Madruga C, Fontana RJ, Sterling RJ,
Kulig CC, Di Bisceglie AM, Morgan TR, Dienstag JL, Everhart JE, Ghany MG,
Gretch DR and the HALT C Trial Group. Health-Related Quality of Life in
Patients with Chronic Hepatitis C and Advanced Fibrosis. J Hepatology 2007;
46(3):420-31.
41
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
194. Balan V, Nelson DR, Sulkowski MS, Everson GT, Lambiase LR, Wiesner RH,
Dickson RC, Garcia A, Moore PA, Yu R, Subramanian GM. Modulation of
interferon-specific gene expression by albumin-interferon-alpha in interferonalpha-experienced patients with chronic hepatitis C. Antivir Ther 2006;11(7):9018.
195. Everson GT, Martucci MA, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, The
HALT-C Trial Group. Portal-systemic shunting in patients with fibrosis or cirrhosis
due to chronic hepatitis C: the minimal model for measuring cholate clearances
and shunt. Aliment Pharmacol Ther, 2007 Aug 1:26(3):401-10.
196. Everson GT, Hoefs JC, Seeff LB, Bonkovsky HL, Naishadham D, Shiffman ML,
Kahn JA, Lok AS, Di Bisceglie AM, Lee WM, Dienstag JL, Ghany MG, Morishima
C; HALT-C Trial Group. Impact of disease severity on outcome of antiviral
therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology. 2006
Dec;44(6):1675-84.
197. Sanyal AJ, Fontana RJ, Di Bisceglie AM, Everhart JE, Doherty MC, Everson GT,
Donovan JA, Malet PF, Mehta S, Sheikh MY, Reid AE, Ghany MG, Gretch DR,
Halt-C Trial Group. The prevalence and risk factors associated with esophageal
varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc.
2006 Dec;64(6):855-64.
198. Everson GT, Shiffman ML, Morgan TR, Hoefs JC, Sterling RK, Wagner DA,
Kugelmas M, Curto T, Wright EC, and the HALT-C Trial Group. The Spectrum of
Hepatic Functional Impairment in Patients with Fibrosis and Compensated
Cirrhosis Due to Chronic Hepatitis C: Results from the HALT-C Trial. Aliment
Pharmacol Ther. 2008 May;27(9):798-809.
199. Fontana RJ, Bieliauskas LA, Lindsay KL, Back-Madruga C, Wright EC, Snow KK,
Lok ASF, Kronfol Z, Padmanabhan L, and the HALT-C Trial Group. Cognitive
function does not worsen during peginterferon and ribavirin treatment of chronic
hepatitis C. Accepted by JINS, 2007.
200. McHutchison J, Everson GT. Interferon Alfa-2b Continuous Long-term Therapy
Versus Repeated 24-Week Cycles for Retreating Chronic Hepatitis C. Submitted
to Antiviral Therapy, January 2007.
201. Hoevenaren IA, Wester R, Schrier RW, McFann K, Doctor RB, Drenth JPH,
Everson GT. Polycystic liver: Clinical characteristics of patients with isolated
polycystic liver disease compared to patients with polycystic liver and autosomal
dominant polycystic kidney disease. Liver International, 2008 Feb;28(2):264-70.
202. Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC,
Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow
KK, Dienstag JL, the HALT-C Trial Group. Prolonged therapy of advanced
chronic hepatitis C with low-dose Peginterferon. N Engl J Med. 2008 Dec
4;359(23):2429-41. PMID: 19052125
42
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
203. McHutchison JG, Patel K, Schiff ER, Gitlin N, Mur RE, Everson GT, Carithers RL
Jr, Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK; International
Hepatitis Interventional Therapy Group.
Clinical trial: interferon alpha-2b
continuous long-term therapy vs. repeated 24-week cycles for re-treating chronic
hepatitis C. Aliment Pharmacol Ther. 2008 Mar 1;27(5):422-32.
204. Seeff LB, Curto TM, Szabo G, Everson GT, Bonkovsky HL, Dienstag JL,
Shiffman ML, Lindsay KL, Lok AS, DiBisceglie AM, Lee WM, Ghany MG, HALT-C
Trial Group. Herbal product use by person enrolled in the Hepatitis C Antiviral
Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology, 2007 Dec
21:47(2): 605-612.
205. Everson GT, Balart L, Lee SS, Reindollar RW, Shiffman ML, Minuk GY, Pockros
PJ, Govindarajan S, Lentz E, Heathcote EJ.
Histologic benefits of virologic
response to peginterferon alfa-2a monotherapy in patients with hepatitis C and
advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther. Apr
1;27(7):542-51.
206. Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT,
Lock AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG, HALT C Trial.
Blunted cytopenias and weight loss: new correlates of virologic null response to
re-treatment of chronic hepatitis C.
Clin Gastroenterol Hepatol. 2008
Feb;6(2):234-41.
207. Everson GT. Is early steroid withdrawal after liver transplantation feasible with
tacrolimus monotherapy?
Nat Clin Pract Gastroenterol Hepatol. 2008
Apr;5(4):194-5.
208. Everson GT, Helmke SM, Doctor B. Advances in management of polycystic liver
disease. Expert Rev Gastroenterol Hepatology. 2008 Aug ;2(4):563-76. PMID:
19072404
209. Hoffenberg AS, Kulig C, Everson G, Brimhall B, Beresford T. Validation
characteristics of fatty acid ethyl ester (FAEE) concentrations in alcohol misuse.
In preparation, May 2008.
210. Pockros PJ, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW,
Ghalib R, Harrison S, Nyberg L, Shiffman ML, Najera I, Chan A, Hill G. R1626
plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA
and significant antiviral synergy in combination with ribavirin. Hepatology 2008
Aug;48(2):385-97.
211. Morishima C, Morgan TR, Everhart JE, Wright EC, Apodaca MC, Gretch DR,
Shiffman ML, Everson GT, Lindsay KL, Lee WM, Lok AS, Dienstag JL, Ghany
MG, Curto TM; HALT-C Trial Group. Interpretation of positive transcriptionmediated amplification test results from polymerase chain reaction-negative
samples obtained after treatment of chronic hepatitis C. Hepatology 2008
Nov;48(5):1412-9.
43
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
212. Pockros P, Nelson D, Godofsky E, Rodriguez-Torres M, Everson GT, Fried MW,
Ghalib R, Harrison S, Nyberg L, Shiffman ML, Chan A, Hill G. High relapse rate
seen at week 72 for patients treated with R1626 combination therapy.
Hepatology 2008 Oct;48(4):1349-50.
213. Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA,
Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a
critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol. 2009
Apr;7(4):397-414; quiz 366. PMID: 19114127
214. Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA,
Desanto JL, Curto TM, Wright EC; HALT-C Trial Group. Quantitative tests of liver
function measure hepatic improvement after sustained virological response:
results from the HALT-C trial. Aliment Pharmacol Ther. 2009 Mar 1;29(5):589601. PMID: 19053983
215. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson
GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C,
Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and
associated risk factors in hepatitis C-related advanced liver disease.
Gastroenterology 2009 Jan;136(1):138-48. PMID: 18848939
216. Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK,
Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG,
Morishima C; HALT-C Trial Group. Evolution of hepatic steatosis in patients with
advanced hepatitis C: results from the hepatitis C antiviral long-term treatment
against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun;49(6):1828-37. PMID:
19291787
217. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman
R, McNair L, Alam J, Muir AJ; PROVE1 Study Team.
Telaprevir with
peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med.
2009 Apr 30;360(18):1827-38. PMID: 19403902
218. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC,
Hutchinson AA, Crenshaw AT, Bashirova A, Carrington M, Dotrang M, Sterling
RK, Lindsay KL, Fontana RJ, Lee WM, Di Bisceglie AM, Ghany MG, Gretch DR,
Chanock SJ, Chung RT, O'Brien TR; HALT-C Trial Group. Variants in interferonalpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin
for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral longterm treatment against cirrhosis trial. Hepatology. 2009 Jun;49(6):1847-58.
PMID: 19434718
219. Burton JR Jr, Everson GT. HCV NS5B polymerase inhibitors. Clin Liver Dis.
2009 Aug;13(3):453-65. PMID: 19628161.
44
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
220. Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC,
Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan
TR, Dienstag JL; HALT-C Trial Group. Predicting Clinical and Histological
Outcomes Based on Standard Laboratory Tests In Advanced Chronic Hepatitis
C. Gastroenterology. 2009 Sep 17. PMID: 19766643
221. Heller JC, Prochazka AV, Everson GT, Forman LM. Long-term management
after liver transplantation: primary care physician versus hepatologist. Liver
Transpl. 2009 Oct;15(10):1330-5. PMID: 19790168
222. Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee
WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima
C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with
lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009
Nov;50(5):1360-9. PMID: 19676128
223. Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright
EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL,
Ghany MG; HALT-C Trial Group. Effect of HCV RNA Suppression During
Peginterferon Alfa-2A Maintenance Therapy on Clinical Outcomes in the HALT-C
Trial. Gastroenterology. 2009 Dec;137(6):1986-94. PMID: 19747918
224. Goodman ZD, Stoddard AM, Bonkovsky HL, Fontana RJ, Ghany MG, Morgan
TR, Wright EC, Brunt EM, Kleiner DE, Shiffman ML, Everson GT, Lindsay KL,
Dienstag JL, Morishima C; HALT-C Trial Group. Fibrosis progression in chronic
hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology. 2009
Dec;50(6):1738-49. PMID: 19824074
225. Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson
GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE; HALT-C Trial
Group.
Factors that Determine the Development and Progression of
Gastroesophageal Varices in Patients with Chronic Hepatitis C.
Gastroenterology. 2010; 138:2321-2331. PMID: 20211180.
226. Pierucci-Lagha A, Covault J, Bonkovsky HL, Feinn R, Abreu C, Sterling RK,
Fontana RJ, Kranzler HR; HALT-C Trial Group.
A functional serotonin
transporter gene polymorphism and depressive effects associated with interferonalpha treatment. Psychosomatics. 2010 Mar;51(2):137-48. PMID: 20332289
227. Merion RM, Shearon TH, Berg CL, Everhart JE, Abecassis MM, Shaked A, Fisher
RA, Trotter JF, Brown RS Jr, Terrault NA, Hayashi PH, Hong JC; A2ALL Study
Group. Hospitalization rates before and after adult-to-adult living donor or
deceased donor liver transplantation. Ann Surg. 2010 Mar;251(3):542-9. PMID:
20130466.
228. Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML,
Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group.
Complication Rate of Percutaneous Liver Biopsies among Persons with
Advanced Chronic Liver Disease in the HALT-C Trial. Clin Gastroenterol
Hepatol. 2010; 8:877-883. PMID: 20362695.
45
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
229. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH,
Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman
RS, Adda N, Di Bisceglie AM; PROVE3 Study Team. Telaprevir for previously
treated chronic HCV infection. N Engl J Med. 2010 Apr 8;362(14):1292-303.
PMID: 20375406.
230. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R,
Rasenack JW, Kryczka W, Lee CM, Bain VG, Pianko S, Patel K, Cronin PW,
Pulkstenis E, Subramanian GM, McHutchison JG; ACHIEVE-2/3 Study Team.
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized
trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology
2010 Oct;139(4):1267-76. PMID: 20600017
231. Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR,
Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E,
Subramanian GM, McHutchison JG; ACHIEVE-1 Study Team. Albinterferon Alfa2b was not inferior to pegylated interferon-α in a randomized trial of patients with
chronic hepatitis C virus genotype 1. Gastroenterology. 2010 Oct;139(4):125766. PMID: 20600013
232. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS,
Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V,
Brass CA, Albrecht JK, Bronowicki JP; SPRINT-2 Investigators. Boceprevir for
untreated chronic HCV genotype 1 infection. N Engl J Med. 2011 Mar
31;364(13):1195-206. PMID: 21449783
233. Dibaise JK, Richmond BK, Ziessman HH, Everson GT, Fanelli RD, Maurer A,
Ouyang A, Shamamian P, Simons RJ, Wall LA, Weida TJ, Tulchinsky M.
Cholecystokinin-Cholescintigraphy in Adults: Consensus Recommendations of an
Interdisciplinary Panel. Clin Gastroenterol Hepatol. 2011 Feb 17. PMID:
21334459
234. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson
GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C,
Morgan TR; HALT-C Trial Group. Maintenance peginterferon therapy and other
factors associated with hepatocellular carcinoma in patients with advanced
hepatitis C. Gastroenterology. 2011 Mar;140(3):840-849. PMID: 21129375
235. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton
MR, the PHOENIX Study Group. PHOENIX: A randomized controlled trial of
peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver
transplantation for hepatitis C virus. Liver Transpl 17:528-538, 2011. PMID:
21506241
236. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT,
Fried MW, Adler M, Reesink H, Martin M, Sankoh AJ, Adda N, Kauffman RS,
George S, Wright CI, Poordad F, the ILLUMINATE Study Team. Duration of
Initial Telaprevir Treatment for HCV Infection. Accepted for publication, N Engl J
Med. 2011.
46
MANUSCRIPTS IN PEER REVIEWED JOURNALS (cont’d)
237. Trotter JF, Gillespie BW, Terrault NA, Abecassis MM, Merion RM, Brown RS Jr,
Olthoff KM, Hayashi PH, Berg CL, Fisher RA, Everhart JE; Adult-to-Adult Living
Donor Liver Transplantation Cohort Study Group. Laboratory test results after
living liver donation in the adult-to-adult living donor liver transplantation cohort
study. Liver Transpl. 2011 Apr;17(4):409-17. doi: 10.1002/lt.22246. PMID:
21445924
238. Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima
C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes
and portal tract cells predict progression and outcomes of patients with advanced
chronic hepatitis C. Gastroenterology. 2011 May;140(5):1490-500.e3. Epub 2011
Feb 15. PMID: 21335007
239. Di Bisceglie AM, Stoddard AM, Dienstag JL, Shiffman ML, Seeff LB, Bonkovsky
HL, Morishima C, Wright EC, Snow KK, Lee WM, Fontana RJ, Morgan TR,
Ghany MG; HALT-C Trial Group. Excess mortality in patients with advanced
chronic hepatitis C treated with long-term peginterferon. Hepatology. 2011
Apr;53(4):1100-8. doi: 10.1002/hep.24169. PMID: 21480316
240. Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY,
Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM,
Lok AS, Morishima C, Stoddard AM, Everhart JE; for the HALT-C Trial Group. A
prospective study of the rate of progression in compensated, histologically
advanced chronic hepatitis C.
Hepatology. 2011 Apr 21. doi:
10.1002/hep.24370. [Epub ahead of print] PMID: 21520194
241. Berg CL, Merion RM, Shearon TH, Olthoff KM, Brown RS Jr, Baker TB, Everson
GT, Hong JC, Terrault N, Hayashi PH, Fisher RA, Everhart JE. Liver transplant
recipient survival benefit with living donation in the MELD allocation era.
Hepatology. 2011 Jun 17. doi: 10.1002/hep.24494. PMID:21688284
242. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej
NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D,
Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL,
George S, Kauffman RS, Zeuzem S; ADVANCE Study Team. Telaprevir for
previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011 Jun
23;364(25):2405-16. PMID:21696307
243. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R,
Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Müllhaupt B, Pockros P,
Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D,
Boogaerts G, Polo R, Picchio G, Beumont M; REALIZE Study Team. Telaprevir
for retreatment of HCV infection. N Engl J Med 2011 Jun 23;364(25):2417-28.
PMID: 21696308
CD ROM DEVELOPMENT
MKSAP XII Audio, Oakstone Publishing, LLC, Birmingham, AL, produced 12/2000
47
WEB-BASED CHAPTERS
Everson GT. Hepatitis C: Choices, Part Two: Treatment Approaches; Chapter 8
Allopathic (Western) Medicine; Section 3, Options for Those Whose Initial Treatment
Failed To Clear the Hepatitis C Virus; Hepatitis C Choices, 2001;
http://www.hepcchallenges.org/manual
Russ PD, Elliott DE, Durham JD, Garg K, Moubry R, Wachs ME, Kam I, Bak TE,
Everson GT, Trotter J, Trouillot T, Kugelmas M,: Liver Transplantation, Complications.
eMedicine
Journal
(serial
online).
2002.
Available
at:
http://www.emedicine.com/radio/topic883.htm
Russ PD, Elliott DE, Durham JD, Garg K, Moubry R, Wachs ME, Kam I, Bak TE,
Everson GT, Trotter J, Trouillot T, Kugelmas M. Liver Transplantation, Complications.
eMedicine
Journal,
2004
(serial
online).
Available
at:
http://www.emedicine.com/rc/index.htm
BOOK CHAPTERS
1. Everson GT, Kern F Jr. Bile acid metabolism. In Advances in Hepatology.
IT MacSween, Editor. Churchill Livingstone, London, pp. 171-189, 1983.
2.
Everson GT. Liver diseases. In Medical Therapeutics. RW Schrier, Editor. Raven
Press, New York, Ch. 12, pp. 264-278, 1984.
3.
Everson GT. Dual isotope techniques for measuring bile acid kinetics in healthy
man: Stable isotopes and serum sampling. In Enterohepatic Circulation of Bile
Acids and Sterol Metabolism. MTP Press Ltd., Falcon Press, Lancaster, England,
Ch. 34, pp 259-261, 1985.
4.
Everson GT. Diseases of the small intestine.
In Decision Making in
Gastroenterology. JS Levine, Editor. BC Decker, Inc., Toronto, pp. 200-236, 1985.
5.
Everson GT. Diseases of the biliary tree. In Decision Making in Gastroenterology.
JS Levine, Editor. BC Decker, Inc., Toronto, pp. 236-258, 1985.
6.
Everson GT, Kern F Jr. Effects of female sex hormones on bile acids. In Trends in
Hepatology. L Bianchi, Gerok, and H Popper, Editors. MTP Press Ltd., Falcon
Press, Lancaster, England, pp. 67-70, 1985.
7.
Everson GT. Bile acid synthesis by liver cell hybrids (rat): Studies of the regulation
of bile acid synthesis by dexamethasone.
In Bile Acids and the Liver.
G Baumgartner, A Stiehl, and W Gerok, Editors. MTP Press Ltd., Ch. 9, pp.
61-63, 1987.
8.
Everson GT. Disorders of motility of the biliary system. In Principles and Practice
of Gastroenterology and Hepatology. G Gitnick, Editor.
John Elsevier, pp.
872-893, 1988.
48
BOOK CHAPTERS (cont’d)
9. Everson GT. Liver and biliary tract disease. In Current Medical Therapy, Second
Edition. R Schrier, Editor. Raven Press, New York, pp. 303-323, 1989.
10. Everson GT. Characteristics of hepatic cysts. In Advances in the Pathogenesis of
Polycystic Kidney Disease. Carone and JW Dobbie, editors. Baxter Healthcare
Corporation/TP&T, Inc., Chicago, IL, pp. 77-78, 1990.
11. Everson GT. Section of: Diseases of the biliary tree. In Decision Making in
Gastroenterology. JS Levine, Editor. JS Levine, Editor. BC Decker, Inc., Toronto,
2nd Edition, pp. 318-341, 1992. Chapters include: Cholelithiasis: Ultrasonography
vs. oral cholecystography, Asymptomatic cholelithiasis, Symptomatic cholelithiasis,
Acute cholecystitis, Postcholecystectomy syndrome, Retained common duct
stones, Acute cholangitis, Sclerosing cholangitis, Cancer of the gallbladder and bile
ducts, Biliary stricture, Cystic lesions of the liver, Cystic lesions of the extrahepatic
biliary tree.
12. Everson GT. Diseases of the liver. In Decision Making in Gastroenterology
JS Levine, Editor.
BC Decker, Inc., Toronto, 2nd Edition, pp. 414-475, 1992.
Chapters included: Surgical risk in the patient with liver disease, Acute viral
hepatitis, Viral hepatitis during Pregnancy, Chronic hepatitis: diagnosis, Chronic
hepatitis:
therapy, hepatoxic drug reactions, Fulminant hepatic failure,
Granulomatous hepatitis, Hepatic consequences of circulatory failure, Fatty liver
(Steatosis), Alcoholic liver disease, Primary biliary cirrhosis, Ascites in liver
disease, Hepatic encephalopathy, Coagulopathy in liver disease, Hepatorenal
syndrome, spontaneous bacterial peritonitis, Variceal hemorrhage, Hemochromatosis, Wilson's disease, Alpha1-antitrypsin deficiency, The Porphyrias, Congenital
hyperbilirubinemias, Hepatic vein thrombosis, Portal vein thrombosis, Hepatic
abscess, Benign hepatic tumors, Hepatocellular carcinoma, Hepatocellular
carcinoma, Hepatic transplantation: selection of patients, Hepatic transplantation:
postoperative management, Hepatic transplantation: abnormal liver tests posttransplantation.
13. Everson GT. Disorders of motility of the biliary system. In Principles and Practice
of Gastroenterology and Hepatology, Editor Gary Gitnick, Daniel Hollander, I.
Michael Samloff, Leslie Schoenfield, and John M. Vierling, 2nd Edition, pp 873-893.
14. Everson GT, Kam I. Liver Transplantation: Current Status and Controversies. In
Advances in Internal Medicine, Editor Robert Schrier, vol. 42, pp. 505-553.
15. Bilir BM, Everson GT. Liver Transplantation. In GI/Liver Secrets, Editor Peter R.
McNally; Pub: Hanley & Belfus, Inc: Philadelphia; 1996, pp. 187-196.
16. Shrestha R, Everson GT. Gallbladder Disease. In GI/Liver Secrets, Editor Peter
R. McNally; Pub. Hanley & Belfus, Inc: Philadelphia; 1996, pp. 237-245.
17. Everson GT, Shrestha R,: Hepatic Encephalopathy, Editor Lawrence Brandt; Pub.
Current Medicine: Philadelphia; 1997, pp 14-29.
49
BOOK CHAPTERS (cont’d)
18. Everson GT, Shrestha R. Management of Fibrocystic Disease of the Liver. Medical
Management of Liver Disease. Ed. Krawitt, Marcel Dekker, Inc., 1999, chapter 32,
pp 445-462.
19. Everson GT, Shrestha R. Cystic Disorders of the Liver and Biliary Tree. Diseases
of the Liver. Ed. Bisceglie, Bacon. 1999.
20. Kam I, Everson T, Trouillot, Wachs M. Post-operative care: Immediate, Lippincott,
Williams and Wilkins. Transplantation of the Liver. Submitted June, 1999.
21. Sandhu I, Jarvis C, Everson GT. Total Parenteral Nutrition and Cholestasis.
Clinics in Liver Disease, August 1999: 3:3; 489-508.
22. Everson GT. Management of Hepatic Failure, Upper Gastrointestinal Bleeding,
and Lower Gastrointestinal Bleeding in the Intensive Care Unit. Editors David J.
Dries, M.S.E., M.D., FCCP, FCCM, Richard K. Albert, M.D., F.C.O.P., Society of
Critical Care Medicine and American College of Chest Physicians. ACCP-SCCM
Combined Critical Care Course, August, 1999. ISBN 0-916609-16-2.
23. Everson GT, Shrestha R.
Hepatic Encephalopathy.
Clinical Practice of
Gastroenterology. Ed Brandt. Pennsylvania: Current Medicine, Inc. Vol. 2 9991009, 1999.
24. Everson GT, Kam I. Postoperative Care: Immediate. Transplantation of the Liver,
Maddrey, Sorrell and Shiff editors. In Press, September, 2000.
25. Everson GT.
Biliary and Cholestatic Diseases.
Hepatology, In Press, May 2000.
Comprehensive Clinical
26. Trotter J, Everson GT. Benign Focal Lesions of the Liver. Clinics in Liver Disease.
Ed. Gaitlin and DiBisceglie. Philadelphia, WB Saunders Company, February
2001;5(1): 17- 42.
27. Everson GT, Kam I. Immediate Postoperative Care. Transplantation of the Liver,
3rd Edition. Ed. Maddrey, Schiff, Sorrell. Philadelphia: Lippincott Williams &
Wilkins. 2001. Chapter 10: 131-162.
28. Everson GT. Maintenance Immunosuppression for Liver Transplantation. Primer
on Transplantation. Ed. Norman and Turka. New Jersey: American Society of
Transplantation. 2001. Section VII, 591-596.
29. Everson GT. Natural History of Hepatitis C. Clinical Gastroenterology Diagnosis
and Therapeutics, Chapter 4:9-94, August, 2001.
30. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding,
and Hepatic Failure.
Ed. Wilhite.
Illinois: Society of Critical Care
Medicine/American College of Chest Physicians. 2002. Chapter, 327- 342;
Combined Critical Care Course, 2002.
50
BOOK CHAPTERS (cont’d)
31. Everson GT. Treatment Options for Those whose Initial treatment Failed to Clear
the Hepatitis C Virus. Hepatitis C Choices. Ed. Sandt and St. John. Hepatitis C
Caring Ambassadors Program. 2002: Chapter 8:104-114.
32. Everson GT. Natural History of Hepatitis C. Chronic Viral Hepatitis: Diagnosis and
Therapeutics. Ed. Koff and Wu. New Jersey: Humana Press. 2002, Chapter 4: 5994.
33. Everson GT, Trotter JF. Transplantation of the Liver. Disease of the Liver, Volume
2. Ed. Schiff, Sorrell, Maddrey. Pennsylvania: Lippincott, Williams, & Wilkins.
2003. Chapter 62:15851614.
34. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding,
and Hepatic Failure, Chapter, 289-302; American College of Chest Physicians,
Critical Care Board Review Course, 2003.
35. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding,
and Hepatic Failure, Chapter, American College of Chest Physicians, Critical Care
Board Review Course, 2004.
36. Everson GT, Membreno F. Biliary Diseases, Gallstones and Cystic Disease,
Chapter 28:435-450; Comprehensive Clinical Hepatology, 2nd Edition. Ed. Bacon,
O’Grady, DiBisceglie, Lake. Elsevier Mosby. Section IV: Chapter 28: 435-451 July
2005.
37. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding,
and Hepatic Failure, Chapter, 315-328; American College of Chest Physicians,
Critical Care Board Review Course, Northbrook, IL USA copyright 2005.
38. Everson GT. Hepatic Encephalopathy. Textbook of Critical Care, Fifth Edition.
Ed. Fink, Abraham, Vincent, Kochnek. Pennsylvania: Elsevier Saunders. 2005.
Chapter 119: 991-1002.
39. Everson GT. Treatment of Hepatitis C in Patients who have Decompensated
Cirrhosis. Clinics in Liver Disease. Ed. Keeffe, Gitlin. Pennsylvania: Elsevier
Saunders. 2005. Volume 9, number 3:473-486.
40. Everson GT, Membreno FE. Liver Transplantation: Indications, Contraindications
and Results. Chapter 25.2; Textbook of Hepatology: From Basic Science to
Clinical Practice, 2006.
41. Doctor RB, Nash Sr, Nichols MT, Everson GT. Fibrocystic Diesaeses of the Liver.
Zakim and Boyer’s Hepatology: A Textbook of Liver Disease, 5th Edition. Ed.
Boyer, Wright, Manns. Pennsylvania: Elsevier Saunders. 2006. Chapter 70:13291353.
42. Everson GT. Treatment of Chronic Hepatitis C in Patients with Cirrhosis. Hot
Topics in Viral Hepatitis. Difficult-to-treat patients with chronic hepatitis C (part
two), Editor-in-chief: Francesco Negro. Italy: FB Communications. 2006. Pages
13-18.
51
BOOK CHAPTERS (cont’d)
43. Everson GT. Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding,
and Hepatic Failure, Chapter, 159-172; American College of Chest Physicians,
Critical Care Board Review Course, Northbrook, IL USA copyright 2006.
44. Everson GT. Treatment of Patients with Compensated and Decompensated
Cirrhosis, Chaper. In 100 Key Questions on Hepatitis C. Spain: Permanyer
Publications, copyright 2008, pages 55-67.
45. Everson, GT. HCV in patients with advanced disease: do you treat them and do
you have any caveats? Clinical Dilemmas in Viral Liver Disease, Ed. Foster,
Reddy. Blackwell Publishing, Ltd. 2010. Chapter 25: 115-122.
BOOKS
1. Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide.
Hatherleigh Press, Inc., New York, NY, 1998.
Pub:
2.
Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 2nd Edition.
Pub: Hatherleigh Press, Inc., New York, NY 1999.
3.
Weinberg, H, Shump S, Everson GT. My Mom Has Hepatitis C. Pub: Hatherleigh
Press, Inc. New York, NY, 2000.
4.
Everson GT, Weinberg H. Living with Hepatitis B: S Survivor’s Guide.
Hatherleigh Press, Inc. New York, NY, 2001.
5.
Everson GT, Weinberg H. Living with Hemochromatosis, Expert Answers to Your
Questions About Iron Overload. Pub: Hatherleigh Press, Inc. New York, NY, 2003.
6.
Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 3rd Edition.
Pub: Hatherleigh Press, Inc., New York, NY 2002.
7.
Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 4th Edition.
Pub: Hatherleigh Press, Inc., New York, NY 2006.
8.
Everson GT, Trotter JF-Editors. Liver Transplantation. Challenging Controversies
and Topics. Humana Press, Totowa, NJ, 2009.
9.
Everson GT, Weinberg H. Living with Hepatitis C: A Survivor’s Guide, 5th edition.
Hatherleigh Press, Inc.,
Long Island City, NY 2009.
Pub:
OTHER ARTICLES
1. Everson GT, Trouillot T. Current Treatments in the Management of Viral Hepatitis.
Primary Care Special Edition, 3:2, 51-56, 1999.
2.
Everson GT, Treating Hepatitis C, An Update. Pub: McMahon Publishing Adapted
from Infectious Disease Special Addition and Gastroenterology & Endoscopy
News. Educational Service by Roche, 2003.
52
OTHER ARTICLES (cont’d)
3. Shiffman M Editor–in-Chief, Everson G-Faculty. Controversies in the Management
of Hepatitis C, CME Monograph, Virginia Commonwealth University Health System,
Scientific Communications, Publisher, 2003.
4.
Everson GT. Is early steroid withdrawal after liver transplantation feasible under
tacrolimus monotherapy? Nature Clin Pract Gastroenterol & Hepatology 2008, In
press.
5.
Everson GT. Interferon or Peginterferon with Ribavirin for treatment of hepatitis C
regarding liver transplantation. Report in US Gastroenterology 2008. In Press.
6.
Everson GT. Polycystic Liver Disease. Gastro & Hepatology, 4(3):179-181, March
2008.
7.
Everson GT, Pruett TL - Faculty Editors. Utilization of Hepatitis B core antibody
positive organ donor: risks, benefits and strategies. Continuing Medical Education
Newsletter, Release date 1/5/08. University of Kentucky Colleges of Pharmacy and
Medicine and CTI Clinical Trial and Consulting Services, Publishers.
8.
Everson GT, Pruett TL - Faculty Editors. Utilization of Hepatitis B core antibody
positive organ donor: risks, benefits and strategies. Continuing Medical Education
Newsletter, Release date 11/9/09. University of Kentucky Colleges of Pharmacy
and Medicine and CTI Clinical Trial and Consulting Services, Publishers.
ABSTRACTS
1. Everson GT, Kern F Jr. Validation and comparison of two methods for measuring
rate constants of gallbladder emptying in control and pregnant subjects. Clin Res,
28(2):275A, 1980.
2.
Everson GT, Johnson M, Kern F Jr. Gallbladder function in pregnancy: Increased
retention of bile from 8 am until midnight. Gastroenterology, 78(5 Pt 2):1162, 1980.
3.
Everson GT, McKinley C, Showalter R, Johnson M, DeMark B, Szczepanik-VanLeeuwen P, Klein P, Kern F. Bile acid (BA) kinetics and gallbladder (GB) function
in pregnancy: The apparent regulatory role of the gallbladder. Gastroenterology,
78(5 Pt 2):1162, 1980.
4.
Kern F, DeMark B, Szczepanik-VanLeeuwen P, Everson GT, Braverman D,
McKinley C, Showalter R, Klein P. Effects of contraceptive steroids (CS) on biliary
lipids and bile acid (BA) kinetics. Clin Res, 28(2):545A, 1980.
5.
Everson GT, Kern F Jr, McKinley C, Showalter R, DeMark B, Szczepanik-VanLeeuwen P, Klein P. A new technique for measuring storage and concentration of
bile acid in the gallbladder in intact subjects. Gastroenterology, 80(5 Pt 2):1144,
1981.
6.
Everson GT,
DeMark B,
Klein P,
Showalter R,
McKinley C,
Kern F Jr.
Measurement of cholic acid (CA) kinetics with 13C-CA using serum: Validation of
method. Gastroenterology, 80(5 Pt 2):1144, 1981.
53
ABSTRACTS (cont’d)
7. Everson GT, Lawson M, McKinley C, Showalter R, Kern F Jr. Differential effects of
liquid formula (F) and amino acid (AA) solutions on gallbladder (GB) emptying,
small bowel transit and biliary lipid secretion. Gastroenterology, 80(5 Pt 2):1145,
1981.
8.
Everson GT, Hachey D, Klein P, Showalter R, McKinley C, Kern F Jr. Simultaneous serum and biliary henodeoxycholic (CDC) kinetics using 13C-CDC.
Gastroenterology, 82(5 Pt 2):1051, 1982.
9.
Everson GT, Lawson M, McKinley C, Kern F Jr. Diminished gallbladder (GB)
concentrating ability in benign recurrent intrahepatic cholestasis (BRIC): A possible
clue to the underlying defect. Gastroenterology, 82(5 Pt 2):1051, 1982.
10. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I,
Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling,
gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Clin Res,
30(1):36A, 1982.
11. Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern
F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Gastroenterology,
82(5 Pt 2):1112, 1982.
12. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in
pregnancy. Clin Res, 31(1):30A, 1983.
13. Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in
pregnancy. Gastroenterology, 84(5 Pt 2):1146, 1983.
14. Everson GT. Failure of short-term intravenous S-adenosylmethionine (SAMe) to
reverse cholestasis in benign recurrent intrahepatic cholestasis (BRIC). Clin Res,
32(1):75A, 1984.
15. Everson GT. Steady-state chenodeoxycholic (CDCA) turnover (FTR) measured
from a single serum sample: Evaluation of a double stable isotope technique.
Clin Res, 32(1):75A, 1984.
16. Everson GT, Fennessey P. A significant advance in the measurement of chenodeoxycholic acid (CDCA) kinetics in healthy man: A double label stable isotope
technique using serum. Gastroenterology, 86(5 Pt 2):1071, 1984.
17. Everson GT, Fausel C, Lawson M, Kern F Jr. Chronic premarin administration does
not alter gallbladder function, bile acid kinetics, or biliary lipid secretion in
postmenopausal women. Hepatology, 4(5):1069, 1984.
18. Everson GT, Polokoff M. Quantitation of bile acid synthesis in hybridomas by gas
chromatography/mass spectrometry/stable isotope radiometry (GC/MS/IR):
Suppression of cholic acid synthesis by dexamethasone plus insulin. Hepatology,
4(5):1066, 1984.
54
ABSTRACTS (cont’d)
19. Everson GT, Krawitt E. S-adenosylmethionine (SAMe) may be deleterious in
familial forms of Intrahepatic cholestasis (FIC). Hepatology, 4(5):1066, 1984.
20. Everson GT, Miles B, Farrell R. Oral contraceptive steroids (CS) depress the
synthesis of chenodeoxycholic acid (CDCA) in healthy women. Gastroenterology,
88(5 Pt 2):1657, 1985.
21. Everson GT, Polokoff M, Nemeth A. Bile acid synthesis in the human hepatoma
cell line, HepG2: Studies of the conversion of deuterium-labeled and isomers of
7-OH cholesterol to chenodeoxycholic (CDCA) and cholic acid (CA).
Gastroenterology, 88(5 Pt 2):1657, 1985.
22. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid
synthesis. Hepatology, 5(5):1022, 1985.
23. Kern F Jr, Everson GT, Showalter R, McKinley C, Fausel C. Contraceptive steroids
(CS) alter the regulatory mechanisms of cholesterol homeostasis and biliary lipid
secretion in healthy young women. Gastroenterology, 88(5 Pt 2):1670, 1985.
24. Everson GT, Nemeth A, Kourieran. A facile method for measuring carbon
monoxide (CO) production rates in intact man. Clin Res, 34(1):28A, 1986.
25. Everson GT, Polokoff M. Effect of dexamethasone on bile acid synthesis by
cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Clin Res,
34(1):28A, 1986.
26. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid
synthesis. Clin Res, 34(1):29A, 1986.
27. Everson GT, Polokoff MA. Effect of dexamethasone on bile acid synthesis by
cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Gastroenterology, 90(1 Pt 2):1724, 1986.
28. Everson GT, Nemeth A, Kourourian S. A method for measuring carbon monoxide
(CO) production rates in intact man. Gastroenterology, 90(1 Pt 2):1724, 1986.
29. Stiegmann GV, Everson GT, Sun J. Variceal size appears independent of shunt
fraction in a canine esophageal varices model. Hepatology, 6(5):1138, 1986.
30. Kern F Jr, Everson GT.
Chronic premarin administration increases biliary
cholesterol (CH) secretion and decreases chenodeoxycholic acid (CDCA) pool and
synthesis. Gastroenterology, 90(5 Pt 2):1738, 1986.
31. Everson GT, Morse L, Stiegmann G, Schmelter R. Determination of nutrient portal
shunt fraction using stable isotope labeled-bile acids: Validation studies. Clin Res,
35(1):184A, 1987.
32. Everson GT, Scherzinger A, Berger-Leff N, Manco-Johnson M, Gabow P. Polycystic liver disease (PKD): Validation of a method for measuring liver and cyst volume.
Clin Res, 35(1):184A, 1987.
55
ABSTRACTS (cont’d)
33. Everson GT, Leff N, Dixon D, Githens J, Pretorius D, Manco-Johnson M.
Gallbladder function is altered in sickle hemoglobinopathies (SH): Potential role in
gallstone formation. Gastroenterology, 92:1731, 1987.
34. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state
kinetics of bile acids. Hepatology, 7(5):1109, 1987.
35. Everson GT, Scherzinger A, Leff N, Lee E, Seibert J, Manco-Johnson M. Liver cell,
liver cyst and kidney volumes in subjects with autosomal dominant polycystic
kidney disease with liver cysts (ADPKD + LC). Hepatology, 7(5):1100, 1987.
36. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state
kinetics of bile acids. Presented at Aspen Conference on Hepatic Lipoprotein and
Cholesterol Metabolism, 1987.
37. Kern F, Everson GT. Mechanisms of effects of contraceptive steroids (CS) on
biliary cholesterol secretion. Gastroenterology, 92:1743, May 1987.
38. Junker L, Straka M, Zogg D, Everson GT, Davis R.
Regulation of rat liver
cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Hepatology,
7(5):1108, 1987.
39. Junker L, Straka MS, Zogg DL, Everson GT, Davis RA. Regulation of cholesterol
7-alpha hydroxylase by microsomal free cholesterol. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.
40. Everson GT, Leff N, Zogg D, Reichen J, Gabow P. Polycystic liver disease:
Quantitative assessment of hepatic and cyst function. Gastroenterology, 94(5 Pt
2):A538, 1988.
41. Everson GT, Kern F Jr. Mechanisms of gallstone formation in post-menopausal
women taking conjugated estrogens (Premarin). Gastroenterology, 94:A538, 1988.
42. Everson GT, Leff N, Brown WR, Emmett M. Characteristics of hepatic cysts in
autosomal dominant polycystic kidney disease (ADPKD). Hepatology, 8(5):1341,
1988.
43. Kern F Jr, Everson GT. Female sex steroid hormones and the pathogenesis of
cholesterol gallstones. Gastroenterology, 94(5 Pt 2):A554, 1988.
44. Kern F Jr, Everson GT. The effects of female sex steroid hormones on cholesterol
and bile acid metabolism. Presented at the Bengt Borgstrom Symposium,
Falsterbo, Sweden, May/June 1988.
45. Everson GT, Butler E, Trombley C. Effects of female steroid hormones on bile acid
synthesis by HepG2 cells. Clin Res, 37(1):111A, 1989.
46. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol
on biliary lipid metabolism in women taking conjugated estrogens. Clin Res,
37(1):111A, 1989.
56
ABSTRACTS (cont’d)
47. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol
on biliary lipid metabolism in women taking either conjugated estrogens
(PremarinR) or medroxyprogesterone (ProveraR). Gastroenterology, 96(5 Pt
2):A596, 1989.
48. Everson GT, Johnson A, Kaehny W, Duley I, Manco-Johnson M, Gabow P. Risk
factors for the development of hepatic cysts in autosomal dominant polycystic
kidney disease (ADPKD). Gastroenterology, 96(5 Pt 2):A144, 1989.
49. Zaccaro L, Sutherland E, Iwahashi M, Burnett R, Everson GT. Acute cholestasis
with taurolithocholate is due to direct reversible non-competitive inhibition of
sodium-dependent taurocholate uptake. Gastroenterology, 6(2):A675, May 1989.
50. Rector WG, DeRoche G, Everson GT. The relationship of portal-systemic shunting
and liver function to sodium retention in patients with alcoholic liver disease.
Hepatology, 10(4):587, 1989.
51. Everson GT.
Bile acid synthesis by HepG2 is regulated by insulin and
dexamethasone. Gastroenterology, 98(5 Pt 2):A585, May 1990.
52. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on
the enterohepatic circulation and metabolism of bile acids. Hepatology, 12(4):1005,
1990.
53. Everson GT, Valdivieso V, Covarrubias C, Espinosa R, Trombley C, Smith P.
Intrahepatic cholestasis of pregnancy:
Effects on bile acid metabolism.
Hepatology, 12(4 Pt 2):898, 1990.
54. Lewis F, Everson GT, White C, Adair O, Hossack K, Rector W. Plasma glucagon
concentration is related to liver function but not portal-systemic shunting, systemic
vascular resistance or urinary sodium excretion in patients with cirrhosis.
Hepatology, 12(4):855, 1990.
55. Everson GT, Ahnen D, Harper PC, Krawitt EL. Benign recurrent intrahepatic
cholestasis: Failure of S-adenosylmethionine therapy. Hepatology Elsewhere,
12(2):367, Aug 1990.
56. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on
gallbladder motility, intestinal transit, and the kinetics of bile acids. Clin Res,
36(1):95A, 1991.
57. Everson GT, Malik R, McKinley C.
Effects of norethindrone on bile acid
metabolism in healthy subjects and subjects post-cholecystectomy.
Gastroenterology, 100:A739, May 1991.
58. Everson GT, Daggy BP, McKinley C, Story JA. Study of mechanisms of the
hypocholesterolemic effect of psyllium in man. Circulation, 84(4 Suppl): II601, Oct
1991.
57
ABSTRACTS (cont’d)
59. Everson GT, Daggy BP, McKinley C, Story JA. Dietary fiber (psyllium) lowers LDL
cholesterol by stimulating bile acid synthesis in man. Hepatology, 14(4 Pt 2):148A,
1991.
60. Pinto PC, Everson GT, Rector WG Jr. Does progressive reduction in hepatic
metabolic capacity signal sodium retention in alcoholic cirrhosis? Hepatology, 14(4
Pt 2):86A, 1991.
61. Suleymanlar I, Suleymanlar G, Chan L, Everson GT, Karrer F, Schroter G, Kam I.
Early postoperative renal failure predicts survival after orthotopic liver
transplantation (OLTX). Hepatology, 14(4 Pt 2):288A, 1991.
62. Everson GT, Butler E, Showalter R, Trombley C. Glucocorticoid regulation of
human bile acid metabolism. Clin Res, 40(1):27A, 1992.
63. Lindsey KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag R, Perrillo R,
Goff J, Everson GT, Tamburro C, Albrecht J, Sanghvi B. Long-term Response to
Higher Doses of Interferon (IFN) Alfa- 2b Treatment of Patients with Chronic
Hepatitis C: A Randomized Multicenter Trial. Hepatology, 18(4 Pt 2):106, 1993.
64. Everson GT, Lezotte DL, Clark A, Kam I. Biochemical Profile in The First 21 Days
After Hepatic Transplantation: The Uncomplicated Course. Hepatology, 18(4 Pt
2):329, 1993.
65. Everson GT, McKinley C, Kam I. Quantitative Tests (QLFT) of Hepatic Function:
Assessment of Patients Prior to Hepatic Transplantation (OLTx). Hepatology, 18(4
Pt 2):330, 1993.
66. Everson GT, McKinley C, Showalter R, Shrestha R, Mills M. Characterizatio of
Hepatic Lipid Metabolism in Obese Subjects Entering a Weight Loss Treatment
Program. Hepatology, 18(4 Pt 2):310, 1993.
67. Stegall M, Everson GT, Karrer F, Schroter G, Kam I. Metabolic Complications After
Liver Transplantation: Diabetes and Hypercholesterolemia. ASTS Meeting, 1994.
68. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT.
Predictors of Dialysis in Liver Transplantation. ASTS Meeting, 1994.
69. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT.
Renal Failure and Dialysis as Predictors of Outcome in Liver Transplant Patients.
ASTS Meeting, 1994.
70. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I., The Clinical
Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver
Transplantation. ASTS Meeting, 1994.
71. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F.
The
Metabolic Basis for Cholesterol Gallstone Formation In Obese Women During
Weight Loss. Clinical Research, 42(1):75A, 1994.
58
ABSTRACTS (cont’d)
72. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson
GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women
with Autosomal Dominant Polycystic Disease (ADPD).
Clinical Research,
42(1):75A, 1994.
73. Everson GT, Shrestha R, McKinley C, Smith P. Complete Response to Interferon is
Associated with Improvement in Hepatic Function. Gastroenterology, 106(4):A889,
1994.
74. Shrestha R, McKinley C, Russ, P, Scherzinger A, Bonner R, Showalter R, Everson
G. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women with
Autosomal Dominant Polycystic Disease (ADPD). Gastroenterology, 106(4):A985,
1994.
75. Mills MR, Butler E, Trombley C, Everson GT. Characterization of Insulin-Induced
Inhibition of Bile Acid Synthesis by Cultured Human Hepatoblastoma Cells (Hep
G2). Gastroenterology, 106(4):A943, 1994.
76. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F. Weight
Loss in Obese Women Markedly Inhibits Bile Acid Synthesis. The Metabolic Basis
for Cholesterol Gallstone Formation? Gastroenterology, 106(4):A889, 1994.
77. Everson GT, Cippola T, McKinley C, Showalter R.
Hepatic Lipid Metabolism
During Severe Cholestasis: Lessons Learned from the Comprehensive Study of a
Single Patient. Gastroenterology, 106(4):A877, 1994.
78. Lindsay KL, Spencer G, Nicoloff J, Milestein S, Davis GL, Schiff E, Bodenheimer H,
Balart L, Dienstag J, Perrillo R, Tamburro C, Everson GT, Sanghvi B, Albrecht J.
Thyroid Peroxidase Antibody-A Potential Predictor of IFN-Associated Thyroid
Disease. Hepatology, 20 (4 Pt.2):168A, October 1994.
79. Everson GT, Bilir BM, Kam I, Karrer F, Mandell S, Katz J, Stegall M, Schroter G,
Steinberg T. Influence of Age on Patient Outcome and Graft Survival After Liver
Transplantation. Hepatology, 20 (4 Pt. 2):346A, October, 1994.
80. Shrestha R, McKinley C, Showalter R, Everson GT. Quantitative Liver Function
Tests (QLFTs) Define the Functional Severity of Liver Disease In Early Stage
Cirrhosis. Hepatology, 20 (4 Pt. 2):119A, October 1994.
81. Shrestha R, Bilir BM, Steinberg SE, Lee RE, Showalter RB, Kumpe DA, Everson
GT. CA 19-9 Is A Constituent of Normal Human Bile and Its Biliary Concentration
Does Not Correlate With Hepatobiliary Malignancy. Hepatology, 20 (4 Pt. 2):399A,
October 1994.
82. Lawrence SP, Lezotte DC, Durham JD, Everson GT, Bilir BM. The Course of
Thrombocytopenia of Cirrhosis After Transjugular Intrahepatic Portosystemic
Shunts. Hepatology, 20 (4 Pt. 2):368A, October 1994.
59
ABSTRACTS (cont’d)
83. Sokol RJ, McKim JM, Devereaux MW, Everson GT. Vitamin E Reduces Oxidant
Injury to Hepatic Mitochondria Caused by Intravenous Taurochenodeoxycholic Acid
in the Rat. Hepatology, 20 (4 Pt. 2):178A, October 1994.
84. Lee WM, Everson GT. Hepatitis Study Group. Does Hepatitis C Viral (HCV)
Genotype or Initial HCV RNA Titer Predict Induction of Response to Interferon Alfa
2a in Chronic Hepatitis C? Hepatology 1995; 22(4):176A.
85. Bilir BM, Durham JD, Kumpe DA, Karrer F, Hanks T, Ostrowska A, Kam I, Trujillo
N, Lear J, Trouillot T, Shrestha R, Everson GT. Critical Analysis of Intra-Splenic
Transplantation of Cryopreserved Human Hepatocytes in a Patient with Acute Liver
Failure. Hepatology 1995; 22(4):203A.
86. Katz JJ, Mandell MS, Barton B, House RM, Bilir BM, Everson GT, Zamudio S.
Preservation of CO2-Dependent Regulation of Cerebral Arterial Blood Flow
Velocity in End Stage Liver Disease. Hepatology 1995; 22(4):260A.
87. Bennet J, Bilir BM, Shrestha R, Kam I, Stegall M, Karrer F, Katz J, Mandell S,
Everson GT. Recovery from Central Pontine Myelinolysis in Patients with Hepatic
Failure and Orthotopic Liver Transplantation. Hepatology 1995; 22(4):394A.
88. Trouillot T, McKinley C, Showalter R, Everson GT. The Effect of Gender on
Gallbladder Motility in Obese and Non-Obese Subjects. Hepatology 1995;
22(4):502A.
89. Shrestha R, Durham JD, Kumpe DA, Bilir BM, DeRoche G, Showalter R, Rector W,
Everson GT. Outcome after Transjugular Intrahepatic Portal-Systemic Shunt for
Refractory Ascites in Patients with Advanced Cirrhosis. Hepatology 1995;
2(4):165A.
90. Shrestha R, Bilir BM, Everson GT, Steinberg SE. Endoscopic Stenting of
Gallbladder for Symptomatic Cholelithiasis in Patients with End Stage Liver
Disease Awaiting Orthotopic Liver Transplantation. Hepatology 1995; 22(4):490A.
91. Gordon SC, Everson GT, McHutchison JG, Reinus J, Regenstein F, Kaplan MM,
Koff RS, Fedorczyk D , Plasse T.
Chronic Hepatitis C in Patients Refractory to Recombinant Interferon Alfa 2B.
Hepatology 1995; 22(4):117A.
92. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson GT, Weiner
F, Plasse T, Fedorczyk D, Einstein A.
Treatment of Chronic Hepatitis C in Previously Untreated Patients. Hepatology
1995; 22(4):151A.
93. Hollinger FB, Tong MJ, Reddy KR, Lee WM, Pockros PJ, Heols JC, Keeffe E,
Heathcote JL, White H, Foust RT, Hensen DM, Krawitt EL, Fromm H, Black M,
Klein M, Lubina J, Manyak C, Blatt LM, and the Consensus Interferon Study
Group*, Baylor College of Medicine, The Consensus Interferon Study Sites and
Amgen Inc. A Phase 3 Study for the Treatment of Patients with Chronic Hepatitis C
(HCV) Infection with Consensus Interferon(CIFN).Hepatology Meeting, Rome, Italy.
60
ABSTRACTS (cont’d)
94. Wilner KD, Foulds GH, Hansen RA, Everson GT, McClain CJ. Multiple Dose
Pharmacokinetics of Sertraline in Subjects with Varying Degrees of Hepatic
Impairment. CINP Meeting, Melbourne, Australia, June 1996.
95. Bharadhwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall
M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to Alcohol Consumption
in Liver Transplant Recipients Followed for More Than One Year: Early Analysis of
a Comprehensive Psychosocial Evaluation. American Society of Transplant
Physicians Meeting, May 1996.
96. Trouillot T, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M,
Ford C, Steinberg T, Everson GT. Successful Steroid Withdrawal after Orthotopic
Liver Transplantation in Patients with Autoimmune Chronic Active Hepatitis.
American Society of Transplant Physicians Meeting, May 1996.
97. Taylor S, Shrestha R, Bilir B, Wachs M, Karrer F, Kam I, Stegall M, Ford C,
Steinberg T, Schroter G, Everson GT. Internalized Biliary Stenting Reduces the
Incidence of Biliary Tract Complications after Liver Transplantation. American
Society of Transplant Physicians Meeting, May 1996.
98. Shrestha R, Durham JD, Kumpe DA, Bilir BM, DeRoche G, Showalter R, Rector W,
Everson GT. Outcome after transjugular intrahepatic portal-systemic shunt for
refractory ascites in patients with advanced cirrhosis. AASLD Single Topic
Symposium Conference, Reston, VA, June 1996.
99. Stegall MD, Everson GT, Wachs M, Schroter G, Karrer F, Bilir B, Shrestha R, Kam
I. Prednisone withdrawal 14 days after adult liver transplantation with
mycophenolate mofetil (MM). Hepatology 1996; 24(4):174A.
100. Pockros PJ, Tong MJ, Lee WM, Van Leeuwen DJ, Keeffe E, Bala K, Killenberg PG,
Foust RT, Rosenblate HJ, Payne KM, Fromm H, Lesesne HR, Black M, Snyder R,
Gerrard T, Conrad A, Blatt LM, and the Consensus Interferon Study Group*.
Relationship between biochemical and virological response to type 1 interferon
therapy of chronic HCV infection. Hepatology 1996; 24(4): 155A.
101. Bilir B, Durham JD, Krystal J, Karrer F, Kumpe D, Ostrowska A, Guenette D,
Trouillot T, Shrestha R, Taylor S, Kam I, Everson GT. Transjugular intra-portal
transplantation of cryopreserved human hepatocytes in a patient with acute liver
failure. Hepatology 1996; 24(4):308A.
102. Bharadwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall
M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to alcohol consumption
in liver transplant recipients followed for more than one year: early analysis of a
comprehensive psychoscocial evaluation. Hepatology 1996; 24(4):244A.
103. Shrestha R, McKinley C, Showalter R, Marsano L, Vivian B, Everson GT.
Quantitative liver function tests (QLFTs) define functional severity and predice
decompensation of liver disease in early stage cirrhosis. Hepatology 1996;
24(4):300A.
61
ABSTRACTS (cont’d)
104. Colton J, Chapman A, Everson GT. Augmentation of the diuretic response to
furosemide by albumin in cirrhotic patients with ascites. Hepatology 1996;
24(4):446A.
105. Shrestha R, McKinley C, Showalter R, Bilir B, Durham J, Kumpe D, Krysl J,
Everson GT. Transjugular intrahepatic portosystemic shunts (TIPS) for ascites: the
prognostic and predictive value of quantitative liver function tests (QLFTs).
Hepatology 1996; 24(4):449A.
106. Sokol RJ, Devereaux MW, Straka MS, Everson GT. Melatonin attenuates
hydrophobic bile acid toxicity to isolated rat hepatocytes. Hepatology 1996;
24(4):338A.
107. Jensen DM, Blatt LM, Tong MJ, Lee WM, Mullen K, Hoefs JC, Keeffe E, Hollinger
FB, Heathcote EJL, White H, Foust RT, Krawitt EL, Fromm H, Black M, Albert D,
Gerrard T, and Consensus Interferon Study Group*. Treatment of high viral titer
chronic HCV patients with consensus interferon (CIFN) results in a significantly
greater number of sustained HCV RNA responders as compared to treatment with
-2b. Hepatology 1996; 24(4):275A.
108. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K,
Everson GT, Pimstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert
D, Gerrard T, and Consensus Interferon Study Group*. Differential response to
-2b in chronic HCV patients
infected with different HCV serotypes. Hepatology 1996; 24)4):275A.
109. Bilir BM, Durham JD, Shrestha R, Karrer FM, Everson GT. Percutaneous
hepatocyte transplantation in acute liver failure. J Investigative Med 1997;
45:161A.
110. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M,
Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver
transplantation in patients with autoimmune chronic active hepatitis. 1997 ASTP
Program and Abstracts issue, 16 Annual Meeting, 237A.
111. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I,
Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver
transplantation for alcoholic liver disease: long-term results. 1997 ASTP Program
and Abstracts issue, 16 Annual Meeting, 261A.
112. Shrestha R, Bilir B, Trouillot T, Stegall M, Wachs M, Steinberg T, Morgan C, Kam I,
Everson GT. Outcome of liver transplantation in chronic hepatitis B, eAg negative
patients using OKT3 induction and maintenance immunosuppression without
prednisone. 1997 ASTP Program and Abstracts issue, 16 Annual Meeting
113. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft
recipients: a controlled three year follow-up. 1997 ASTP Program and Abstracts
issue, 16 Annual Meeting, 262A.
62
ABSTRACTS (cont’d)
114. Stegall MD, Wachs ME, Kam I, Bilir B, Shrestha R, Karrer F, Everson GT.
Prednisone withdrawal 14 days after liver transplantation with mycophenolate : A
prospective trial of cyclosporine and tacrolimus. 1997 ASTP Program and
Abstracts issue, 16 Annual Meeting, 40A.
115. Craig JR, Bain VG, Ehrinpreis M, Doust R, Lee W, Smith CI, VanLeeuwen DJ, and
the Consensus Interferon Study Group*. Liver histology improves in both cirrhotic
and non-cirrhotic patients with chronic HCV infection following consensus interferon
(CIFN) therapy. Gastroenterology 1997; 112(4):A1248.
116. Jensen D, Shafritz D, Craig JR, Krawitt E, and the CIFN Study Group*. Nonresponders to CIFN show clinically relevant improvements in liver histology.
Gastroenterology 1997; 112(4):A1294.
117. Lee WM, Reddy KR, van Leeuwen DJ, Hollinger FB, and the Consensus Interferon
Study Group*. Undetectable HCV RNA concentrations at early time points predict
sustained virological responses after treatment with consensus interferon (CIFN).
Gastroenterology 1997; 112(4):A1317.
118. Pockros P, Bain V, Hunter E, Conrad A, Balart LA, Hollinger FB, and the
Consensus Interferon Study Group*. Rt-PCR and BDNA assays for hepatitis C
virus correlate at high but not low viral titers.
Gastroenterology 1997;
112(4):A1360.
119. Heathcote J, Keeffe E, Lee S, Feinman S, Tong M, and the Consensus Interferon
consensus interferon (CIFN) produces sustained responses in non-responders and
relapsers. Gastroenterology 1997; 112(4):A1280.
120. Keeffe EB, Hollinger FB, and the Consensus Interferon Study Group*. Consensus
interferon trials. Submitted to NIH Consensus Development Conference on the
Management of Hepatitis C.
121. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M,
Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver
transplantation in patients with autoimmune chronic active hepatitis. ILTS Meeting,
October 1997.
122. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft recipients:
a controlled three year follow-up. ILTS Meeting, October 1997.
123. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I,
Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver
transplantation for alcoholic liver disease: long-term results. ILTS Meeting, October
1997.
124. Shrestha R, Bilir B, Trouillot T, Stegall M, Wachs M, Steinberg T, Morgan C, Kam I,
Everson GT. Outcome of liver transplantation in chronic hepatitis B, eAg negative
patients using OKT3 induction and maintenance immunosuppression without
prednisone. ILTS Meeting, October 1997.
63
ABSTRACTS (cont’d)
125. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trepo C, Shiffman M,
Zeuzem S, Craxi A, Raffanel C, Reindollar R, Rizzetto M, and the International
Hepatitis Interventional Therapy Group (IHIT). Retreatment
of relapse after
interferon therapy for chronic hepatitis C: An international randomized controlled
trial of interferon plus ribavirin vs. interferon alone. Hepatology 1997; 26(4): 247A.
126. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T,
Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T.
Relapse to drinking after liver transplantation: failure of explant histology to predict
relapse. Hepatology 1997; 26(4): 472A.
127. Amponsah A, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I, Steinberg T,
Morgan C, Fey B, Ray C, Everson GT. Do first-week post-transplant plasma levels
of cyclosporine (neoral) or tacrolimus predict early rejection within first 30 days?
Hepatology 1997; 26(4): 236A.
128. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T,
Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T.
Correlation of explant histology with pre-transplant alcohol dependence (DSM IV).
Hepatology 1997; 26(4): 472A.
129. Trouillot TE, McKinley CL, Showalter RB, Everson GT. Gallbladder motility in
obese subjects after diet-induced weight loss relative to gallstone formation.
Hepatology 1997; 26(4): 399A.
130. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. The link
between weight loss, gallstones, and insulin action: a pathophysiologic study in
humans. Hepatology 1997; 26(4): 399A.
131. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. Hepatic
and total body insulin sensitivities are disassociated in obese subjects after dietinduced weight loss followed by isocaloric weight maintenance. Hepatology 1997;
26(4): 380A.
132. Shrestha R, Wachs M, Kam I, Karrer F, Steinberg T, Morgan C, Bilir B, Trouillot T,
Everson GT. Endoscopic management of biliary anastomotic strictures after
orthotopic liver transplantation. Hepatology 1997; 26(4): 598A.
133. Bilir BM, Guenette D, Ostrowska A, Durham J, Kumpe D, Krysl J, Shrestha R,
Trouillot T, Teitelbaum I, Everson GT. Percutaneous hepatocyte transplantation
(PHT) in liver failure. Hepatology 1997; 26(4): 252A.
134. Everson G, Craig JR, Jensen D, van Leeuwen DJ, and the Consensus Interferon
Study Group*. Cirrhotic patients demonstrate similar response pattern compared to
noncirrhotic patients when treated with consensus interferon. Hepatology 1997;
26(4): 422A.
64
ABSTRACTS (cont’d)
135. Stephens JK, Everson GT, McCune C, Kam I, Shrestha R, Bilir B, Wachs M, Haney
J, Franklin WA. Transmission of fatal malignant melanoma from a single donor to
multiple allograft recipients. United States and Canadian Academy of Pathology
Conference.
136. Stephens JK, Frost M, Everson GT, Steinberg T, and the University of Colorado
Liver Transplant Group. Post-transplant (OLT) liver pathology after rapid steroid
withdrawal (14 days): effects of immunosuppression
and hepatitis C (HCV).
United States and Canadian Academy of Pathology Conference; ILTS Program
137. Sandhu IS, Stephens J, Krysl J, Durham JD, Kumpe DA, Shrestha R, Trouillot TE,
Everson GT, Bilir BM. Utility of Transjugular Liver Biopsy Using Liver Access
Biopsy Automated Needle. Gastroenterology 1998: 114(4): A1332.
138. Bilir BM, Kumpe D, Krysl J, Guenette D, Ostrowska A, Everson GT, Shrestha R, Lin
TC, Cole W, Lear J, Durham JD. Hepatocyte Transplantation (HT) in Patients with
Liver Cirrhosis. Gastroenterology 1998; 114(4):A1212.
139. JS Goff, RF Hamman, FS Wamboldt, Everson GT, Shrestha R, Kam I, Wachs M,
Lezotte DC, Steinberg T, Talamantes M, Bilir BM. Quality of life after liver
transplantation in patients with hepatitis C. Gastroenterology 1998; 114(4):A1247.
140. Shrestha R, Wachs M, Kam I, Bilir B, Trouillot T, Everson GT. Endoscopic stenting
of the gallbladder for symptomatic cholelithiasis in patients with end-stage liver
disease awaiting orthotopic liver transplantation. American Society of Transplant
Physicians Meeting, May, 1998. (Not accepted/not published)
141. Shrestha R, Ryu R, Durham J, Krysl J, Kam I, Wachs M, Bilir B, Trouillot T,
Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to
transplantation in Budd-Chiari syndrome. Transplantation 1998; 65(12):S54.
142. Shrestha R, Wachs M, Kam I, Karrer F, Steinberg T, Morgan C, Bilir B, Trouillot T,
Everson GT. Endoscopic management of biliary anastomotic strictures after
orthotopic liver transplantation. American Society of Transplant Physicians Meeting,
May, 1998. (Not accepted/not published)
143. Stephens JK, Everson GT, McCune C, Kam I, Shrestha R, Bilir B, Wachs M, Haney
J, Franklin WA. DNA analysis by polymerase chain reaction assay (PCR)
establishes the donor origin of post-transplantation malignancy. American Society
of Transplant Physicians Meeting, May, 1998. (Not accepted/not published)
144. Talamantes M, Everson GT, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I,
Steinberg T, Morgan C, House R, Mandell S. Katz J, Fey B, Ray C. Successful
outcome after liver transplantation of patients with a high-risk at pre-transplant
psychosocial evaluation. Transplantation 1998; 65 (12): S52.
65
ABSTRACTS (cont’d)
145. Everson GT, Stephens J, Tannenbaum T, Amponsah A, Shrestha R, Trouillot T,
Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Mandell S, Katz J,
Beresford T. A controlled study of explant histology in liver transplant recipients
with pre-transplant alcohol dependence. American Society of Transplant Physicians
Meeting, May, 1998. (Not accepted/not published)
146. Everson GT, Shrestha R, Wachs M, KAM I, Bilir B, Trouillot T, Nold K, Mandell S,
Katz J, Fey B, Ray C, Steinberg T, Morgan C. Components of care responsible for
the rising costs incurred during the pre-transplant period in liver transplant
recipients. Transplantation 1998; 65 (12): S25.
147. Everson GT, Shrestha R, Trouillot T, Bilir B, Amponsah A, Wachs M, Stegall M,
Mandell S, Katz J, Steinberg
T, Morgan C, Fey B, Ray C, Kam I. Costs of
cyclosporine (Neoral) and tacroliums (Prograf) in the first year after liver
transplantation (OLT). Transplantation 1998; 65 (12): S51.
148. Everson GT, Stephens J, Tannenbaum M, Amponsah A, Shrestha R, Trouillot T,
Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Mandell S, Katz J,
Beresford T. Explant histology suggesting ongoing alcohol-induced injury fails to
predict relapse to drinking after liver transplantation. American Society of
Transplant Physicians Meeting, May, 1998. (Not accepted/not published).
149. Shivaram K, Winklhofer-Roob B, Straka M, Devereaux M, Everson GT, Mierau G,
Sokol R. The effect of idebenone, a coenzyme Q analogue, on hydrophobic bile
acid toxicity to isolated rat hepatocytes and hepatic mitochondria. Free Biology &
Medicine, March 1998; 25 (4/5):480-492.
150. Everson GT, Folan R, Goff J, Richman L, Ansel C, Trouillot T, Shrestha R,
McKinley C. The Colorado Hepatitis Treatment Group: Early results of the use of
combination interferon-alfa-2B (intron A) plus ribavirin (rebetrol) in the treatment of
non-responders. Hepatology October 1998, 476A.
151. Stephens JK, Kam I, Wachs M, Trouillot T, Thompson H, Frost M, Everson GT,
UCHSC Liver Transplant
Group, Departments of Pathology, Medicine,
Anesthesiology and Surgery. Post-transplant (OLT) liver pathology after rapid
steroid withdrawal (14 days): effect of immunosuppression and hepatitis C (HCV).
AASLD November 1999; Liver Transplantation and Surgery, October, 1999.
152. Everson GT, Trouillot T, Wachs M, Bak T, Kam I, Nedrow A, Stephens JK, UCHSC
Liver Transplant Group, Departments of Medicine, Surgery, Pathology and Tumor
Registry. Increased incidence of HCV-related hepatocellular (HCC) from 1988 to
1997 in the state of Colorado: Implications for liver transplantation (LTx). AST May,
1999; Liver Transplantation and Surgery, October, 1999; ILTS Program Abstracts.
153. Bak T, Everson GT, Wachs M, Trouillot T, Kam I, Departments of Surgery and
Hepatology. Living-donor liver transplantation for adults with fulimant hepatic
failure (FHF): an under-utilized resource? AST May, 1999; Liver Transplantation
and Surgery, October, 1999; ILTS Program Abstracts.
66
ABSTRACTS (cont’d)
154. Sato S, Everson GT, Trouillot TE, Chen M, Steinberg T, Bak T, Wachs ME, Kam I,
Departments of Surgery and Medicine. Effect of hepatitis C on survival in
orthotopic liver transplant recipients undergoing rapid steroid withdrawal. AST May
1999; Liver Transplantation and Surgery, October, 1999; ILTS Program Abstract.
155. Trouillot T, Wachs M, Kam I, Everson GT, Depts of Medicine and Surgery. Steadystate serum cholesterol levels after liver transplantation: effects of cyclosporine
(CSA) and tacrolimus (TAC) monotherapy. ILTS Program Abstracts, October, 1999.
156. Trouillot T, Steinberg T, Bak T, Talamantes M, Wachs M, Kam I, Everson GT.
Quality of life (QOL) after liver transplantation external validation of the NIDDK QOL
instrument. AST, International Hep C Conference, May, June, 1999; Liver
Transplantation and Surgery, October, 1999 and ILTS Program Abstracts.
157. Davis, GL, Schiff E, Marcellin P, Esteban Mur R, Goodman Z, Harvey J, Albrecht
JK, S Fang JW, University of Florida College of Medicine, Gainesville, University of
Miami Hospital, Miami, Hospital Beacon , FR; Hospital Valie Hebron, Spain; Armed
Forces Institute. Long-term continuous recombinant interferon alfa-2b (intron A)
versus repeated 24-week cycles for disease suppression in IFN-Relapsers with
chronic hepatitis C. AASLD Annual Meeting, Dallas, TX November, 1999.
158. Hann HW, Wright T, Baker A, Everson GT, Schiff E, Riely C, Riker-Hopkins M,
Harnedani A, Brown N. Lamivudine treatment for decompensated cirrhosis due to
hepatitis B: A multicenter longitudinal study. Submitted to DDW, 1999.
159. Fontana R, Hie-Won L Hann, Wright T, Everson GT, Baker A, Schiff E, Reily C,
Riker-Hopkins M, Harnedani A, Brown N, University of Michigan, Ann Arbor, MI,
Jefferson Medical College, Philadelphia, PA, United States Veterans Affairs
Medical Center, San Francisco, CA, University of Colorado Health Sciences
Center, Denver, CO University of Chicago, Chicago, IL, University of Miami, Miami,
FL, University of Tennessee,
Memphis, TN, Glaxo Wellcome, RTP, NC.
Lamivudine treatment of hepatitis B following liver transplantation: a multi-center
U.S. study. AST Transplant 2000 Joint Meeting.
160. Trotter JF, Wachs M, Nold K, Trouillot TE, Bak T, Steinberg T, Everson GT, Kam I,
University of Colorado Health Sciences Division of Gastroenterology/Hepatology/
Transplant Surgery/Office of Clinical Practice, Denver, CO. A comparison of
charges for organ acquisition: adult cadaveric vs. adult living donor transplantation.
AST Transplant 2000 Joint Meeting.
161. Trotter JF, Wachs M, Trouillot TE, Bak T, Steinberg T, Everson GT, Kam I,
University
of
Colorado
Health
Sciences
Division
of
Gastroenterology/Hepatology/Transplant Surgery, Denver, CO. The evaluation of
one-hundred potential recipients for liver donor liver transplantation.
AST
Transplant 2000 Joint Meeting.
162. Sim S, Wachs M, Kam I, Everson GT, Trouillot T, Steinberg T, Foraged E, Lin T,
Chen Y, Division of Gastroenterology & Hepatology, Transplant Surgery, University
of Colorado Health Sciences Center, Denver, CO. Liver transplant-related biliary
complications in the post T-tube era. AST Transplant 2000 Joint Meeting.
67
ABSTRACTS (cont’d)
163. Trouillot TE, Eckel R, Wachs M, Kam I, Bak T, Trotter JF, Everson GT, University
of Colorado Health Sciences Transplant Surgery, Denver, CO. Patterns of
dyslipidemia in patients on cyclosporine and tacrolimus monotherapy after liver
transplantation. AST Transplant 2000 Joint Meeting, 1999.
164. DiBisceglie A, Bonkovsky H, Dienstag J, Everson GT, Lindsay K, Gretch D, Hoefs
J, Lee W, Lok A, Tralka T, Shiffman M, Wright T. Design of the HALT-C trial
(hepatitis C antiviral long term treatment to prevent cirrhosis). Submitted to DDW
2000; In Press Gastroenterology, May, 2000.
165. Wachs M, Bak T, Everson GT, Trotter JF, Trouillot TE, Steinberg T, Kam I, Division
of Transplant Surgery, UCHSC, Denver, CO. Adult to Adult Living Donor Liver
Transplants Using a Right Hepatic Lobe. AST 2000 Joint Meeting, May, 2000.
166. Everson GT, Trouillot T, Trotter J, Skilbred J, Tomasi C, McKinley C, Halprin A, Fey
B, Ray C, Epp J. Treatment of Decompensated Cirrhotics with a Low-Accelerating
Dose Regimen of Interferon alfa-2b and Ribavirin (LADR): Safety and Efficacy.
AASLD Annual Meeting, October, 2000.
167. Trotter J, Wachs M, Bak T, Trouillot T, Everson GT, Kam I, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center, Denver, CO. Liver Transplantation with Using
Sirolimus and Three-Day Corticosteroid Taper. AASLD Annual Meeting, October,
2000.
168. Trotter J, Wachs M, Trouillot T, Bak T, Everson GT, Kam I, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center. The Effect of Living Donor Liver Transplantation
(LDLT) on Median Waiting Times for UNOS Status IIB Cadaveric Recipients at One
Center. AASLD Annual Meeting, October, 2000.
169. Stolpman N, Kam I, Wachs M, Bak T, Trouillot T, Trotter J, Steinberg T, Stephens
J, Everson GT. Mycophenolate Mofetil Does Not Lower the Incidence or Cost of
Rejection, Use of OKT3, or Improve Survival After Liver Transplantation and Rapid
(14d) Steroid Withdrawal. AASLD Annual Meeting, October, 2000.
170. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R,
McKinley C, University of Colorado School of Medicine and General Clinical
Research Center, Denver, CO. The Colorado Hepatitis Treatment Group:
Interferon-Alfa 2b (Intron A ) Plus Ribavirin (Rebetol) is Efficacious in Nonresponders to Prior Interferon Monotherapy. AASLD Annual Meeting October 2000.
171. Heimbach J, Wachs M, Bak T, Steinberg T, Stolpman N, Calkins C, Everson GT,
Kam I, Trotter J, University of Colorado Health Sciences Center, Denver, CO.
OKT-3 Does Not Increase the Incidence of Lymphoprolifeative Disease After Adult
Liver Transplantation. AASLD Annual Meeting, October, 2000.
68
ABSTRACTS (cont’d)
172. Trouillot T, Stolpman N, Wachs M, Bak T, Trotter J, Kam I, Everson GT, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center, Denver, CO. Mycophenolate Mofetil-Based
Immunosuppression Does Not Increase the Risk of Cytomegalovirus Disease in
Patients Treated with Rapid (14d) Steroid Withdrawal After Liver Transplantation.
AASLD Annual Meeting, October, 2000.
173. Stolpman N, Stephens J, Trouillot T, Trotter J, Kugelmas M, Wachs M, Bak T,
Steinberg T, Kam I, Everson GT. Apparent Slowing of Hepatitis C Recurrence and
Progression after Liver Transplantation Using Very Early (14d) Steroid Withdrawal.
AST Transplant 2001 Meeting, May, 2001.
174. Everson GT, Halprin A, Trouillot T, Trotter J, Kugelmas M, Skilbred J, Tomasi C,
McKinley C, Fey B, Ray C, Epp J, Department of Medicine, University of Colorado
School of Medicine, Denver, CO. Treatment of Decompensated Cirrhotics May
Reduce Recurrence of Hepatitis C After Liver Transplantation. AST Transplant
2001 Meeting, May, 2001.
175. Zeuzem S, Manns M, Rustgi V, Aurora S, Smith C, Shiffman M, Reddy R,
Reindollar R, Slaker D, Rai R, Keeffe E, International Interferon alfacon-1 Study
Group. Daily Interferon Alfazon-1 (Infergen) Therapy: Interim Results from an
Ongoing International Clinical Trial to Compare Daily Interferon Alfacon-1 Therapy
(9 mcg) for Treatment of Chronic Hepatitis C Virus. European Association for the
Study of the Liver Annual Conference, 2001.
176. Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T,
Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C
Patients: Short-Term Results Compared to Cadaveric Transplantation. AST
Transplant 2001 Meeting, May, 2001.
177. Talamantes M, Trotter J, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M,
Steinberg T, Everson GT, Kam I. Assessment of the Impact of Living Donor Liver
Transplantation on Quality of Life in Donors. AST Transplant 2001 Meeting, May,
2001.
178. Wachs M, Bak T, Everson GT, Trotter J, Trouillot T, Kugelmas M, Steinberg T,
McClure M, Brackett T, Kam I, Division of Transplant Surgery. Adult Living Donor
Liver Transplant: The University of Colorado Experience. AST Transplant 2001,
May, 2001.
179. Trotter J, Wachs M, Trouillot T, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus
is Not Associated with Hypercholesterolemia in the Absence of Prednisone in Liver
Transplant Recipients. AST Transplant 2001, May, 2001.
180. Shiffman M, Everson GT, Lindsay K, DiBisceglie A, Lok A, Bonkovsky H, Everhart
J, Dienstag J, Seeff L, Lee W, Wright L, Chihiro M, Ghany M, Morgan T, Hoofnagel
J. Retreatment of Interferon and Interferon-Ribavirin Non-Responders with Peginterferon-Alpha 2A and Ribavirin: Initial Results from the Lead-In Phase of the
HALT-C Trial. Hepatology 2001; 34(4):243A.
69
ABSTRACTS (cont’d)
181. Halprin A, Trotter J, Everson GT, Wachs M, Bak T, Kugelmas M, Kam I. PostTransplant Eradication of Hepatitis C by Pre-Transplant Treatment in Living Donor
Liver Transplant Recipients. AASLD, 2001.
182. Pauls T, Trotter J, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Increased
Immunosuppressant Levels in Hepatitis C Liver Transplant Recipients Receiving
Sirolimus. AASLD, 2001.
183. Dunkelberg J, Trotter J, Steinberg T, Wachs M, Bak T, Kugelmas M, Everson GT,
Kam I. Sirolimus is Not Associated with a Higher Incidence of Wound or Hepatic
Artery Complications in Liver Transplant Recipients. AASLD, 2001.
184. Trotter J, Bock SA, Wachs M, Kam I, Everson GT. Transference of Peanut Allergy
Through Liver Transplantation. AASLD, 2001.
185. Stevens A, Busuttil R, Han S, Baquerizo A, Fair J, Shrestha R, Johnson M,
Bloomer J, McGuire B, Rosenthal P, Ascher N, Freise V, Watanabe F, Rogiers X,
Schulte J, Nyberg S, Wiesner RH, Broelsch C, Malago M, Kribben A, Lerut J,
Laterre P, Salizzoni M, Lavezzo B, Brown R, Emond J, Lobritto S, De Hemptinne B,
Colardyn F, Hoste E, Fagan E, McChesney L, Muraca M, Mas Ordeig A, Salmeron
G, Rabkin J, Pratt D, de la Mata M, Montero J, Pozo J, Metselaar H, Everson GT,
Pitkin Z, Mullon C, Solomon B, Demetriou A. In Interim Analysis of Phase II.III
Prospective Randomized, Multicenter, Controlled Trial of the Hepatassist
Bioartificial Liver Support System for the Treatment of Fulminant Hepatic Failure.
AASLD, 2001
186. Trotter J, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living
Donor Liver Transplant Recipients Achieve Higher Immunosuppressive Levels than
Cadaveric Recipients. AASLD, 2001
187. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, DiBisceglie A,
Bonkovsky H, Everson G, Lok ASF, Lee WM, Deinstag J, Morgan T, Morishima C,
Ghany M for the HALT-C Study Group. There is a High Lifetime Incidence of
Substance Abuse but not Mood Disorders in Hepatitis C Non-Responders with
Advanced Fibrosis: Results from the HALT-C Trial. Gastroenterol 2002;122:A-164.
188. Shiffman M, HALT-C Trial Investigators. Retreatment of HCV Non-Responders
with Peginterferon and Ribavirin: Results from the Lead-In Phase of the Hepatitis C
Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2002;
336(4):295A.
189. Lok AS, Everhart JE, Everson G, Wright EC, Sterling R, Ghany M, Goodman Z,
HALT-C Trail Investigators. Clinical Model to Predict Cirrhosis in Patients in the
Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
Hepatology 21002;36(4):315A.
190. Trotter J, Pearson M, Ferrell B, Everson GT, Shrestha R. The Effect of Altitude on
the Prevalence and Severity of Pulmonary Hypertension in End-Stage Liver
Disease. Accepted, Ninth Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona
Spain, 2003.
70
ABSTRACTS (cont’d)
191. Stolpman N, Kam I, Wachs M, Bak T, Trotter J, Everson GT, Department of
Medicince, Surgery and Pharmacy, UCHSC. Pharmacoeconomic Analysis of Four
Maintenance Immunosuppressive Regimes Used in Liver Transplantation. Ninth
Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona Spain, 2003.
192. Hayashi P, Steinberg T, Forman L, Kugelmas M, Trotter J, Wachs M, Bak T, Kam I,
Everson GT, Hepatology Division, Transplant Surgery, UCHSC. Impact of
Pretransplant Diagnosis of Hepatocellular Carcinoma on Cadaveric Liver Allocation
in the Era of MELD. Ninth Meeting of ILTS, 13th Meeting of the LICAGE, Barcelona
Spain, 2003.
193. Kulig CC, Trotter JF, Everson GT. Treatment of lamivudine-resistant chronic
hepatitis B with tenofovir. Gastroenterol 2003; 124(4, Suppl 1). Abstract M2029, p
A-763. DDW, Orlando, FL, 2003.
194. Osborne JC, Heller MA, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M,
Kam I, Trotter JF. Tacrolimus level/dose ratio is significantly higher in hepatitis C
liver transplant recipients: impact on cost. Hepatology 2003, 38(4). Abstract 150,
p. 228A. AASLD, Boston, MA, 2003.
195. Balan V, Sulkowski M, Nelson D, Everson GT, Bambury J, Recta J, Zhong H,
Mesghali J, Murray B, Osborn L, Novello W, Freimuth G, Subramanian G. A Phase
½ Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immungenicity and
Pharmacodynamics of Albuferon in Treatment Experienced Subject with Chronic
Hepatitis C. Hepatology 2003,38(4). Abstract 313, 307A. AASLD Boston,MA, 2003.
196. Everson GT, Lauriski S, DeSanto J, Kugelmas M, Shiffman ML, Hofmann C,
Sterlling R, Morgan T, Hoefs J, Miline N, Rietker W, Wagner D. Quantitative Tests
(QLFTs) Detect Impaired Hepatic Function in a High Proportion of Chronic Hepatitis
C Patients with Fibrosis or Compensated Cirrhosis and May Predict Risk of
Cirrhosis, Splenomegaly, and Varices. Hepatology 2003,38(4). Abstract 309,
p.304A. AASLD, Boston, MA, 2003.
197. Osgood MJ, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter
JF. Preliminary analysis: graft loss from recurrent hepatitis C is not increased in
patients receiving sirolimus as primary immunosuppression. Hepatology 2003,
38(4). Abstract 764, p. 529A. AASLD, Boston, MA, 2003.
198. Osgood M, Hayashi PH, Ludkowski M, Johnson S, Durham J, Brackett T, Steinberg
T, Forman L, Kugelmas M, Trotter J, Bak T, Wachs M, Kam I, Everson GT.
Hepatic artery chemoembolization for hepatocellular carcinoma: an intentinot9=transplant analysis. Hepatology 2003, 38(4). Abstract 1259, p. 766A. AASLD,
Boston, MA, 2003.
199. Taniguchi M, Wachs M, Bak T, Trotter J, Kugelmas M, Everson G, Kam I. Hepatitis
C recurrence in living donor liver transplantation (abstract). Am J Transplantation,
2(suppl 2): 138, 2002.
200. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic Palliation of Polycystic
Liver Disease. SAGES Conference.
71
ABSTRACTS (cont’d)
201. Forman L, Kam I, Everson GT. Maintenance of excellent patients survival after
liver transplantation for chronic hepatitis C in a single center during three eras of
immunosuppression characterized by wide variation in use of OKT3. Am J of
Transplant 2004; 4(8). Abstract 722, p. 355. ATC Conference, Boston, MA, 2004.
202. Everson GT, Marder B, Levi M, Laird SP, McNutt T, Pape WJ, Forman L,
Kleinschmidt-DeMaster, BK, Tyler KL. Community-Acquired West Nile Virus
Encephalomyelitis in Solid Organ and Bone Marrow Transplant Recipients: Clinical,
Diagnostic, and Neuropathological Features.
Am J of Transplant 2004; 4(8).
Abstract 974, p. 424. ATC conference, Boston, MA, 2004.
203. Stolpman NM, Valuck R, Lezotte D, Glazner J, Everson GT. A PHarmacoeconomic
Assessment of the Benefits and Costs of Managing Immhnosuppression in PostLiver Transplant Patients: A University Hospital Perspective. ISPOR 9th Annual
International Meeting.
204. Everson GT. Shiffman ML, Hoefs JC, Kugelmas M, Sterling RK, Morgan TR,
DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N,
Wagner D, Doherty MC, Wright EC. Quantitative Liver Function Tests Predict
Sustained Virologic Response to Retreatment with Peginterferon alfa-2a plus
Ribavirin: Results of the Lead-In Phase of the HALT-C trial. Hepatology, Vol. 40,
No.4, Suppl. 1, 2004, page 113a.
205. Everson GT, Hoefs JC, Malet P, The HALTC Trial Group. Impaired Virologic
Response in Patients with Advanced Liver Disease due to Chronic Hepatitis C is
Independently Linked to Severity of Disease: Results from the HALT C Trial.
Hepatology, Vol. 40, No.4, Suppl. 1, 2004, page 180-181a.
206. Shiffman ML, Morgan TR, Ghany MG, Wright EC, the HALT-C Trial Group. The
Impact of Peginterferon (PEGIFN) and Ribavirin (RBV) Dosing on Sustained
Virologic Response (SVR) in Patients with Chronic Hepatitis C Virus (HCV)
Undergoing Retreatment in the HALT-C Trial. Hepatology, Vol. 40, No.4, Suppl. 1,
2004, page 314a.
207. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Shiffman ML, Everson GT,
Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG,
Morishima C, for the HALT-C Trial Investigators. Prevalence of insulin resistance
(IR) and impact on treatment in chronic hepatitis C (CHC). Hepatology, Vol. 40,
No.4, Suppl. 1, 2004, page 314a-315a.
208. Talamanes M, McClure M, Bak T, Wachs M, Kam I, Foreman L, Everson GT,
Trotter J. Impact of Right Hepatic Lobe Donation on Donor Quality-of-Life: LongTerm Follow-Up of The University of Colorado Cohort. Hepatology, Vol. 40, No.4,
Suppl. 1, 2004.
209. Balan V, Sulkowski M, Nelson D, Everson GT, Lambiase L, Post A, Redfield R,
Wiesner, R, Davis G, Neumann A, Rectal J, Moore P, Osborn B, Novello L,
Freimuth W, Sumramanian M. Albuferon – A Novel Therapeutic Agent for Hepatitis
C: Results of a Phase ½ Study In Treatment Experienced Subjects with Chronic
Hepatits C. Hepatology, Vol. 40, No. 4, Suppl 1, 2004.
72
ABSTRACTS (cont’d)
210. Everson G, Heathcote J, Pappas SC, Govindarajan S, Lentz E, Lopez-Talavera JC,
Hoffman F. Histological Beneit of Pegintergeron Alfa-2A (40KD) (Pegasys ®)
Monotherapy in Patients with Advanced Fibrosis or Cirrhosis Due to Chronic
Hepatitis C. Hepatology, Vol. 40, No. 4, Suppl 1, 2004.
211. Robinson TN, Stiegmann GV, Everson GT. Laparoscopic palliation of polycystic
liver disease. Surgical Endoscopy November 11, 2004.
212. Braddock AL, Kulig CC, Morfin JP, Beresford TP, Everson GT. Fatty Acid Ethyl
Esters and Blood Alcohol Level: Intoxication, Tolerance, and Influence of Gender
and Age. W2005, Category: Gastroenterology and Hepatology, Category Number:
8, Affiliations: WSMR,WSCI.
213. Everson GT, Bangaru S. Portal-Systemic Shunting and Fractional Turnover of Bile
Acids in Polycystic Liver Disease: Implications for Pre- and Post-transplant
Management. Liver Transpl 2005, 11(7):C-24, abstract 94.
214. Everson. Treatment of Patients with Decompensated Cirrhosis due to Chronic
Hepatitis C: Results with a Low Accelerating Dose Regimen (LADR) of Antiviral
Therapy. Liver Transpl 2005, 11(7):C-37, abstract 145.
215. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Seeff LB, and the
A2ALL Study Group. Transplant Center Experience Explains Differences in the
Risk of Graft Failure between Hepatitis C Virus (HCV)-Infected Recipients of Living
donor (LDLT) and Decreased donor (DDLT) Liver Transplant Recipients. Hepatol
Vol 42, No 4, Suppl 1, 2005; abstract 7, p 198A.
216. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes
of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver
transplantation from a single center. Hepatol Vol 42, No 4, Suppl 1, 2005; abstract
644, p 450A.
217. Campsen J, Wachs M, Bak T, Forman L, Everson G, Kam I, Trotter JF. Is liver
biopsy mandatory for all donors for adult-to-adult right hepatic lobe living donor liver
transplantation? Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 653, p 454A.
218. Bonkovsky HL, Di Bisceglie AM, Morishima C, Chung RT, Everosn GT, Ghany MC,
Hoofnagle JH, Lindsay KL, Hoefs JC, Lee WM, Lok, As, Shiffman ML, Wright EC.
Iron and HFE gene mutations in advance chronic hepatitis C (CHC): results from
the lead-in phase of the HALT-C Trial. Hepatol Vol 42, No 4, Suppl 1, 2005;
abstract 894, p 548A.
219. Forman L, Everson G. Nonalcoholic fatty liver disease hospitalizations in the
United States in 202: characteristics and comparison to chronic hepatitis C.
Hepatol Vol 42, No 4, Suppl 1, 2005; abstract 1083, p 622A.
73
ABSTRACTS (cont’d)
220. Everson GT, Shiffman ML, Sterling Rk, Hoefs JC, Morgan T, DeSanto J, Lauriski S,
Shea S, Hofmann C, Rietker W, Milne N, Wright E, Doherty M. Hepatic function
improves after sustained virologic response in hepatitis C paitents with advanced
fibrosis and cirrhosis: Results of the lead-in phase of the HALT-C Trial. Hepatol Vol
42, No 4, Suppl 1, 2005; abstract 1265, p 697A.
221. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL,
Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Five-Year long term
follow up of sustained viologic responders to interferon-alfa-2b +/- ribavirin therapy.
Submitted to EASL, Vienna, April 2006.
222. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL,
Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Sustained virologic
response (SVR) to interferon-alfa-2b +/- ribavirin therapy at 6 months reliably
predicts long-term clearance of HCV at 5-year follow up. Submitted to EASL,
Vienna, April 2006.
223. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL,
Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Five-Year long term
follow up of sustained viologic responders to interferon-alfa-2b +/- ribavirin therapy.
Submitted to DDW, May 2006.
224. McHutchison JG, Patel K, Schiff ER, GItlin N, Mur RE, Everson GT, Carithers RL,
Davis GL, Marcellin P, Shiffman ML, Harvey J, Albrecht JK. Sustained virologic
response (SVR) to interferon-alfa-2b +/- ribavirin therapy at 6 months reliably
predicts long-term clearance of HCV at 5-year follow up. Submitted to DDW, May
2006.
225. Everson GT, Kulig CC, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, Curto
TM, Everhart JE, Wagner D, DeSanto J, McKinley C, Hofmann C, Smith P,
Rietkerk W, Lauriski S, Milne N. Altered Hepatic Metabolic Function in Patients
with Chronic Hepatitis C is Associated with Obesity, Insulin Resistance, or Hepatic
Steatosis, Independent of Cirrhosis: Results from the HALT-C Trial. Poster
Presentation, AASLD 2006.
226. Hoefs, JC, Everson GT, Shiffman ML, Morgan TR, Naishadham D, Wright EC.
Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease
Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis. Poster
Presentation, AASLD 2006.
227. Seeff L, Herbal and Milk Thistle Use in the HALT-C Trial of Advanced Chronic
Hepatitis C. Poster Presentation, DDW 2007.
228. Everson GT, Jacobson IM, Gordon SC, McHutchison JG, Kaufman R, McNair L,
Muir A. Prove 1: Results from a Phase 2 Study of Telaprevir with Peginterferon
Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Hepatitis C.
Gastroenterology 2008;134:A-758 (AASLD abstract number 223).
PRESENTATIONS AT SCIENTIFIC MEETINGS
1. Everson GT, Johnson M, Kern F Jr. Gallbladder function in pregnancy: Increased
retention of bile from 8 am until midnight. Gastroenterology, 78(5 Pt 2):1162, 1980.
74
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
2. Everson GT, McKinley C, Showalter R, Johnson M, DeMark B, Szczepanik-VanLeeuwen P, Klein P, Kern F. Bile acid (BA) kinetics and gallbladder (GB) function
in pregnancy: The apparent regulatory role of the gallbladder. Gastroenterology,
78(5 Pt 2):1162, 1980.
3.
Kern F, DeMark B, Szczepanik-VanLeeuwen P, Everson GT, Braverman D,
McKinley C, Showalter R, Klein P. Effects of contraceptive steroids (CS) on biliary
lipids and bile acid (BA) kinetics. Clin Res, 28(2):545A, 1980.
4.
Everson GT, Lawson M, McKinley C, Showalter R, Kern F Jr. Differential effects of
liquid formula (F) and amino acid (AA) solutions on gallbladder (GB) emptying,
small bowel transit and biliary lipid secretion. Gastroenterology, 80(5 Pt 2):1145,
1981.
5.
Everson GT, Hachey D, Klein P, Showalter R, McKinley C, Kern F Jr. Simultaneous serum and biliary chenodeoxycholic (CDC) kinetics using 13C-CDC.
Gastroenterology, 82(5 Pt 2):1051, 1982.
6.
Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I,
Kern F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling,
gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Clin Res,
30(1):36A, 1982.
7.
Lawson M, Everson GT, McKinley C, Konterski E, Klingensmith W, Taylor I, Kern
F Jr. Relations of gastric emptying, gallbladder (GB) emptying and refilling, gastrointestinal transit (GIT) and serum pancreatic polypeptide (PP). Gastroenterology,
82(5 Pt 2):1112, 1982.
8.
Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in
pregnancy. Clin Res,1(1):30A, 1983.
9.
Everson GT, Lawson M, McKinley C, Kern F Jr. Small bowel transit time (SBTT) in
pregnancy. Gastroenterology, 84(5 Pt 2):1146, 1983.
10. Everson GT, Polokoff M, Nemeth A. Bile acid synthesis in the human hepatoma
cell line, HepG2: Studies of the conversion of deuterium-labeled and isomers of
7-OH cholesterol to chenodeoxycholic (CDCA) and cholic acid (CA). Gastroenterology, 88(5 Pt 2):1657, 1985.
11. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid
synthesis. Hepatology, 5(5):1022, 1985.
12. Kern F Jr, Everson GT, Showalter R, McKinley C, Fausel C. Contraceptive steroids
(CS) alter the regulatory mechanisms of cholesterol homeostasis and biliary lipid
secretion in healthy young women. Gastroenterology, 88(5 Pt 2):1670, 1985.
13. Everson GT, Polokoff M. Effect of dexamethasone on bile acid synthesis by
cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Clin Res,
34(1):28A, 1986.
75
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
14. Everson GT, Polokoff MA. HepG2: A cell line exhibiting defects in bile acid
synthesis. Clin Res, 34(1):29A, 1986.
15. Everson GT, Polokoff MA. Effect of dexamethasone on bile acid synthesis by
cultured cells: Studies of rat hepatocyte X rat hepatoma hybrids. Gastroenterology, 90(1 Pt 2):1724, 1986.
16. Kern F Jr, Everson GT.
Chronic premarin administration increases biliary
cholesterol (CH) secretion and decreases chenodeoxycholic acid (CDCA) pool and
synthesis. Gastroenterology, 90(5 Pt 2):1738, 1986.
17. Everson GT, Leff N, Dixon D, Githens J, Pretorius D, Manco-Johnson M.
Gallbladder function is altered in sickle hemoglobinopathies (SH): Potential role in
gallstone formation. Gastroenterology, 92:1731, 1987.
18. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state
kinetics of bile acids. Hepatology, 7(5):1109, 1987.
19. Everson GT, Scherzinger A, Leff N, Lee E, Seibert J, Manco-Johnson M. Liver cell,
liver cyst and kidney volumes in subjects with autosomal dominant polycystic
kidney disease with liver cysts (ADPKD + LC). Hepatology, 7(5):1100, 1987.
20. Everson GT, Fennessey P, Kern F Jr. Contraceptive steroids alter the steady-state
kinetics of bile acids. Presented at Aspen Conference on Hepatic Lipoprotein and
Cholesterol Metabolism, 1987.
21. Junker L, Straka M, Zogg D, Everson GT, Davis R.
Regulation of rat liver
cholesterol 7-alpha hydroxylase by microsomal free cholesterol. Hepatology,
7(5):1108, 1987.
22. Junker L, Straka MS, Zogg DL, Everson GT, Davis RA. Regulation of cholesterol
7-alpha hydroxylase by microsomal free cholesterol. Presented at Aspen Conference on Hepatic Lipoprotein and Cholesterol Metabolism, 1987.
23. Everson GT, Leff N, Zogg D, Reichen J, Gabow P. Polycystic liver disease:
Quantitative assessment of hepatic and cyst function. Gastroenterology, 94(5 Pt
2):A538, 1988.
24. Everson GT, Kern F Jr. Mechanisms of gallstone formation in post-menopausal
women taking conjugated estrogens (Premarin). Gastroenterology, 94:A538, 1988.
25. Everson GT, Leff N, Brown WR, Emmett M. Characteristics of hepatic cysts in
autosomal dominant polycystic kidney disease (ADPKD). Hepatology, 8(5):1341,
1988.
26. Kern F Jr, Everson GT. The effects of female sex steroid hormones on cholesterol
and bile acid metabolism. Presented at the Bengt Borgstrom Symposium,
Falsterbo, Sweden, May/June 1988.
76
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
27. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol
on biliary lipid metabolism in women taking conjugated estrogens. Clin Res,
37(1):111A, 1989.
28. Everson GT, McKinley C, Showalter R, Kern F Jr. Influence of dietary cholesterol
on biliary lipid metabolism in women taking either conjugated estrogens
(PremarinR) or medroxyprogesterone (ProveraR). Gastroenterology, 96(5 Pt
2):A596, 1989.
29. Everson GT, Johnson A, Kaehny W, Duley I, Manco-Johnson M, Gabow P. Risk
factors for the development of hepatic cysts in autosomal dominant polycystic
kidney disease (ADPKD). Gastroenterology, 96(5 Pt 2):A144, 1989.
30. Everson GT.
Bile acid synthesis by HepG2 is regulated by insulin and
dexamethasone. Presented at the 32nd IUPAC Congress. Stockholm, Sweden,
August 1989.
31. Zaccaro L, Sutherland E, Iwahashi M, Burnett R, Everson G. Acute cholestasis
with taurolithocholate is due to direct reversible non-competitive inhibition of
sodium-dependent taurocholate uptake. Gastroenterology, 6(2):A675, May 1989.
32. Everson GT.
Bile acid synthesis by HepG2 is regulated by insulin and
dexamethasone. Presented at the 32nd IUPAC Congress. Stockholm, Sweden,
August 1989.
33. Rector WG, DeRoche G, Everson GT. The relationship of portal-systemic shunting
and liver function to sodium retention in patients with alcoholic liver disease.
Hepatology, 10(4):587, 1989.
34. Kam I, Everson GT, Sokol R, Schroter G, Lawton C, Armstead V, Karrer F. Liver
transplant activity of 1st year program at University of Colorado Health Sciences
Center. Presented at American College of Surgeons, Colorado Chapter Meeting,
May 1990.
35. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on
the enterohepatic circulation and metabolism of bile acids. Hepatology, 12(4):1005,
1990.
36. Everson GT, Valdivieso V, Covarrubias C, Espinosa R, Trombley C, Smith P.
Intrahepatic cholestasis of pregnancy:
Effects on bile acid metabolism.
Hepatology, 12(4 Pt 2):898, 1990.
37. Everson GT, Malik R, McKinley C. Effects of synthetic progestin (norethindrone) on
gallbladder motility, intestinal transit, and the kinetics of bile acids. Clin Res,
36(1):95A, 1991.
38. Everson GT, Daggy BP, McKinley C, Story JA. Study of mechanisms of the
hypocholesterolemic effect of psyllium in man. Circulation, 84(4 Suppl): II601, Oct
1991.
77
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
39. Everson GT, Daggy BP, McKinley C, Story JA. Dietary fiber (psyllium) lowers LDL
cholesterol by stimulating bile acid synthesis in man. Hepatology, 14(4 Pt 2):148A,
1991.
40. Pinto PC, Everson GT, Rector WG Jr. Does progressive reduction in hepatic
metabolic capacity signal sodium retention in alcoholic cirrhosis? Hepatology, 14(4
Pt 2):86A, 1991.
41. Hall R, Reveille RM, Karrer F, Everson G, Goff J, Kam I. Bile leaks after T-tube
removal following orthotopic liver transplantation. American College of Surgeons,
Colorado Chapter Meeting, May 1992.
42. Mandell S, Karrer F, Everson GT, Urban K, Kam I. Selective Use of VenousVenous Bypass in Liver Transplant. International Society for Hepatic
Transplantation; Toronto, Canada, 1993.
43. Everson GT, Lezotte DL, Clark A, Kam I. Biochemical Profile in The First 21 Days
After Hepatic Transplantation: The Uncomplicated Course. International Society for
Hepatic Transplantation. Hepatology, 1993.
44. Everson GT, McKinley C, Kam I. Quantitative Tests (QLFT) of Hepatic Function:
Assessment of Patients Prior to Hepatic Transplantation (OLTx). International
Society for Hepatic Transplantation. Hepatology, 18(4 Pt ):330, 1993.
45. Mandell S, Karrer F, Everson G, Urban K, Kam I. Selective Use of Venous-Venous
Bypass in Liver Transplant. International Society for Hepatic Transplantation.
Hepatology, 1993.
46. Durham JD, LaBerge J, Altman SD, Stauffer JT, Kam I, Everson GT, Kumpe DA.
Departments of Radiology, Hepatology, and Surgery, University of Colorado Health
and Sciences Center, Denver, and Department of Radiology. Percutaneous Portal
Vein Recanalization and Closure of Competitive Portosystemic Shunts in Patients
with Portal Vein Thrombosis Following Orthotopic Liver Transplantation. University
of California, San Francisco, International Society for Hepatic Transplantation.
Hepatology, 1993.
47. Lindsey KL, Davis GL, Schiff E, Bodenheimer H, Balart L, Dienstag J, Perrillo R,
Goff J, Everson GT, Tamburro C, Albrecht J, Sanghvi B. Long-term Response to
Higher Doses of Interferon (IFN) Alfa- 2b Treatment of Patients with Chronic
Hepatitis C: A Randomized Multicenter Trial. AASLD Meeting 1993. Toronto,
Canada, 1993; Hepatology 18(4 Pt 2):106, 1993.
48. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F, Department
of Medicine, University of Colorado Medical School, Denver, and Sandoz Nutrition,
Minneapolis, MN. The Metabolic Basis for Cholesterol Gallstone Formation in
Obese Women During Weight Loss. Carmel, CA, 1993.
78
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
49. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson
GT, Department of Medicine, University of Colorado School of Medicine, Denver,
CO. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women
with Autosomal Dominant Polycystic Disease (ADPD). Carmel, CA, 1993.
50. Stegall M, Everson GT, Karrer F, Schroter G, Kam I, University of Colorado Medical
Center, Denver, CO. Metabolic Complications After Liver Transplantation: Diabetes
and Hypercholesterolemia. ASTS Meeting 1994
51. Slater J, Chan L, Kam I, Schroter G, Karrer F, Bilir B, Howell C, Coll J, Everson GT.
Renal Failure and Dialysis as Predictors of Outcome in Liver Transplant Patients.
ASTS Meeting, 1994.
52. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I. The Clinical
Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver
Transplantation. 1994.
53. Shrestha R, McKinley C, Russ P, Scherzinger A, Bonner R, Showalter R, Everson
GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women
with Autosomal Dominant Polycystic Disease (ADPD). World Congresses of
Gastroenterology, Gastroenterology, 106(4):A985, DDW Meeting, 1994.
54. Kaur S, Carey WD, Bacon BR, Gollan JL, Rustgi VK, Sandha GS, Everson GT.
Performance Characteristics of a Large Scale Screening Program (LSSP) for Viral
Hepatitis (VH) B and C - Results of the National Hepatitis Surveillance Program.
DDW Meeting, 1994.
55. Kaur, S, Carey WD, Bacon BR, Gollan JL, Rustgi VK, Everson, GT. Risk Factors
for Viral Hepatitis (VH) B and C Exposure in Subjects Presenting to a Voluntary
Large Scale Screening Program (LSSP) - Results of the National Hepatitis
Surveillance. Program. DDW Meeting, 1994.
56. Everson GT, Stegall M, Karrer F, Schroter G, Howell C, Bilir B, Kam I. The Clinical
Characteristics of Adult Patients Who Develop Hypercholesterolemia After Liver
Transplantation (OLTx). World Congress of Gastroenterology Meeting, 1994.
57. Everson GT, McKinley C, Mills M, Cippola T, Showalter R, Peterson F. Weight
Loss in Obese Women Markedly Inhibits bile Acid Synthesis. The Metabolic Basis
for Cholesterol Gallstone Formation? World Congress of Gastroenterology, 1994.
58. Shrestha R, McKinley C, Ross P, Scherzinger A, Bonner R, Showalter R, Everson
GT. Estrogens Inhibit the Metabolism of Antipyrine in Postmenopausal Women
with Autosomal Dominant Polycystic Disease (ADPD). World Congress of
Gastroenterology, 1994.
59. Shrestha R, Everson GT, McKinley C, Showalter R, Smith P. Complete Response
to Interferon is Associated with Improvement in Hepatic Function. World Congress
of Gastroenterology, 1994.
79
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
60. Lindsay KL, Spencer G, Nicoloff J, Milestein S, Davis GL, Schiff E, Bodenheimer H,
Balart L, Dienstag J, Perrillo R, Tamburro C, Everson GT, Sanghvi B, Albrecht J.
Thyroid Peroxidase Antibody--A Potential Predictor of IFN Associated Thyroid
Disease. AASLD Meeting. Hepatology, 20 (4 Pt. 2):168A, October 1994.
61. Shrestha R, McKinley C, Showalter R, Everson GT. Quantitative Liver Function
Tests (QLFTs) Define the Functional Severity of Liver Disease In Early Stage
Cirrhosis. AASLD Meeting. Hepatology, 20 (4 Pt. 2):119A, October 1994.
62. Sokol RJ, McKim JM, Devereaux MW, Everson GT. Vitamin E Reduces Oxidant
Injury to Hepatic Mitochondria Caused by Intravenous Taurochenodeoxycholic Acid
in the Rat. Hepatology, 20 (4 Pt.2):178A, October 1994.
63. Bilir B, Durham JD, Kumpe DA, Karrer F, Hanks T, Ostrowska A, Kam I, Trujillo N,
Lear J, Trouillot T, Shrestha R, Everson GT. Critical Analysis of Intra-Splenic
Transplantation of Cryopreserved Human Hepatocytes in a Patient with Acute Liver
Failure. AASLD Meeting, Chicago, IL, November 1995.
64. Katz JJ, Mandell MS, Barton B, House RM, Bilir B, Everson GT, Zamudio S.
Preservation of CO2-Dependent Regulation of Cerebral Arterial Blood Flow
Velocity in End Stage Liver Disease. AASLD Meeting, Chicago, IL,November 1995.
65. Shrestha R, Durham JD, Kumpe DA, Bilir B, DeRoche G, Showalter R, Rector W,
Everson GT. Outcome after Transjugular Intrahepatic Portal-Systemic Shunt fro
Refractory Ascites in Patients with Advanced Cirrhosis. AASLD Meeting, Chicago,
IL, November 1995.
66. Gordon SC, Everson GT, McHutchison JG, Reinus J, Regenstein F, Kaplan MM,
Koff RS, Fedorczyk D , Plasse T.
Chronic Hepatitis C in Patients Refractory to Recombinant Interferon Alfa 2B.
AASLD Meeting, November 1995.
67. Simon DM, Gordon SC, Kaplan MM, Koff RS, Regenstein F, Everson GT, Weiner
Treatment of Chronic Hepatitis C in Previously Untreated
Meeting, November 1995.
Patients.
AASLD
68. Stegall MD, Everson GT, Wachs M, Schroter G, Karrer F, Bilir B, Shrestha R, Kam
I.
Prednisone withdrawal 14 days after adult liver transplantation with
mycophenolate mofetil (MM). AASLD Meeting, November 1996. Hepatology
1996; 24(4):174A.
69. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K,
Everson GT, Piemstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert
D, Gerrard T, and the Consensus Interferon Study Group*. Differential response to
treatment with consensus interferon (CIFN) a
-2b in chronic HCV patients
infected with different HCV serotypes.
AASLD Meeting, November 1996.
Hepatology 1996; 24(4):275A.
80
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
70. Bilir B, Durham JD, Krystal J, Karrer F, Kumpe D, Ostrowska A, Guenette D,
Trouillot T, Shrestha R, Taylor S, Kam I, Everson GT. Transjugular intra-portal
transplantation of cryopreserved human hepatocytes in a patient with acute liver
failure. AASLD Meeting, November 1996. Hepatology 1996; 24(4):308A.
71. Bharadhwaj G, Everson GT, Bilir B, Shrestha R, Kam I, Karrer F, Wachs M, Stegall
M, Schroter G, Steinberg T, Ford C, Beresford T. Relapse to alcohol consumption
in liver transplant recipients followed for more than one year: early analysis of a
comprehensive psychosocial evaluation.
AASLD Meeting, November 1996.
Hepatology 1996; 24(4):244A.
72. Shrestha R, McKinley C, Showalter R, Marsano L, Vivian B, Everson GT.
Quantitative liver function tests (QLFTs) define functional severity and predict
decompensation of liver disease in early stage cirrhosis. AASLD Meeting,
November 1996. Hepatology 1996; 24(4):300A.
73. Colton J, Chapman A, Everson GT. Augmentation of the diuretic response to
furosemide by albumin in cirrhotic patients with ascites. AASLD Meeting,
November 1996. Hepatology 1996; 24(4):446A.
74. Shrestha R, McKinley C, Showalter R, Bilir B, Durham J, Kumpe D, Krysl J,
Everson G. Transjugular intrahepatic portosystemic shunts (TIPS) for ascites: the
prognostic and predictive value of quantitative liver function tests (QLFTs). AASLD
Meeting, November 1996. Hepatology 1996; 24(4):449A.
75. Sokol RJ, Devereaux MW, Straka MS, Everson GT. Melatonin attenuates
hydrophobic bile acid toxicity to isolated rat hepatocytes. AASLD Meeting,
November 1996. Hepatology 1996; 24(4):338A.
76. Jensen DM, Blatt LM, Tong MJ, Lee WM, Mullen K, Hoefs JC, Keeffe E, Hollinger
FB, Heathcote EJL, White H, Foust RT, Krawitt EL, Fromm H, Black M, Albert D,
Gerrard T, and Consensus Interferon Study Group*. Treatment of high viral titer
chronic HCV patients with consensus interferon (CIFN) results in a significantly
greater number of sustained HCV RNA responders as compared to treatment with
interferon -2b. AASLD Meeting, November 1996. Hepatology 1996; 24(4):275A.
77. Keeffe E, Blatt LM, Dusheiko G, Tong MJ, Hollinger FB, James S, Mullen K,
Everson GT, Pimstone N, Heathcote EJL, Donovan J, Conrad A, Schmid P, Albert
D, Gerrard T, and Consensus Interferon Study Group*. Differential response to
-2b in chronic HCV patients
infected with different HCV serotypes.
AASLD Meeting, November 1996.
Hepatology 1996: (24)4:275A.
78. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M,
Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver
transplantation in patients with autoimmune chronic active hepatitis. ASTP 16th
Annual Meeting, May 1997.
81
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
79. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I,
Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver
transplantation for alcoholic liver disease: long-term results. ASTP 16th Annual
Meeting, May 1997.
80. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft
recipients: a controlled three year follow-up. ASTP 16th Annual Meeting, May 1997.
81. Stegall MD, Wachs ME, Kam I, Bilir B, Shrestha R, Karrer F, Everson GT.
Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a
prospective trial of cyclosporine and tacrolimus. ASTP 16th Annual Meeting, May
1997.
82. Trouillot TE, Stegall M, Bilir B, Shrestha R, Kam I, Schroter G, Karrer F, Wachs M,
Ford C, Steinberg T, Everson GT. Successful prednisone withdrawal after liver
transplantation in patients with autoimmune chronic active hepatitis. ILTS Meeting,
October 1997.
83. Beresford TP, Bharadhwaj G, Everson GT. Alcohol dependent liver graft
recipients: a controlled three year follow-up. ILTS Meeting, October 1997.
84. Everson GT, Bharadhwaj G, House R, Talamantes M, Bilir B, Shrestha R, Kam I,
Wachs M, Karrer F, Fey B, Ray C, Steinberg T, Morgan C, Beresford T. Liver
transplantation for alcoholic liver disease: long-term results. ILTS Meeting,
October 1997.
85. Trouillot TE, McKinley CL, Showalter RB, Everson GT. Gallbladder motility in
obese subjects after diet- induced weight loss relative to gallstone formation.
AASLD Meeting, November 1997.
86. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. The link
between weight loss, gallstones, and insulin action: a pathophysiologic study in
humans. AASLD Meeting, November 1997.
87. Trouillot TE, Eckel RH, McKinley CL, Showalter RB, Yost TJ, Everson GT. Hepatic
and total body insulin sensitivities are disassociated in obese subjects after dietinduced weight loss followed by isocaloric weight maintenance. AASLD Meeting,
November 1997.
88. Bilir BM, Guenette D, Ostrowska A, Durham J, Kumpe D, Krysl J, Shrestha R,
Trouillot T, Teitelbaum I, Everson GT. Percutaneous hepatocyte transplantation
(PHT) in liver failure. AASLD Meeting, November 1997.
89. Amponsah A, Everson GT, Stephens J, Tannenbaum M, Shrestha R, Trouillot T,
Bilir B, Wachs M, Kam I, Steinberg T, Morgan C, Fey B, Ray C, Beresford T.
Relapse to drinking after liver transplantation: failure of explant histology to predict
relapse. AASLD Meeting, November 1997.
82
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
90. Sandhu IS, Stephens J, Krysl J, Durham JD, Kumpe DA, Shrestha R, Trouillot TE,
Everson GT, Bilir BM Utility of Transjugular Liver Biopsy Using Liver Access
Biopsy Automated Needle. DDW, May 16-22, 1998.
91. Bilir BM, Kumpe D, Krysl J, Guenette D, Ostrowska A, Everson GT, Shrestha R, Lin
TC, Cole W, Lear J, Durham JD. Hepatocyte Transplantation (HT) in Patients with
Liver Cirrhosis. DDW, May 16-22, 1998.
92. Goff JS, Hamman RF, Wamboldt FS, Everson GT, Shrestha R, Kam I, Wachs M,
Lezotte DC, Steinberg T, Talamantes M, Bilir B. Quality of life after liver
transplantation in patients with hepatitis C. DDW, May 16- 22, 1998.
93. Talamantes M, Everson GT, Shrestha R, Trouillot T, Bilir B, Wachs M, Kam I,
Steinberg T, Morgan C, House R, Mandell S. Katz J, Fey B, Ray C. Successful
outcome after liver transplantation of patients with a high-risk at pre-transplant
psychosocial evaluation. American Society of Transplant Physicians Meeting, 1998.
94. Everson GT, Shrestha R, Wachs M, KAM I, Bilir B, Trouillot T, Nold K, Mandell S,
Katz J, Fey B, Ray C, Steinberg T, Morgan C. Components of care responsible for
the rising costs incurred during the pre-transplant period in liver transplant
recipients. American Society of Transplant Physicians Meeting, 1998.
95. Everson GT, Shrestha R, Trouillot T, Bilir B, Amponsah A, Wachs M, Stegall M,
Mandell S, Katz J, Steinberg T, Morgan C, Fey B, Ray C, Kam I. Costs of
cyclosporine (Neoral) and tacroliums (Prograf) in the first year after liver
transplantation (OLT). American Society of Transplant Physicians Meeting, 1998.
96. Shrestha R, Ryu R, Durham J, Krysl J, Kam I, Wachs M, Bilir B, Trouillot T,
Everson GT. Use of transjugular intrahepatic portosystemic shunt as a bridge to
transplantation in budd-chiari syndrome.
American Society
of Transplant
Physicians Meeting, 1998.
97. Everson GT. Medical management of hepatitis B. University of Maryland Division of
Gastroenterology, Third Annual Liver Diseases Seminar, 1999.
98. Everson GT. Management of hepatic failure, upper gastrointestinal bleeding, and
lower gastrointestinal bleeding in the intensive care unit, American College of
Chest Physicians and Society of Critical Care Medicine Combined Meeting, 1999.
99. Everson GT. Increased incidence of HCV-related hepatocellular (HCC) from 1988
to 1997 in the state of Colorado: implications for liver transplantation (LTx).
American Society of Transplantation, May, 1999.
100. Everson GT. Effect of hepatitis C on survival in orthotopic liver transplant recipients
undergoing rapid steroid withdrawal. American Society of Transplantation, May,
1999.
83
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
101. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R,
McKinley C, University of Colorado School of Medicine and General Clinical
Research Center. The Colorado hepatitis treatment group: early results of the use
of combination interferon-alfa-2B (Intron A) plus ribavirin (Rebetrol) in the treatment
of non-responders. US Rebetron Investigators Meeting, February, 1999.
102. Everson, GT. Cholestasis following bone marrow transplantation,
presentation. American College of Gastroenterology, October, 1999.
case
103. Everson GT, Trouillot T, Trotter J, Skilbred J, Tomasi C, McKinley C, Halprin A, Fey
B, Ray C, Epp J. Treatment of Decompensated Cirrhotics with a Low-Accelerating
Dose Regimen of Interferon alfa-2b and Ribavirin (LADR): Safety and Efficacy.
AASLD Annual Meeting, October, 2000.
104. Trotter J, Wachs M, Bak T, Trouillot T, Everson GT, Kam I, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center, Denver, CO. Liver Transplantation with Using
Sirolimus and Three-Day Corticosteroid Taper. Accepted, AASLD Annual Meeting,
October, 2000.
105. Trotter J, Wachs M, Trouillot T, Bak T, Everson GT, Kam I, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center. The Effect of Living Donor Liver Transplantation
(LDLT) on Median Waiting Times for UNOS Status IIB Cadaveric Recipients at One
Center. Accepted, AASLD Annual Meeting, October, 2000.
106. Stolpman N, Kam I, Wachs M, Bak T, Trouillot T, Trotter J, Steinberg T, Stephens
J, Everson GT. Mycophenolate Mofetil Does Not Lower the Incidence or Cost of
Rejection, Use of OKT3, or Improve Survival After Liver Transplantation and Rapid
(14d) Steroid Withdrawal. Accepted, AASLD Annual Meeting, October, 2000.
107. Everson GT, Folan R, Goff J, Richman L, Anselm C, Trouillot T, Shrestha R,
McKinley C, University of Colorado School of Medicine and General Clinical
Research Center, Denver, CO. The Colorado Hepatitis Treatment Group:
Interferon-Alfa 2b (Intron A) Plus Ribavirin (Rebetol) is Efficacious in Nonresponders to Prior Interferon Monotherapy. Accepted, AASLD Annual Meeting,
October, 2000.
108. Heimbach J, Wachs M, Bak T, Steinberg T, Stolpman N, Calkins C, Everson GT,
Kam I, Trotter J, University of Colorado Health Sciences Center, Denver, CO. OKT3 Does Not Increase the Incidence of Lymphoprolifeative Disease After Adult Liver
Transplantation. Accepted, AASLD Annual Meeting, October, 2000.
109. Trouillot T, Stolpman N, Wachs M, Bak T, Trotter J, Kam I, Everson GT, Division of
Gastroenterology and Hepatology, Division of Transplant Surgery, University of
Colorado Health Sciences Center, Denver, CO. Mycophenolate Mofetil-Based
Immunosuppression Does Not Increase the Risk of Cytomegalovirus Disease in
Patients Treated with Rapid (14d) Steroid Withdrawal After Liver Transplantation.
Accepted, AASLD Annual Meeting, October, 2000.
84
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
110. Stolpman N, Stephens J, Trouillot T, Trotter J, Kugelmas M, Wachs M, Bak T,
Steinberg T, Kam I, Everson, GT. Apparent Slowing of Hepatitis C Recurrence and
Progression after Liver Transplantation Using Very Early (14d) Steroid Withdrawal.
AST Transplant 2001 Meeting, May, 2001.
111. Everson GT, Halprin A, Trouillot T, Trotter J, Kugelmas M, Skilbred J, Tomasi C,
McKinley C, Fey B, Ray C, Epp J, Department of Medicine, University of Colorado
School of Medicine, Denver, CO. Treatment of Decompensated Cirrhotics May
Reduce Recurrence of Hepatitis C After Liver Transplantation. Accepted, AST
Transplant 2001 Meeting, May, 2001.
112. Zeuzem S, Manns M, Rustgi V, Aurora S, Smith C, Shiffman M, Reddy R,
Reindollar R, Slaker D, Rai R, Keeffe E, International Interferon alfacon-1 Study
Group. Daily Interferon Alfazon-1 (Infergen) Therapy: Interim Results from an
Ongoing International Clinical Trial to Compare Daily Interferon Alfacon-1 Therapy
(9 mcg) for Treatment of Chronic Hepatitis C Virus. Accepted, European
Association for the Study of the Liver Annual Conference, 2001.
113. Trotter J, Schiano T, Wachs M, Kim-Schluger L, Bak T, Kugelmas M, Trouillot T,
Everson GT, Miller C, Kam I. Living Donor Liver Transplantation in Hepatitis C
Patients: Short-Term Results Compared to Cadaveric Transplantation. AST
Transplant 2001 Meeting, May, 2001.
114. Talamantes M, Trotter J, McClure M, Wachs M, Bak T, Trouillot T, Kugelmas M,
Steinberg T, Everson GT, Kam I. Assessment of the Impact of Living Donor Liver
Transplantation on Quality of Life in Donors. AST Transplant Meeting, May, 2001.
115. Wachs M, Bak T, Everson GT, Trotter J, Trouillot T, Kugelmas M, Steinberg T,
McClure M, Brackett T, Kam I, Division of Transplant Surgery. Adult Living Donor
Liver Transplant: The University of Colorado Experience. AST Transplant, May,
2001.
116. Trotter J, Wachs M, Trouillot T, Bak T, Kugelmas M, Everson GT, Kam I. Sirolimus
is Not Associated with Hypercholesterolemia in the Absence of Prednisone in Liver
Transplant Recipients. AST Transplant 2001, May, 2001.
117. Halprin A, Trotter J, Everson GT, Wachs M, Bak T, Kugelmas M, Kam I. PostTransplant Eradication of Hepatitis C by Pre-Transplant Treatment in Living Donor
Liver Transplant Recipients. AASLD, 2001.
118. Pauls T, Trotter J, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Increased
Immunosuppressant Levels in Hepatitis C Liver Transplant Recipients Receiving
Sirolimus. AASLD, 2001.
119. Dunkelberg J, Trotter J, Steinberg T, Wachs M, Bak T, Kugelmas M, Everson GT,
Kam I. Sirolimus is Not Associated with a Higher Incidence of Wound or Hepatic
Artery Complications in Liver Transplant Recipients. AASLD, 2001.
120. Trotter J, Bock SA, Wachs M, Kam I, Everson GT. Transference of Peanut Allergy
Through Liver Transplantation. Accepted, AASLD, 2001.
85
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
121. Stevens A, Busuttil R, Han S, Baquerizo A, Fair J, Shrestha R, Johnson M,
Bloomer J, McGuire B, Rosenthal P, Ascher N, Freise V, Watanabe F, Rogiers X,
Schulte J, Nyberg S, Wiesner RH, Broelsch C, Malago M, Kribben A, Lerut J,
Laterre P, Salizzoni M, Lavezzo B, Brown R, Emond J, Lobritto S, De Hemptinne B,
Colardyn F, Hoste E, Fagan E, McChesney L, Muraca M, Mas Ordeig A, Salmeron
G, Rabkin J, Pratt D, de la Mata M, Montero J, Pozo J, Metselaar H, Everson GT,
Pitkin Z, Mullon C, Solomon B, Demetriou A. In Interim Analysis of Phase II/III
Prospective Randomized, Multicenter, Controlled Trial of the Hepatassist Bioartificial Liver Support System for the Treatment of Fulminant Hepatic Failure.
AASLD, 2001
122. Trotter J, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living
Donor Liver Transplant Recipients Achieve Higher Immunosuppressive Levels
Than Cadaveric Recipients. AASLD, 2001
123. Shiffman M, Everson GT, Lindsay K, DiBisceglie A, Lok A, Bonkovsky H, Everhart
J, Dienstag J, Seeff L, Lee W, Wright L, Chihiro M, Ghany M, Morgan T, Hoofnagel
J. Retreatment of Interferon and Interferon-Ribavirin Non-Responders with Peginterferon-Alpha 2A and Ribavirin: Initial Results from the Lead-In Phase of the
HALT-C Trial. Oral Presentation, AASLD, 2001.
124. Fontana RJ, Kronfol Z, Wright E, Lindsay K, Seeff L, Shiffman M, DiBisceglie A,
Bonkovsky H, Everson G, Lok ASF, Lee WM, Deinstag J, Morgan T, Morishima C,
Ghany M for the HALT-C Study Group. There is a High Lifetime Incidence of
Substance Abuse but not Mood Disorders in Hepatitis C Non-Responders with
Advanced Fibrosis: Results from HALT-C Trial. Oral Presentation, DDW May 2002.
125. Shiffman M, HALt-C Trial Investigators. Retreatment of HCV Non-Responders with
Peginterferon and Ribavirin: Results from the Lead-In Phase of the Hepatitis C
Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
Oral
Presentation, AASLD 2002.
126. Lok AS, Everhart JE, Everson G, Wright EC, Sterling R, Ghany M, Goodman Z,
HALT-C Trail Investigators. Clinical Model to Predict Cirrhosis in Patients in the
Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Oral
Presentation, AASLD 2002.
127. Kulig CC, Trotter JF, Everson GT. Treatment of lamivudine-resistant chronic
hepatitis B with tenofovir. DDW, Orlando, FL, 2003.
128. Osborne JC, Heller MA, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M,
Kam I, Trotter JF. Tacrolimus level/dose ratio is significantly higher in hepatitis C
liver transplant recipients: impact on cost. AASLD, Boston, MA, 2003.
129. Balan V, Sulkowski M, Nelson D, Everson GT, Bambury J, Recta J, Zhong H,
Mesghali J, Murray B, Osborn L, Novello W, Freimuth G, Subramanian G. A Phase
½ Study to Evaluate the Pharmacokinetics, Safety, Tolerability, Immungenicity and
Pharmacodynamics of Albuferon™ in Treatment Experiences Subject with Chronic
Hepatitis C. AASLD, Boston, MA, 2003.
86
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
130. Everson GT, Lauriski S, DeSanto J, Kugelmas M, Shiffman ML, Hofmann C,
Sterlling R, Morgan T, Hoefs J, Miline N, Rietker W, Wagner D. Quantitative Tests
(QLFTs) Detect Impaired Hepatic Function in a High Proportion of Chronic Hepatitis
C Patients with Fibrosis or Compensated Cirrhosis and May Predict Risk of
Cirrhosis, Splenomegaly, and Varices. AASLD, Boston, MA, 2003.
131. Osgood MJ, Forman L, Kugelmas M, Everson GT, Bak T, Wachs M, Kam I, Trotter
JF. Preliminary analysis: graft loss from recurrent hepatitis C is not increased in
patients receiving sirolimus as primary immunosuppression. AASLD, Boston, MA,
2003.
132. Osgood M, Hayashi PH, Ludkowski M, Johnson S, Durham J, Brackett T, Steinberg
T, Forman L, Kugelmas M, Trotter J, Bak T, Wachs M, Kam I, Everson GT.
Hepatic artery chemoembolization for hepatocellular carcinoma: an intentinot9=transplant analysis. AASLD, Boston, MA, 2003.
133. Forman L, Kam I, Everson GT. Maintenance of excellent patients survival after
liver transplantation for chronic hepatitis C in a single center during three eras of
immunosuppression characterized by wide variation in use of OKT3. Am J of
Transplant 2004; 4(8). Abstract 722, p. 355. ATC Conference, Boston, MA, 2004.
134. Everson GT, Marder B, Levi M, Laird SP, McNutt T, Pape WJ, Forman L,
Kleinschmidt-DeMaster, BK, Tyler KL. Community-Acquired West Nile Virus
Encephalomyelitis in Solid Organ and Bone Marrow Transplant Recipients: Clinical,
Diagnostic, and Neuropathological Features.
Am J of Transplant 2004; 4(8).
Abstract 974, p. 424. ATC conference, Boston, MA, 2004.
135. Stolpman NM, Valuck RJ, Lezotte D, Malone DC, Glazner J, Everson GT. A
Pharmacoeconomic Assessment of the Benefits and Costs of Managing Immunosuppression in Post-Liver Transplant Patients: A University Hospital Perspective.
Poster Presentation, ISPOR 9th Annual International Meeting, May 2004.
136. Everson GT. Shiffman ML, Hoefs JC, Kugelmas M, Sterling RK, Morgan TR,
DeSanto J, McKinley C, Hofmann C, Smith P, Rietkerk W, Lauriski S, Milne N,
Wagner D, Doherty MC, Wright EC. Quantitative Liver Function Tests Predict
Sustained Virologic Response to Retreatment with Peginterferon alfa-2a plus
Ribavirin: Results of the Lead-In Phase of the HALT-C trial. Poster Presentation,
AASLD, October 2004.
137. Everson GT, Hoefs JC, Malet P, The HALTC Trial Group. Impaired Virologic
Response in Patients with Advanced Liver Disease due to Chronic Hepatitis C is
Independently Linked to Severity of Disease: Results from the HALT C Trial. Oral
Presentation, AASLD, October 2004.
138. Shiffman ML, Morgan TR, Ghany MG, Wright EC, the HALT-C Trial Group. The
Impact of Peginterferon (PEGIFN) and Ribavirin (RBV) Dosing on Sustained
Virologic Response (SVR) in Patients with Chronic Hepatitis C Virus (HCV)
Undergoing Retreatment in the HALT-C Trial. Poster Presentation, AASLD,
October 2004.
87
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
139. Lok AS, Everhart JE, Chung RT, Padmanabhan L, Shiffman ML, Everson GT,
Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Ghany MG,
Morishima C, for the HALT-C Trial Investigators. Prevalence of insulin resistance
(IR) and impact on treatment in chronic hepatitis C (CHC). Poster Presentation,
AASLD, October 2004.
140. Talamantes M, McClure M, Bak T, Wachs M, Kam I, Foreman L, Everson GT,
Trotter J. Impact of Right Hepatic Lobe Donation on Donor Quality-of-Life: LongTerm Follow-Up of The University of Colorado Cohort. Oral Presentation, AASLD,
October 2004.
141. Balan V, Sulkowski M, Nelson D, Everson GT, Lambiase L, Post A, Redfield R,
Wiesner, R, Davis G, Neumann A, Rectal J, Moore P, Osborn B, Novello L,
Freimuth W, Sumramanian M. Albuferon – A Novel Therapeutic Agent for Hepatitis
C: Results of a Phase ½ Study In Treatment Experienced Subjects with Chronic
Hepatits C. Oral Presentation, AASLD, October 2004.
142. Everson G, Heathcote J, Pappas SC, Govindarajan S, Lentz E, Lopez-Talavera JC,
Hoffman F. Histological Beneit of Pegintergeron Alfa-2A (40KD) (Pegasys ®)
Monotherapy in Patients with Advanced Fibrosis or Cirrhosis Due to Chronic
Hepatitis C. Poster Presentation, AASLD, October 2004.
143. Moore PA, Balan V, Nelson D, Sulkowski M, Everson G, Lambiase L, Neumann A,
Garcia A, Osborn B, Bagchi P, Novello L, Freimuth W, Subramanian M.
Modulation of Interferon Specific Gene Expression by Albuferon in Subjects with
Chronic Hepatitis C and Correlation with Anti-Viral Response. Poster Presentation,
EASL 2005.
144. Martucci MA, Everson GT, Shiffman, ML, Hoefs, JC, HALT-C QLFT Investigators.
Minimal Model to Determine First-Pass Hepatic Extraction of Cholate in Humans.
Oral Presentation, Western Society for Clinical Investigation Meeting, Carmel, CA
February 2005.
145. Terrault NA, Shiffman ML, Lok ASF, Saab S, Gillespie BW, Seeff LB, and the
A2ALL Study Group. Transplant Center Experience Explains Differences in the
Risk of Graft Failure between Hepatitis C Virus (HCV)-Infected Recipients of Living
donor (LDLT) and Decreased donor (DDLT) Liver Transplant Recipients.
Presentation, AASLD 2005.
146. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes
of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver
transplantation from a single center. Poster Presentation, AASLD 2005.
147. Campsen J, Wachs M, Bak T, Kam I, Forman L, Everson G, Trotter JF. Outcomes
of donor candidates evaluated fro adult-to-adult right hepatic lobe living donor liver
transplantation from a single center. Poster Presentation, AASLD 2005.
88
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
148. Bonkovsky HL, Di Bisceglie AM, Morishima C, Chung RT, Everosn GT, Ghany MC,
Hoofnagle JH, Lindsay KL, Hoefs JC, Lee WM, Lok, As, Shiffman ML, Wright EC.
Iron and HFE gene mutations in advance chronic hepatitis C (CHC): results from
the lead-in phase of the HALT-C Trial. Poster Presentation, AASLD 2005.
149. Forman L, Everson G. Nonalcoholic fatty liver disease hospitalizations in the
United States in 202: characteristics and comparison to chronic hepatitis C. Poster
Presentation, AASLD 2005.
150. Everson GT, Shiffman ML, Sterling Rk, Hoef JC, Morgan T, DeSanto J, Lauriski S,
Shea S, Hofmann C, Rietker W, Milne N, Wright E, Doherty M. Hepatic function
improves after sustained virologic response in hepatitis C paitents with advanced
fibrosis and cirrhosis: Results of the lead-in phase of the HALT-C Trial. Poster
Presentation, AASLD 2005.
151. Sterling RK, Lok ASF, Seeff LB, Hoefs JC, Wright EC, and the HALT-C Trial
Investigators. Clinical Utility of Alpha Fetoprotein (AFP) L3 and Des-gamma
Carboxy Prothrombin (DCP) to Predict Hepatocellular Carcinoma in Patients with
Hepatitis C and Advanced Fibrosis Results from the lead in phase of the HALT-C
Trial. Poster Presentation, DDW 2005
152. Everson GT, Kulig CC, Shiffman ML, Sterling RK, Morgan TR, Hoefs JC, Curto
TM, Everhart JE, Wagner D, DeSanto J, McKinley C, Hofmann C, Smith P,
Rietkerk W, Lauriski S, Milne N. Altered Hepatic Metabolic Function in Patients
with Chronic Hepatitis C is Associated with Obesity, Insulin Resistance, or Hepatic
Steatosis, Independent of Cirrhosis: Results from the HALT-C Trial. Poster
Presentation, AASLD 2006.
153. Hoefs, JC, Everson GT, Shiffman ML, Morgan TR, Naishadham D, Wright EC.
Enhanced Quantitative Liver Spleen Scan (QLSS) Prediction of Liver Disease
Severity in Baseline HALT-C Patients with Moderate Fibrosis or Cirrhosis. Poster
Presentation, AASLD 2006.
154. Seeff L, Herbal and Milk Thistle Use in the HALT-C Trial of Advanced Chronic
Hepatitis C. Poster Presentation, DDW 2007.
155. Jing T, Shah R, Chen Y, Brauer B, Baker M, Everson G. Does pre-transplant
ERCP with stenting (ERCPST) or PTC with drainage tubes (PTCDT) impact posttransplant complications in patients with primary sclerosing cholangitis (PSC)?
Poster Presentation, DDW 2007.
156. J Lalezari, E Gane, M Rodriguez-Torres, E DeJesus, D Nelson, G Everson, I
Jacobson, R Reddy, G Hill, A Beard, WT Symonds, MM Berrey, JG McHutchison.
Potent antiviral activity of the HCV nucleoside polymerase inhibitor R7128 with
PEG-IFN and Ribavirin: Interim results of R7128 500mg BID for 28 days. Oral
Presentation, EASL in Milan, April 2008.
89
PRESENTATIONS AT SCIENTIFIC MEETINGS (cont’d)
157. Dudekula A, Kulig C, Everson GT. Five year experience with tenofovir for
lamivudine resistant hepatitis B virus. Poster Presentation, ACP Internal
Medicine 2008, Washington, DC.
158. Everson GT, Jacobson IM, Gordon SC, McHutchison JG, Kaufman R, McNair L,
Muir A. Prove 1: Results from a Phase 2 Study of Telaprevir with Peginterferon
Alfa-2a and Ribavirin in Treatment-Naïve Subjects with Hepatitis C. Presentation
at DDW 2008.
90